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Abstract 
 
Observational and analytical research of results of experimental and theoretical studies on 
etiology and pathogenesis of psoriatic disease is carried out. The new model of pathogenesis 
of psoriasis – skin reaction to systemic psoriatic process SPP is formulated.  
Because of PAMP-nemia in blood flow fractions of tolerized monocytes Mo-T and dendritic 
cells DC-T are formed. Tolerized Mo-T and DC-T also are kPAMP-carriers.  Within the limits of 
PAMP-nemia also (PG-Y)-nemia takes place. Therefore in tolerized fractions subfractions of 
monocytes Mo-R and dendritic cells DC-R are formed. These Mo-R and DC-R also are          
(PG-Y)-carriers.  Tolerized Mo-T and DC-T (incl. Mo-R and DC-R) have chemostatuses similar  
to nonactivated ones. Therefore these cells participate in homeostatic and-or inflammatory 
renewal of pool of dermal macrophages and dendritic cells of non-resident origin. 
Psoriatic inflammation is regarded as a reaction of the skin immune system to activity of 
Mo-R and DC-R involved in derma from blood flow. They contain Y-antigen and, getting to 
derma, can be transformed in mature maDC-Y and present this antigen to Y-specific 
T-lymphocytes as well as activate them. Y-antigen is a part of the interpeptide bridge IB-Y. 
Therefore, the skin immune system can incorrectly interpret Y-antigen presentation as a sign 
of external PsB-infection and switch one of mechanisms of protection against bacterial 
infection – epidermal hyperproliferation.  
Psoriatic plaque can be initiated only during action of local inflammatory process LP2 in 
derma causing not only innate, but also adaptive response. In particular, it is possible at 
LP2(IN) - open trauma of derma or at LP2(HPV) - HPV-carriage of keratinocytes. The level of 
Y-priming (presence and concentration of Y-specific T-lymphocytes in prepsoriatic derma and 
in lymph nodes) also determines possibility of psoriatic plaque initiation.  
Existence and severity of psoriatic plaque is determined by intensity of Y-antigen income 
into derma (inside Mo-R and DC-R). Severity of plaque is aggavated by intensity of kPAMP 
income into derma (inside Mo-T and DC-T). Intensity of both incomes depends on SPP severity.  
Severity of plaque is aggravated by LP2-inflammation if it persists after this plaque 
initiation. New Mo-T, DC-T (incl. Mo-R, DC-R) and Y-specific T-lymphocytes are constantly 
attracted into plaques from blood flow, and so support vicious cycles. Only at decrease of SPP 
severity, these vicious cycles weaken and natural remission of plaques takes place, up to their 
complete disappearance. 
The detailed analysis comparing the new model of pathogenesis with five other previously 
published models is carried out.  
The given monograph is the authorized translation of the book, published in Russian  
(ISBN 978-5-905504-03-7; edition r1.3). 
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«Is it true that firemen put fires out instead of going to start them?» 
Ray Bradbury, «Fahrenheit 451» 
Introduction 
This book represents the second part of the monograph «Model of pathogenesis of psoriasis».  
The first part of the monograph “Model of pathogenesis of psoriasis. Part 1. Systemic psoriatic 
process” has been published earlier (Peslyak 2011). For possible reader it is highly desirable to 
complete reading of Part 1, before starting Part 2. References to concrete sections of Part 1 are used, 
if necessary.  
Part 2 is devoted to description and analysis of local processes determining skin manifestations of 
psoriatic disease - consequences of SPP – systemic psoriatic process. Their detailed description is 
given in the section "Y-model of pathogenesis". 
Research objective  
The present work represents observational and analytical research of results of experimental and 
theoretical studies on etiology and pathogenesis of psoriatic disease. The main objective of the 
monograph is construction of a new model of pathogenesis of psoriasis (further called Y-model), 
based on results of latest researches (Fig. 2-6).  
Research methods  
At creation of the second part of the book, search and analysis of works where well-based models 
of pathogenesis of psoriasis are offered have been carried out. Experimental works supporting these 
models have also been studied.  
Besides, results of important experimental researches, those not yet employed in the creation of 
models of pathogenesis of psoriasis, were studied. 
Also, publications investigating the condition of prepsoriatic skin and events initiating psoriatic 
plaque (Koebner's effect) have been analysed. Search of publications was carried out using Medline 
and Embase, publications in Russian – Central Scientific Medical Library and Scientific Electronic 
Library. Review and-or analysis of results of these researches are given at the description of 
(sub)processes. Real or prospective interaction of (sub)processes is given in the end of the 
description of dependent (sub)process. 
Abbreviations and terms 
Appendices contains decoding of conventional and new abbreviations (App. 2-1 and App. 2-1a). 
Where possible, links to Wikipedia are given in these tables. App. 2-2 contains the list of new terms 
(sample from App. 2, Part 1).  
Novelty and hypotheses 
A model cannot be called “new” if it does not contain new fragments that are absent in other 
models, including hypothetical (sub)processes and-or dependencies. All new fragments of Y-model do 
not contradict to commonly accepted facts. And some of new fragments are based on recently 
discovered facts. In the section "Discussion" and App. 2-9, the comparative analysis of Y-model with 
five other models of pathogenesis published earlier is carried out (Nestle 2009a and Nestle 2009b, 
Guttman-Yassky 2011, Tonel 2009,  Gilliet 2008, Sabat 2011). The results of this comparison are 
collected in the block «Y-model novelty», presented in the same section. Similarly to Part 1, in 
App. 2-4 references to publications explaining some local processes are given. If such publications are 
not present, a brief suggested hypothesis has been formulated.  
Some facts and assumptions 
The top layer of skin, epidermis, provides the first barrier of protection against external influence. 
Derma is separated from epidermis by the basal membrane, and contains vascular network for 
supplying with nutrients epidermis, which is lacking its own blood vessels. 
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Apparently healthy skin of patients with psoriasis (further psoriatics) without plaques (uninvolved, 
nonlesional, symptomless) is also called "prepsoriatic" or the abbreviation NLS is used (NonLesional 
Skin). Psoriatic skin is designated by the abbreviation PLS (Psoriatic Lesional Skin). Further, these 
terms and abbreviations will be used everywhere. 
NLS is characterized by mild dermal inflammation (not exceeding basal layers of epidermis), 
increased vascularity, itch, dryness, decrease of barrier function of the cornual layer, larger 
vulnerability. After psoriatic plaque (further PLS-plaque or plaque) appearance, active priming of 
surrounding skin occurs (increase of Tem concentration). The width of the priming ring depends on the 
severity, size and growth rate of plaque and can reach 5-10 centimeters. The internal border of the 
ring (directly near to plaque) by its characteristics is very close to condition of skin inside the focus of 
plaque. At relapses and aggravations the width of the ring increases, at natural remission - decreases 
(Cameron 2002, van de Kerkhof 1996, Vissers 2004).  
Immunocytes are present in both derma and in epidermis. These are epidermal dendritic LC 
(Langerhans cells) and dermal DC (DDC), macrophages (MF), mast cells and T-lymphocytes (TL). In 
the absence of inflammation, insufficient number of B-lymphocytes and NK cells is present in derma, 
and plasmacytoid DC (PDC) and neutrophils (Neu) are practically absent. All epidermal LC, as well as 
a big part of DDC (about 60%) at the homeostatis state are originated from the precursors constantly 
presented in skin. However, a smaller part (about 40%) of DDC and practically all MF are originated 
from attracted blood DC and Mo. At inflammation, LC pool starts to be replenished by blood 
CCR2+CD14+Mo attracted in skin and are gradually transformed in LC. At inflammation, the most part 
of DDC pool is replenished by blood DC and, probably, from blood Mo attracted in skin that can be 
transformed in DDC (Bogunovic 2006, Ginhoux 2007, Ginhoux 2006, Koch 2002). DDC are more 
active in presentation of antigens and make most part of traffic in regional lymph nodes. LC play the 
leading role in formation of tolerance of the skin immune system in relation to skin commensals. DDC 
provide adaptive response against bacteria and viruses during trauma or dermal infection 
(Baker 2006c). 
Similar processes of renewal of DDC and MF pools occur in NLS and PLS. The critical role of 
dermal DC and MF in initiation and development of PLS-plaques became doubtless last years 
(Clark 2006b, Jariwala 2007, Marble 2007, Wang 2006, Zaba 2009b). First of all, these are 
proinflammatory tissue CD11c+DDC, actively secreting TNF-alpha and iNOS, so-called TipDC. In 
PLS, quantity of TipDC increases in derma and sublayers of epidermis as much as 4-6 times, and the 
most part of these cells is attracted from blood flow (Lowes 2005, Zaba 2009a). The reason of activity 
of TipDC is unknown. The cause of activity of part of dermal CD68+Mo and MF, intensively secreting 
TNF-alpha, is also unknown (Fig. 2-4, Fig. 2-5). 
For the first time it has become possible to prove presence of PG in PLS with the help of 2E9 monoclonal 
antibodies in the study (Baker 2006a). PG has been found in CD68+MF and (possibly) in CD1a(-)DDC and has not 
been found in CD207+DC and CD83+DC. These results correlate with presviously obtained (Zaba 2009a) interms of 
CD11c+BDCA-1(-)TipDC expressing CD14 (and, therefore, almost not expressing CD1a (Angel 2006) and weakly 
expressing CD83).  
In spite of the fact that BDCA-1(low)CD14+DDC are less mature than BDCA-1(high)CD1a+DDC, they may carry 
out presentation and activate TL (Angel 2006).  
Precursors of BDCA-1(-)TipDC can be blood BDCA-1(-)CD14(-)CD16+slanDC (Hansel 2011) and blood 
CD14+CD16+Mo (Piccioli 2007). Among all fractions of blood DC and Mo, these cells secrete TNF-alpha in reply to 
PAMP-influence most actively. 
For the first time the assumption that antigen presented by TipDC, is a fragment of the interpeptide bridges of 
BSPG made in (Baker 2006a). However, PG has not been found in CD83+maDC. Probably, during transformation of 
DC-R and Mo-R into CD83+maDC-Y, PG fragments degraded in such a way that epitopes corresponding to 2E9 
monoclonal antibodies were not preserved. 
Presence of DC-R and Mo-R in NLS is necessary, but not enough for transformation of NLS in 
PLS. Transition of DC-R and Mo-R from passive condition in the active one can occur only during 
adaptive response against local initiating and aggravating process (further process LP2). Existence 
and development of PLS-plaque is determined by constant attraction into derma of new DC-R and 
Mo-R from blood flow (more precisely – by the quantity of PG-Y fragments brought by them). At 
decrease of the level or full termination of such attraction remission of PLS-plaque up to its full 
disappearance in connection with natural extinction of maDC-Y pool occurs. 
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Y-model of pathogenesis 
For the detailed description of Y-model, all events, both previous and concurrent with development 
of one plaque, should be divided on processes and phases. Y-model in the form of the scheme of 
interaction of local processes is represented in Fig. 2-6. Plaque development by phases is shown in 
Fig. 2-8 (colors as well as in Tab. 2.1). Initiating and aggravating process LP2 is not specified in these 
schemes. 
The most important causal dependencies are represented by color arrows. The color of an arrow 
depends on the color of a causative process. For simplification of schemes, some dependencies are 
not designated. In App.2-3, the table including all causal dependencies between processes and 
subprocesses is given. 
The more detailed interaction scheme is developed for two cases of LP2: LP2(IN) - open trauma of 
derma (Fig. 2-9) and at LP2(HPV) - HPV-carriage KC (Fig. 2-18).  
For each cytokine (active in LP2- and-or at PLS-inflammation), secreting cells and effected cells are 
specified (App. 2-7). 
Table 2-1 contains processes and phases of plaque development during constant action of SPP. 
Each phase is characterized by occurring (sub)processes (+ or *) during its duration, and also by their 
intensity. For each phase, one or two marker characterizing processes are is chosen.  
It is supposed that Y-priming of skin has already occurred and, consequently, phase 0 is absent. 
More information about phase 0 and Y-priming is given in the section «Phases of psoriatic plaque 
development». 
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Тable 2-1. Processes and phases of psoriatic plaque development  
 Prepsoriasis Psoriasis 
 Phases Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6 
The phase start determines: - LP2 start LP4 
start 
Start of 
LP5 and/or 
LP7.1 
LP8 start End of LP2, LP3  
and LP5 
Marker processes Homeostatic 
LP1 
LP2 and 
LP3  
LP4 LP5 LP5 and 
LP8 
Self-sufficient LP8 
 
 
(Sub)processes 
Comment LP2 is 
absent. 
Common  
for any LP2. 
    LP2 ended.  
Common  
for any LP2. 
  SPP Systemic psoriatic 
process. * * * * * * 
  
LP1 Attraction of 
immunocytes from 
blood flow. 
+ ++ +++ +++ +++ +++ 
  LP2 Initiating and 
aggravating process.  ++ +++ +++ +++  
  LP3 Innate response 
against LP2.  ++ +++ +++ +++  
  LP4 Trigger of adaptive 
response against LP2.   +++ ++   
  LP5 Adaptive response 
against LP2.    +++ +++  
  LP6 Mo and DC transformations.  
  LP6.1 Loss of tolerance  
to kPAMP.    ++ +++ +++ 
  LP6.2 MF and MoDC 
formation.  + ++ ++ +++ +++ +++ 
  LP6.3 maDC-Z formation.   ++ +++ +++  
  LP6.4 maDC-Y formation.    ++ +++ +++ 
  LP7 Lymph nodes. Clonal proliferation. 
  LP7.1 TL-Z formation.    ++ +++  
  LP7.2 TL-Y formation.      ++ +++ 
  LP8 False adaptive response to imaginary PsB-infection. 
 
LP8.1 Y-antigen presentation 
by maDC-Y to effector 
ThN-Y. 
    +++ +++ 
 
LP8.2 KC hyperproliferation. 
Change of skin 
architecture. Growth of 
basal membrane area 
and vascularity 
increase. 
    +++ +++ 
 
Notes to Tab. 2-1.  
Color in the first column (here and everywhere further) is used for highlighting of particular process and its 
subprocesses. An empty table cell means that (sub)process does not occur. SPP activity mark with the symbol *.  
SPP occurs constantly with intensity not depending on local processes. However, initiation and support of any 
PLS-plaque depends on SPP intensity.  Local (sub)process: + (white) - occurs with mild intensity; ++ (beige) - 
inflammatory, average intensity; +++ (pink) - inflammatory, high intensity; 
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Illustrations of interacting processes for each phase (under condition of Y-priming preceding 
PLS-plaque initiation) are presented in the series of figures. The figures corresponding to phase 1 and 
phase 6, do not depend from LP2 (Tab.2-2). 
Table 2-2. Processes and phases in figures 
 
Prepsoriasis Psoriasis 
Initial and  
aggravating  
process 
Model  
of patho-
genesis 
Graphs  
of antigenic 
presentation 
and  
Tem level 
Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6 
LP2(IN) – open 
trauma of derma Fig. 2-9 Fig. 2-10 No Fig. 2-14 Fig. 2-15 Fig. 2-16 
LP2(HPV) – Human 
Papilloma Virus – 
HPV-carriage KC 
Fig. 2-18 Fig. 2-19 
Fig. 2-11 
Fig. 2-20 Fig. 2-21 Fig. 2-22 Fig. 2-23 
Fig. 2-17 
 
In illustrations, symbols from Part 1 (Fig. 2-1, Fig. 2-2) and additional symbols offered here (Fig. 
2-3) are used. In following section the detailed description of each local process is given. 
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Local processes  
 
Process LP1. Attraction of immunocytes from blood flow.  
Renewal of pool of dermal immunocytes of non-resident origin is constant process occurring in the 
absence of local inflammation as well (Fig. 2-11). Process LP1 occurs during any of phases (Tab.2-1).  
After LP2 start, process LP1 is intensified.  
Renewal of this pool takes place due to action of chemokines, as well as AMP (antimicrobial 
proteins) and some cytokines possessing chemokine properties. All of them are produced by various 
skin cells, and their assortment and quantity depend on skin condition. Ligands of chemokines are 
certain chemokine receptors expressed by blood immunocytes. The list and description of all 
chemokines and their corresponding receptors, as well as parameters of their interaction, can be 
found in (Commins 2010) and on the resource IUPHAR (Murphy 2010). The observational information 
on chemokine receptors, chemokines and AMP, involved in the given process, can be found in two 
mutually supplementing Appendices: 
Appendix 2-5. Chemokine receptors, chemokines and AMP, certainly or possibly involved in LP1 
process. 
Appendix 2-6. Chemokine receptors and blood immunocytes. 
Subprocess LP1.1. Attraction of Mo and DC, Mo-T and DC-T (incl. Mo-R and DC-R) 
 from blood flow. 
The nomenclature of blood monocytes and dendritic cells has been recently accepted (Ziegler-Heitbrock 
2010). It is based on results of many previous studies including (Piccioli 2007, Serbina 2008, Tacke 2006).  
According nomenclature population of blood Mo consists of three fractions: Classical CD14++CD16(-)Mo 
(in the normal state - to 90%, everywhere further they are designated as CD14++Mo), intermediate 
CD14+CD16+Mo (in the norm - to 10%) and nonclassical CD14(low)CD16+Mo (in the norm to 5%). So far 
monocytes from two last fractions together taken are considered, they can be is designated as CD16+Mo. 
According to this nomenclature, the population of blood myeloid DC consists of two fractions: BDCA-1+DC 
and BDCA-3+DC. However, the fraction of CD14(-)CD16+BDCA-1(-)slanDC does not match this 
nomenclature completely, as they express CD16, and expression of BDCA-3 is not obligatory for cells of this 
fraction (Hansel 2011, Schakel 2006). Therefore, authors of reports devoted to slanDC divide the population 
of blood myeloid dendritic cells in two fractions: BDCA-1+DC (smaller) and BDCA-1(-)DC (bigger). They 
include slanDC subfraction in BDCA-1(-)DC fraction. Such divergence in classification can be explained by 
affinity of characteristics of slanDC to characteristics of CD14(-)CD16+Mo (Schakel 2006). Some authors 
believe that slanDC should be considered as monocytes, namely a part of the fraction of nonclassical 
CD14(low)CD16+Mo (Teunissen 2011).   
In Fig. 2-4 variants of origin of dermal macrophages MF (further DMF) and dermal dendritic cells DC 
(further DDC) are represented. This figure also represents the subsequent possible transformation of DDC 
and MoDC in mature dendritic cells maDC (Angel 2006, Haniffa 2009, Zaba 2009a).  
The role of chemokines and AMP, determining traffic of Mo and DC is analysed in some works 
(Bachmann 2006, Diamond 2009, Gautier 2009, Sozzani 2005). Attraction of Mo and DC from blood flow into 
derma takes place due to interaction of their chemokine receptors and chemokines expressed by endothelial 
cells and secreted in derma. This attraction occurrs at homeostasis and at inflammation due to various 
combinations of chemokine receptors and chemokines. This attraction is analysed for fraction of medium-
classical monocytes CD14+CD16+Mo (Part 1, SP8, fig. 9).  
In PLS-derma abrupt (more than 30 times) growth of BCDA-1(-)TipDC number can be seen (Zaba 2009a).  
They can originate from blood tolerized BDCA-1(-)DC, in particular from the subfraction 
CD14(-)CD16+slanDC well expressing CX3CR1 (Hansel 2011). However, they can originate from blood 
tolerized CD14+CD16+Mo those well expressing CCR2 and CX3CR1.  
Attraction of these cells from blood flow occurs first due to chemokine CX3CL1 (fractalkine) secreted by 
keratinocytes KC (Sugaya 2003) and DDC (Raychaudhuri 2001) in PLS, and, additionally, CCL2, HBD-2 and 
HBD-3, abundantly secreted in PLS-derma. 
Recently it has been proved that CD163+MF in PLS-derma are classically activated (Fuentes-Duculan 
2010), it is probable that their part originates from CD14++Mo (Fig. 2-4). 
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As it is known, at intensive inflammation the part of LC is formed from Mo and-or DC attracted from blood 
(Angel 2006, Ginhoux 2007, Ginhoux 2010). In PLS-epidermis the quantity of LC is not increased in 
comparison with the norm (Jariwala 2007, Sabat 2007). Within Y-model limits, LC may play the most 
essential role during LP5, while it still depends on LP2.  
At inflammation, CCL2 secretion (ligand of CCR2) essentially increases, therefore attraction of 
CD14++Mo, CD14+CD16+Mo, as well as parts of DC and PDC increases too.  
It has been established recently that HBD-2 and HBD-3 are ligands of CCR2 and support attraction of 
immunocytes as well as CCL2 (Rohrl 2010). At inflammation, secretion of CX3CL1 (ligand of CX3CR1) 
increases, which promotes CD16+Mo attraction. At inflammation, secretion of CCL20 (ligand of CCR6) 
increases, which strengthens attraction of CCR6+DC. At inflammation, chemerin secretion (ligand of 
ChemR23) increases, which strengthens attraction of PDC, as well as parts of DC and CD16+Mo. 
All tolerized Mo-T and DC-T (incl. Mo-R and DC-R) participate in renewal of pool of dermal macrophages 
MF and dendritic cells DC of non-resident origin. It occurs because their chemostatuses are similar to 
chemostatuses of nonactivated Mo and DC (Part 1, App. 4; App. 2-2). 
Subprocess LP1.2. Attraction of other immunocytes from blood flow.  
Homeostatic attraction of other blood immunocytes - plasmacytoid dendritic cells PDC, natural killers NK, 
neutrophils Neu, and also T-lymphocytes (TL) occurs in the absence of local inflammation as well. This 
attraction is intensified during local inflammation. It is necessary during immune responses LP3, LP5 or LP8. 
PDC play key role in LP4. Mass secretion of IFN-alpha by PDC precedes plaque development (Nestle 
2005a). Attraction of PDC in NLS-derma takes place due to the receptor ChemR23 - ligand of chemerin 
(Albanesi 2010, Nakajima 2010, Skrzeczynska-Moncznik 2009b). In PLS, chemerin is secreted both in 
epidermis and in dermal fibroblasts, while in NLS and in the norm - mainly in epidermis. NLS surrounding 
active and early PLS, is characterized by strong expression of chemerin in derma and presence of 
CD15+Neu and CD123+BDCA-2+ChemR23+pDC (Albanesi 2009). PDC traffic at homeostasis and 
inflammation in skin, besides receptor ChemR23, is also provided by receptors CXCR3 (ligand of CXCL10) 
and CXCR4 (ligand of CXCL12) (Sozzani 2010).  
The role of natural natural killers NK and NKT (TL with properties of killers) at psoriasis has been carefully 
studied for the last decade. Their distribution in NLS and PLS studied in (Cameron 2002). In one study 
(Gilhar 2002) it is shown that at injection of NK in NLS-transplant replaced to SCID-mice, PLS-plaque 
develops, which proves NK role in psoriasis pathogenesis. Later, the same researchers have made an 
attempt to define this role more precisely (Gilhar 2006). The observational study (Peternel 2009) is devoted to 
NKT role at psoriasis. Attraction of NK is carried out due to receptors CCR5, CXCR1, CXCR3, CX3CR1, 
ChemR23. 
The role of neutrophils Neu in SPP has been suggested in Part 1. Experimental decrease of Neu level in 
PLS does not render a positive influence and, hence, skin Neu are not obligatory for maintenance of already 
existing plaques (Numerof 2006). However, Neu play essential role in LP4, actively secreting LL37. Attraction 
of Neu to inflammation locus is carried out with the help of CXCR1 and CXCR2 (ligands of CXCL8 and 
CXCL1), as well as CCR2. 
Attraction of TL from blood flow is carried out with the help of CCR4, CCR6, CCR10 and CXCR3 
expressed by various TL fractions in various combinations (Teraki 2004, Kagami 2010). CCR6 is considered 
as a key receptor on attraction of Th1 and Th17 in PLS (Hedrick 2010). 
 More information about expression of chemokine receptors in immunocytes, and their interaction with 
ligands (chemokines and AMP) can be found in App. 2-5 and 2-6. 
 
LP1.1 depends on SPP. A share of Mo-T and DC-T (incl. Mo-R and DC-R) among attracted blood 
Mo and DC depends on SPP intensity. 
LP1 depends on LP3 and LP5.  From phase 2 and to phase 4 (i.e. at the prepsoriasis stage), the 
spectrum of secreted chemokines and antimicrobial proteins with chemokine properties is determined 
exclusively by LP2.  
CCL2 and CX3CL1 are actively secreted at LP2(IN), as well as antimicrobial proteins LL37, HBD-2 
and HBD-3 (Fig. 2-9). The detailed information about it is given at description of LP3(IN) and LP5(IN) 
processes. At LP2(HPV), CCL2, HBD-2 and HBD-3 are actively secreted (Fig. 2-18). The detailed 
information about it is given at description of LP3(HPV) and LP5(HPV). 
LP1 depends on LP8. After phase 5 start (i.e. after LP8 start) the spectrum of dermal chemokines 
and AMP extends, and their secretion increases. For example, HBD-2 and HBD-3 are secreted in 
large amounts (De Jongh 2005, Gambichler 2008). Thereby, the rate of attraction of all blood 
immunocytes (in comparison with previous phases) is amplified. 
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Process LP2. Initiating and aggravating process.  
LP2 is specific local inflammatory process in skin, at which conditions for initiation (and, maybe, 
support) of process LP8 - false adaptive response against PsB-infection can be created. It can occur, 
if LP3 (innate response against LP2) will be insufficient for suppression and elimination of LP2. In this 
case, LP4 switches (phase 3 begins) and then LP5 begins (phase 4 begins).  
During phase 4, conditions for LP6.1 start, and then for LP6.4 start can appear.  
Without action of these subprocesses the start and support of LP8 is impossible.  
With LP2 start - phase 2 begins, with LP2 end - phase 5 terminates (Tab.2-1, Fig. 2-8). 
If LP2 exists for long time after LP8 initiation (phase 5), it aggravates LP8 through LP3 and LP5 as 
intensive functioning of vicious cycles B and C is maintained (Fig. 2-6): 
B = {LP1.1 > LP6 > LP8 > LP1};  
C = {LP6.4 > LP7.2 > LP1.2 > LP8 > LP6}.  
If the vicious cycle B has begun acting, LP2 end may not render an influence on functioning of this 
cycle. If the vicious cycles B and C (with SPP support) appear to be self-sufficient, phase 6 begins.  
LP2 role may be played by any of the following influences and-or processes (Fry 2007b):   
 
 LP2(IN) = open trauma of derma (Fig. 2-9; Fig. 2-10; Fig. 2-11; Fig. 2-14; Fig. 2-15; Fig. 2-16; 
Fig. 2-17)  
 LP2(HPV) = HPV-carriage KC (Fig. 2-18; Fig. 2-19; Fig. 2-11; Fig. 2-21; Fig. 2-22; Fig. 2-23; 
Fig. 2-17) 
 LP2(PsB) = skin PsB-infection  
 Combustion, contact dermatitis 
 S. aureus (further SA) 
 Malassezia Species (further MS) 
 Candida Albicans (further CA). 
 
The trauma and any PsB-infection of skin are only initiating processes since, as a rule, at the very 
initial stage of PLS-plaque they are usually eliminated (rapid transition to phase 6 takes place).  
Bacterial or virus LP2 can persist in PLS-epidermis (phase 5). Diffusion of LP2 outside PLS-plaque 
on surrounding NLS can promote expansion of this plaque. Diffusion of LP2 on remote NLS provokes 
appearance of new PLS-plaques. 
Microflora in normal skin and PLS-microflora was investigated and compared several times. It is 
well-known that SA, MS and CA in PLS-plaques are found more often than in the norm and, as a rule, 
aggravate such plaques (Kozlova 2007, Fomina 2009, Balci 2009, Chiller 2001, Doern 1999, 
Gao 2008). The suggestion about their triggerring role is based also on results of studeis 
(Ashbee 2002, Lober 1982, Tomi 2005).    
However, at psoriasis the most widely spread is HPV-carriage of KC, and its rate essentially 
exceeds such one in healthy patients (Cronin 2008, Mahe 2003, Majewski 2003, Prignano 2005). It is 
interesting that prevailing HPV types depend on a region, in which researches were conducted. It is 
probable that HPV-carriage of KC is the most widespread process initiating and aggravating 
PLS-plaques. Therefore, further in processes and subprocesses connected with LP2, Y-model is 
specified and illustrated at LP2(IN) - trauma and at LP2(HPV) - HPV-carriage of KC.  
LP2 is suppressed by LP3 and LP5. 
LP2 is suppressed by LP8.2. It is not represented in schemes.  
At LP2(IN), hyperproliferation of KC promotes the prompt healing of trauma area. 
At LP2(HPV), hyperproliferation of KC reduces the time of stay of KC (including KC-v) in basal 
layers of epidermis. As a result, HPV-virions concentration goes down in intercellular space of these 
layers, and, as a consequence, the probability of HPV diffusion among basal KC decreases.   
LP2(IN). Open trauma of derma 
Trauma of NLS does not always cause the subsequent PLS-plaque initiation (it is known, the Koebner effect 
appears in 25-30% of cases). The Koebner effect is impossible, when derma remains intact and if trauma is closed 
(Kalayciyan 2007, Weiss 2002). Wound repair is always accompanied by inflammation, but only invasion of bacterial 
and virus epidermal commensals into derma can cause dermal LP3 and LP5 against them. Further everywhere we 
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consider only open trauma of derma, at which the Koebner effect, i.e. PLS-plaque initiation, is possible. During trauma 
activation of resident and attraction of blood Mo, DC and PDC occurs. While being destructed, damaged skin cells 
release intracellular proteins into the intercellular medium, including fragments of self-DNA and self-RNA. 
LP2(HPV). HPV-carriage KC  
HPV - Human Papilloma Virus (Hebner 2006, Stanley 2006, Stanley 2009). Chronic asymptomatic HPV-carriage 
of KC (including stem basal) not oncogenous or of weak-oncogenous HPV types can last for years without any 
external manifestations. Simultaneous carriage of several various HPV types is possible. Extraneous contamination 
may be developed by trauma, infection or from adjacent KC-v. 
 
For the first time, connection of psoriasis with HPV-carriage of KC of prepsoriatic and psoriatic skin was noted in 
(Favre 1998). It has been shown that epidermal flakes in 92% of psoriatics (37 people) contain DNA of EV-HPV (HPV 
types connected with epidermodysplasia verruciformis). There it has been shown that in blood of 24,5% of psoriatics 
(38 from 155) antibodies to HPV5 are detected. In the control group, they have been found in 5% of healthy subjects 
(3 of 60). The similar result has been observed for antibodies to HPV8 (43% of psoriatics against 7% controls) 
(Pfister 2003). 
 
In one study (Pfister 2003) it is shown that epidermal flakes (54 people) contain DNA of HPV5 in 74% of cases if 
the biological material is taken from PLS, and in 33%, if samples are received from NLS. At the same time, in the 
control group (20 people) DNA of HPV5 was not found.  
Similar results were received in one study (Weissenborn 1999). DNA of HPV was found in 83% of samples of skin 
taken from PLS (54 people), while in control group DNA of HPV was found in 19% (42 people). Types of HPV were 
the most common 36 (62%), 5 (38%), 38 (24%). Later, model of pathogenesis of psoriasis based only on 
EV-HPV-influence was suggested (Majewski 2003). 
Many types of HPV (including EV-HPV) are skin commensals. Skin of 74% of healthy patients (23 people) 
contains constant set of beta-HPV without any external manifestations (more than 6 months) (De Koning 2005).  
This is proved by extended research work (lasting more than 6 years), which showed  that 70% of healthy patients 
(42 people) have constant skin HPV-carriage without any external manifestations (samples undertook from forehead). 
During the term of observation, the spectrum of HPV types found in one patient, changed, but not completely.  In 48% 
of patients, at least one, but being of the same type of HPV was detected (Hazard 2007).  
However, in (Cronin 2008) it has been shown that EV-HPV-spectrum of carriage in psoriatics is similar to the 
spectrum of carriage in control groups, and any specific HPV types do not prevail. Prevalent spread of 
EV-HPV-carriage in psoriatics is connected by many authors with earlier treatment (first of all, with PUVA-therapy). 
For this reason, psoriatics (20 people), who never received UV-therapy, external or systemic immunodepressants 
were selected and enrolled in the study. Samples of NLS (forearm) and follicles of hair from brows were taken and 
investigated. The general HPV prevalence in psoriatics appeared to exceed the control group of 23 people (83% 
against 46%). EV-HPV (HPV5, HPV36) were found not more often than other types.  
Commensal HPV-carriage of KC is proved in on study (Viviano 2005), when HPV was found in PLS in 71% of 
psoriatics (38 people) and only in 58% of the control group (36 people).  
DNA of HPV is found in 87% of samples of PLS (60 of 69), and only in 44% of samples of normal skin of the 
control group (20 of 46) (p <0,001). Virus load HPVL = lg ((amount of HPV DNA) / (105 human cells)) was determined.  
It has appeared that HPVL < 2 for 40% of HPV+psoriatic samples and for 83% of HPV+norm, 2 < HPVL < 3 for 
45% of HPV+psoriatic samples and for 17% of HPV+norm and HPVL >3 for 15% of HPV+psoriatic samples and for 
0% of HPV+norm. So, it has appeared that excess of HPVL in psoriatics compared with healthy subjects from the 
control group is a reliable fact. Also, it has been shown that HPVL is significantly lower in psoriatics in the remission 
stage in comparison with the aggravation stage. HPVL increase in PLS correlates with disturbances of skin microflora, 
in particular, the number of S.aureus increases (Kozlova 2007, Fomina 2009). 
It correlates with the average value (n - number of carriers) on virus load for PLS (HPV5, n=19, HPVL=2,3); 
(HPV20, n=11, HPVL=3); (HPV36, n=41, HPVL=2). These results are presented in (Pfister 2003, Tab. 1) and for 
comparison are recalculated using the logarithmic formula for HPVL (Fomina 2009).  
The answer to the question on primacy or secondariness of increased HPV-carriage in psoriatics is in one 
research (Mahe 2003), where it is shown that the frequency of EV-HPV detection in psoriatic flakes in children 
coincides with its detection frequency in adult patients. It means that HPV-carriage is of primary character in relation 
to psoriasis initiation. In the same research it is shown that connection between EV-HPV-carriage and severity or 
duration of psoriasis is absent.  
Examination of 26 psoriatics (average age 44, average PASI 10,2) has shown 100% HPV-carriage in hair from 
brows (including hair bulb). On the average, 4,8 various types of HPV were found. Antibodies to HPV were present in 
blood of 56% of psoriatics. It was not revealed any correlation between age and quantity of found types HPV and-or 
presence of HPV-antibodies at psoriatics while such correlations it is observed at the healthy population 
(De Koning 2011). 
The results of researches listed above corresponds to the trigger role of HPV-carriage in Y-model. High % of 
HPV-carriage in psoriatics means that LP2(HPV) can be the basic trigger of PLS-plaques.   
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Process LP3. Innate response against LP2.  
During LP3, process LP1 is always intensified. If LP3 is insufficient for LP2 elimination (restraint), 
LP4 works and LP5 begins against LP2. Within LP3 limits PDC attraction from blood flow takes place, 
without which LP4 is impossible. Other immunocytes (which assortment depends on specific LP2) are 
also attracted from blood flow.  
LP3 operates simultaneously with LP2, i.e. begins at phase 2 start, and terminates at phase 5 end 
(Tab.2-1). 
LP3 depends on LP1.2. LP3 intensity is defined not only by resident, but also by non-resident 
immunocytes, such as Neu, NK, PDC and others.  
LP3 is initiated and supported by LP2. 
LP3 depends on LP5. It well-known that innate and adaptive responses strengthen each other.  
This dependence is represented only in schemes at LP2(IN) and at LP2(HPV). 
LP3 depends on LP6.2. LP3 intensity is defined by MF, formed from Mo (both resident and non-
resident origin), as well as MF-T and MF-R, formed from Mo-T and Mo-R. This dependence is not 
shown in schemes. 
LP3(IN). Innate response after trauma. 
Owing to trauma, release of AMP (antimicrobial proteins) and chemokines takes place (Fig. 2-9, Fig. 2-14). In 
particular, neutrophils Neu are the first cells that start to secrete LL37 saved in advance, and KC secrete HBD-2, 
HBD-3, LL37, CCL2, CX3CL1, etc. (Gillitzer 2001, Ishida 2008).  
CCL2, HBD-2 and HBD-3 actively support chemotaxis of blood CCR2+Mo and CCR2+DC.  
CX3CL1 actively supports chemotaxis of blood CX3CR1+Mo. Thus, intensification of LP1.1 occurs.  In the course 
of healing, all antibacterial and anti-virus systems of skin protection are activated.  
LP3(HPV). Innate response against HPV. 
KC-v (KC, infected by HPV) secrete cytokines, chemokines and AMP (in particular, IL-8, CCL2, CCL5, CXCL10, 
HBD-2, HBD-3, etc.), initiating LP3 against HPV (Chong 2006, De Andrea 2007, Kreuter 2009, Woodworth 2002). As 
a consequence, in addition to the resident, attraction of CXCR2+Neu, CCR2+Mo, CCR2+DC and CCR5+NK from 
blood flow into derma takes place. Also, attraction of CXCR3+PDC and ТL takes place (Fig. 2-18, Fig. 2-20). 
Let's notice that at HPV-affection of epithelial tissues, mRNA HBD-2 exceeds the normal range more than 1000 
times (Chong 2006), which correlates with its high level of presence in PLS (Harder 2005) and excess of mRNA 
HBD-2 in PLS in 5000 (Gambichler 2008) or 20000 (De Jongh 2005) times. 
Excess mRNA of HBD-3 in PLS in comparison with the norm is less considerable - 50 times (Gambichler 2008). 
Mo (MF) and DC interact with HPV-antigenes, secrete TNF-alpha, IL-1beta, IL-6, IL-12, IL-23. Under the influence 
of these cytokines, initial events of angiogenesis and increase of endothelium permeability appear.  
LP3 can be insufficient for complete release from HPV, but it is sufficient for restraint of its expansion and external 
HPV-manifestations. The balance between LP2(HPV) and LP3(HPV) processes leads to latent HPV-carriage.  
Intensity of LP3(HPV) can be sufficient for epidermal HPV-expansion restraint (increase of KC-v number in basal 
layers). But some types of HPV influence invasiveness of KC-v, i.e. their ability to get through the basal membrane 
into derma. For example such ability is known for HPV8, HPV16 and HPV18 (Akgul 2005, Barbaresi 2010, 
Yoshida 2008).  
Invasiveness of KC-v is raised by HPV-proteins, such as E2, E7, etc. In particular, they force KC-v to secrete 
metalloproteinases MMP (MMP1, MMP9, MMP14, etc.) actively. MMP influence permeability of basal membrane for 
KC-v and, thereby, let the beginning of dermal HPV-expansion. 
MF, NK can distinguish KC-v and destroy them (Fig. 2-20, green arrows kill) both in epidermis, and in derma 
(Woodworth 2002). At disintegration of destroyed KC-v, the whole virions and fragments of HPV-DNA containing CpG 
get to the extracellular space.  
At dermal HPV-expansion, the quantity of such virions and fragments of HPV-DNA in derma increases. On the 
other hand, in NLS-derma the most of PDC are located. It inevitably cause operation of LP4(HPV) - trigger of adaptive 
response against HPV. 
It is possible to assume that at LP2(HPV), KC-v invasiveness (depending on specific HPV types) determines 
possibility of transition from latent HPV-carriage (phase 2) to the subsequent phases up to LP8 initiation (phase 5). 
I.e. determines ability of LP2(HPV) to be initiating and aggravating process. Let's notice that the increased level of 
various MMP in NLS and PLS is well-known (Lee 2009). 
 
KC-v can process viral antigens and present them on MHC of class I (Black 2007). Thus, KC-v are transformed in 
KC-Z1 and become capable of interaction with TcN-Z1 (LP5.2). And, if TcN-Z1 is already in NLS, LP5.2(HPV) will 
begin earlier than LP5.1(HPV). 
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Subprocess LP3.1. Formation of LL37-complexes. 
LP3.1(IN). Formation of self-DNA-LL37 and self-RNA-LL37 complexes. 
At LP2(IN), KC and FB are damaged and self-DNA and self-RNA get into the extracellular dermal space. During 
LP3(IN) KC, Neu and FB actively secrete LL37 (Dorschner 2001).  
At interaction of LL37 with self-DNA and self-RNA, complexes self-DNA-LL37 and self-RNA-LL37 are formed 
(Ganguly 2009, Gregorio 2010, Nograles 2010, Tang 2010). Only in a form of such complexes, PDC are able to both 
endocytose and deliver self-DNA and self-RNA to endosomal TLR9 for interaction. 
Process LP4 (phase 3) begins when PDC endocytose complexes self-DNA-LL37 (cooperating with endosomal 
TLR9), and when PDC start to secrete IFN-alpha actively. 
Complexes self-RNA-LL37 promote DC maturation (LP6.3 and LP6.4) (Ganguly 2009, Nograles 2010). 
LP3.1(HPV). Formation of complexes self-DNA-LL37 and self-RNA-LL37 as well as CpG-LL37. 
At LP2(HPV), occurrence of self-DNA, self-RNA and HPV-DNA in the extracellular dermal space happens at 
destruction of KC-v getting from epidermis into derma. Such destruction occurs during LP3 and LP5 against HPV.  
Immune response against HPV includes increased secretion of LL37 (Conner 2002). 
At interaction of LL37 with self-DNA and self-RNA complexes self-DNA-LL37 and self-RNA-LL37 are formed.  
At interaction of LL37 with CpG-motives complexes CpG-LL37 are formed. These complexes are able to be 
endocytosed by PDC much better (than free CpG), and then be delivered to endosomal TLR9 (Hurtado 2010).   
Process LP4 (phase 3) begins when PDC endocytose free CpG-motives, complexes CpG-LL37 and 
self-DNA-LL37 (interacting with endosomal TLR9) and start to secrete IFN-alpha actively. 
Complexes self-RNA-LL37 promote DC maturation (LP6.3 and LP6.4) (Ganguly 2009, Nograles 2010). 
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Process LP4. Trigger of adaptive response against LP2. 
Active peak-like secretion of IFN-alpha by PDC, is a signal formed only during innate response LP3 
against LP2. This trigger signal provides active start of adaptive response LP5 against LP2 
(Lande 2010, McKenna 2005, Seo 2010, Tang 2010, Zhang 2005).  
This trigger starts working if LP2 intensity is combined with LP3 insufficiency.  
LP4 start determines phase 2 end and short-term phase 3 start. This short-term phase 3 terminates 
at phase 4 start, namely with the launch of adaptive response LP5 against LP2.  
During phase 4, process LP4 goes down (being suppressed) and by the time of phase 5 start, 
practically stops (Tab.2-1, Fig. 2-7, Fig. 2-8, Fig. 2-10).  
LP4 has limited duration, occuring and initiating other processes and subprocesses (LP5, LP6.2 
and LP6.3) one time (Fig. 2-6, dot-dash line).   
 
PDC produce and secrete considerable amount of IFN-alpha approximately 7 days prior to 
appearance of pinpoint psoriatic plaque. For the first time it has been proved at carrying out 
experiments with NLS-transplants transferred to AGR129-mice (Boyman 2004, Nestle 2005a). More 
information about these experiments: 
 
Appendix 2-8. Psoriasis on NLS-transplants transferred to AGR129-mice. 
 
The majority of models of pathogenesis of psoriasis, published in recent years (App. 2-9), include 
dermal PDC as obligatory components. Those dermal PDC transitively and actively secrete IFN-alpha 
before plaque development (Albanesi 2010, Gilliet 2008, Nestle 2009a, Nestle 2009b, Tonel 2009).  
When plaque has already started to develop, the level of IFN-alpha gradually decreases to the 
norm (LP4 calms down). Therefore, only in acute (but not chronic) plaques high level of MxA protein 
(which is a marker of previously high level of IFN-alpha) is detected (Fah 1995, Nestle 2005a).  
PDC continue to be involved into PLS-derma and appear there in increased amount, however they 
lose their ability to intensive secretion of IFN-alpha (despite increased level of CpG-motives or 
self-DNA-LL37 complexes). It occurs under the influence of suppressive activity of high level of 
TNF-alpha (being secreted during LP5 and-or LP8) on PDC (Palucka 2005).  
According to other data, PDC are represented also in PLS-derma, but only at early stages of 
plaque development, while at later stages they are absent (Albanesi 2010).  
 
Decrease of IFN-alpha level by a single intravenous injection of MEDI-545 (monoclonal antibodies to IFN-alpha) 
does not influence psoriasis condition. 36 psoriatics participated in this study (Bissonnette 2010). This negative result 
confirms that IFN-alpha plays only a transit role during plaque initialization.  
 
PDC attraction is carried out through their receptors CXCR3 (ligand of CXCL9, CXCL10, CXCL11) and ChemR23 
(ligand of chemerin) (App. 2-5 and 2-6). In NLS, PDC level is essentially higher than in norm.  
Levels of mRNA CXCR3 and its ligands CXCL9, CXCL10, CXCL11 are considerably increased in PLS in 
comparison with NLS, and in NLS they are significantly higher than the norm. The majo rity of CXCR3+ cells are 
localized in PLS-derma and almost all BDCA-2+PDC in PLS were CXCR3+ (Chen 2010). 
Chemerin providing attraction of PDC, is mostly secreted by fibroblasts, as well as by mast and endothelial cells 
(Albanesi 2009, Albanesi 2010).  
Increased HPV-carriage in NLS (Favre 1998, Prignano 2005) can cause increased secretion of both chemerin and 
CXCL10. Attraction of PDC during LP3 plays important preparatory role. 
Condition for LP4 launch is an increased level of CpG-motives (or self-DNA-LL37 complexes) in the amount 
sufficient for activation of PDC, which massive secrete IFN-alpha. At psoriasis, LL37 are secreted by KC in all layers 
of epidermis (initially KC have its stocks in granules). LL37 is also represented in derma near to PDC accumulation. 
Fibroblasts and-or Neu can produce it (Lande 2007, Gilliet 2008).  
At LP2 (PsB) Neu secrete LL37 in large amounts as they contain its stocks in granules (Dorschner 2001). Blood 
Neu are involved through CXCL8 (IL-8), secreted by Mo and MF in reaction to PsBP (in particular, PG-Y). 
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LP4 depends on LP1.2. Increased level of PDC arrived from blood flow in the area of future plaque 
development provides intensity of subsequent LP4.  
LP4 depends on LP2. Intensity of LP2 at insufficiency of LP3 makes LP4 inevitable. At LP2(IN) this 
dependence is defined by the amount of self-DNA and self-RNA getting to the extracellular space. At 
LP2(HPV) this dependence is defined by the amount of CpG-motives. 
LP4 depends on LP3. Insufficiency of LP3 at intensity of LP2 makes LP4 inevitable. At LP3(IN), the 
amount of secreted LL37 determines the amount of formed self-DNA-LL37 and self-RNA-LL37 
complexes. At LP3 (HPV) the amount of HPV-DNA in the extracellular dermal space is determined by 
cytotoxic activity of NK, Mo and MF. 
LP4 is suppressed by LP5. It occurs because of TNF-alpha, increased level of which is formed 
during LP5. If this suppression appears insufficient, additional suppression takes place from the 
moment of LP8 start (it is not shown in schemes and figures). 
LP4(IN). Trigger of adaptive response after trauma.  
PDC endocytose self-DNA-LL37 and self-RNA-LL37 complexes, formed during LP3.1(IN). Inside PDC they are 
delivered to endosomal TLR7 and TLR9 and interact with them (self-DNA-LL37 with TLR9, self-RNA-LL37 with TLR7). 
Thereof PDC in large quantities secrete IFN-alpha (Ganguly 2009, Gregorio 2010, Nograles 2010, Tang 2010). 
Such mechanism of activation PDC also works in case of combustion or contact dermatitis when the commensal 
(pathogenic) invasion almost or absolutely is not present. Owing to trauma irrespective of commensal (or pathogenic) 
invasions PDC intensively secretes IFN-alpha (Fig. 2-9, Fig. 2-14). It occurs right after traumas, therefore phase 2 
which take place at HPV-carriage, is absent. 
LP4(HPV). Trigger of adaptive response against HPV.  
During HPV-expansion, PDC react through TRL9 to increased concentration of HPV-DNA - fragments of dsDNA 
(two-chained DNA), containing CpG (Fig. 2-18, Fig. 2-21).  
Such reaction develops at active epidermal HPV-expansion, and is almost inevitable at attempt of dermal 
HPV-expansion, i.e. at carriage of invasive HPV types.  
PDC endocytose HPV-DNA, CpG-LL37 complexes (LP3.1(HPV)), so that CpG optimally gets to endosomal TLR9. 
As a result of interaction of CpG with TLR9, PDC secrete IFN-alpha intensively. At that, TNF-alpha and small amount 
of IL-6 are also being secreted.  
Intensive secretion of IFN-alpha is a signal to LP5(HPV) start - adaptive response against HPV. During LP5(HPV), 
effector Tem-Z should at least promote suppression of HPV-expansion and, as maximum, - complete destruction of 
KC-v, i.e. HPV-carriage termination. 
Increase of amount of dermal PDC at HPV-carriage was studied only for oncogenous types of virus (HPV16, 
HPV33 and HPV18). Attraction of PDC in derma also takes place through CXCR3, being a ligand of CXCL10, 
secretion of which at HPV-carriage is essentially increased (Santegoets 2008, van Seters 2008). It is possible to 
assume that the increase of PDC amount observed in NLS is connected with latent HPV-carriage of other types 
(Favre 1998).  
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Process LP5. Adaptive response against LP2.  
Trigger process LP4 provides active start of LP5 – adaptive response against LP2 (Lande 2010, 
McKenna 2005, Seo 2010, Tang 2010, Zhang 2005).  
Processing and presentation of Z-antigens (Z1 or Z2) can be carried out by both maDC (LP5.1), 
and KC (LP5.2) (Nestle 2009a). This possibility for KC is considered only at LP2(HPV), since at 
LP2(IN) it is supposed to be insignificant. 
At LP2(HPV), Z1 is a dominant HPV-antigen presented through MHC class I and distinguished by 
TcN-Z1, and Z2 is a dominant HPV-antigen, presented through MHC class II and distinguished by 
ThN-Z2. For example, at LP2(HPV16) Z1 is mainly E6, and at Z2 is mainly E2 (Stanley 2009). 
As a result of interaction with maDC-Z or with KC-Z1 effector Tem-Z are activated, proliferate and 
secrete cytokines (Clark 2010).  
At LP2(IN), Tem-Z mainly consist from ThN-Z, and at LP2(HPV), Tem-Z mainly consist from helper 
ThN-Z2 and cytotoxic TcN-Z1. Interaction of TcN-Z1 and KC-Z1 leads to destruction of KC-Z1.  
Cytokines secreted by Tem-Z, influence FB and KC. 
KC and FB secrete chemokines and AMP with chemokine properties.  
These are CCL2, CCL20, CX3CL1, LL37, HBD-2, HBD-3 and others, assortment of which depends 
on concrete LP2. Thereby, LP1 is intensified. 
Process LP5 exists during phases 4 and 5 (Tab.2-1). LP5 start determines transition of NLS in 
phase 4. If during phase 4 dermal secretion of cytokines-deprogrammers IFN-gamma and GM-CSF is 
sufficient to start LP6.1, launch of LP6.4 becomes possible.  
If action of LP6.4 provides enough maDC-Y, preconditions for LP8.1 start , i.e. phase 5, will appear. 
During phase 5, active coexistence and interaction of processes LP2, LP3, LP5 and LP8 take 
place. Process LP4 becomes suppressed while level of TNF-alpha increases. 
To provide certain duration of phase 5, it is necessary to achieve the state when processes do not 
suppress but support each other (for example, at LP2(HPV)). Otherwise, phase 5 will not be able to 
last long (for example, at LP2(IN)) and, either plaque will be able to pass into phase 6, or return to 
phase 4.  
LP5 depends on LP1.2. First of all, it depends on income from blood flow of Tem-Z already 
presented in it or are recently formed during subprocess LP7.1. 
LP5 depends on LP2. For LP5 begins because of LP2, operates against LP2 and comes to the end 
at LP2 completion. 
LP5 depends on LP3. Innate and adaptive responses strengthen each other. This dependence is 
represented only in schemes at LP2(IN) and LP2(HPV). 
LP5 depends on LP4. IFN-alpha also influences activation of Tem-Z, especially, if LP2 is a virus (in 
particular HPV) (Seo 2010, Zhang 2005). IFN-alpha promotes activation of Th1 and increase their 
secretion of IFN-gamma (Eriksen 2005). Besides, LP6 is intensified during LP4. And since LP5 
depends on LP6.2 and LP6.3, LP5 (indirectly through LP6) depends on LP4. 
LP5 depends on LP6. First - the more maDC-Z is formed, the more intensity of LP5.1 is. And, 
secondly, all Mo and DC (irrespective of their origin) transformed during LP6 secrete TNF-alpha, 
IL-1beta, IL-12, IL-23, etc. and thus actively influence LP5.  
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Subprocess LP5.1. Z-antigen presentation by maDC-Z to effector Tem-Z. 
This process interacts with subprocess LP6.3 as intensity of presentation depends on maDC-Z amount, 
and maDC-Z continue maturation during presentation.  
LP5.1(IN).  
Tem-Z, resident and involved from blood flow are mostly ThN-Z.  
maDC-Z process and present Z-antigens to ThN-Z (Fig. 2-9; Fig. 2-15; Fig. 2-16). At that, ThN-Z are activated, 
proliferate and secrete TNF-alpha, IFN-gamma, IL-17 and IL-22 (Eyerich 2009, Sasaki 2011), and maDC-Z secrete 
IL-12 and IL-23.  
LP5.1(HPV).  
Tem-Z, resident and coming from blood flow are mainly TcN-Z1 and ThN-Z2.  
Cytotoxic TcN-Z1 are formed as a result of interaction with maDC-Z1, carrying out cross-presentation of virus 
Z1-antigen on MHC class I.  
TcN-Z1 are intended for KC-v destruction.  
Helper ThN-Z2 are formed as a result of interaction with maDC-Z2 that present virus Z2-antigen on MHC class II.  
ThN-Z2 are intended for coordination and intensification of immune response against HPV, as a whole. 
maDC-Z (maDC-Z1 and maDC-Z2) process and present endocytosed Z-antigens (Z1 and Z2) to Tem-Z (TcN-Z1 
and ThN-Z2, accordingly) (Fig. 2-18; Fig. 2-22; Fig. 2-23). At that, Tem-Z are activated, proliferate and secrete 
TNF-alpha, IFN-gamma, IL-17, IL-22, and maDC-Z secrete IL-12 and IL-23.  
Subprocess LP5.2(HPV). Z1-antigen presentation by KC-Z1 to effector TcN-Z1. 
KC-v can process virus antigens and present them on MHC class I. At that, KC-v are transformed into 
KC-Z1 (LP3(HPV)). Interaction of TcN-Z1 and KC-Z1 leads to destruction of KC-Z1. IFN-gamma intensifies 
this subprocess (Black 2007). 
At that, TcN-Z1 are activated, proliferate and secrete TNF-alpha, IFN-gamma, IL-17, IL-22. 
If HPV-infection in the given site is not a primary one, skin is Z-primed, i.e. already contains TcN-Z1 and 
ThN-Z2.  
I.e. in Z-primed skin subprocess LP5.2(HPV) can begin right after KC-Z1 formation. In particular, before 
LP5.1(HPV) start. 
In the norm, the most part of Tem is located in derma, and the smaller one - in epidermis (Clark 2006a). 
Epidermal Tem are located mainly in basal and spinous layers. The beginning of pinpoint plaque is mutually 
connected with active attraction of dermal CD8+TL (i.e. TcN) in epidermis (Nestle 2009a, Nestle 2009b, 
Tonel 2009).  
It is known that long latent HPV-carriage is possible, in particular, because LC practically do not react to 
HPV existence in epidermis. And only dermal DC appear to be capable of it (Stanley 2009).  
It is possible to assume that at LP2(HPV) subprocess LP5.2 is the very first link of adaptive response 
against HPV (phase 4 start).  
Processes LP5.2 and LP5.1 strengthen each other.  
At destruction of KC-Z1, great amount of virus antigens (in particular, Z1 and Z2) enter the extracellular 
space, then being absorbed by phagocytes, including dermal Mo, MoDC and DC. Hence, maDC-Z amount is 
enlarged that intensifies LP5.1.  
On the other hand, dermal interaction of maDC-Z1 with TcN-Z1 leads to their proliferation and activation 
and, hence, the larger amount of dermal TcN-Z1 can get to epidermis for participation in LP5.2.  
And, if phase 4 appears intensive enough, LP6.1 and LP6.4 can begin during it, and LP6.2 can be 
activated.   
In plaque the most part of epidermal TL is CD8+ (i.e. TcN), and the most part of dermal TL is CD4+ (i.e. 
ThN) (Cameron 2002). 
If processes LP3 and LP5 fail to stop LP2(HPV) because of accelerated desquamation of KC-v, the 
number of virions produced per one unit of time multiplies, and that leads to increase of probability of 
infection of other skin areas. 
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Process LP6. Mo and DC transformations. 
Process LP6 consists of four subprocesses (Tab. 2-3). All dermal Mo and DC have possibility to be 
transformed. How this transformation will occur depends on their type and origin (resident or non-
resident). And also from phase of psoriatic plaque development. 
During phase 1 (homeostatic condition) only LP6.2 partly develops (Mo are transformed in MF, 
Mo-T in MF-T and Mo-R in MF-R), and subprocesses LP6.1, LP6.3 and LP6.4 do not take place at all. 
With the beginning of LP2-inflammation (phase 2) other subprocesses LP6 begin and will be 
intensified during the subsequent phases (Fig. 2-8). 
Loss of tolerance of PG-Y(-)Mo-T, PG-Y(-)DC-T and PG-Y(-)MoDC-T (LP6.1) gives the chance of  
their participations in LP6.2 and LP6.3. In the right part of Tab. 2-3 all possible transformations of 
these cells are specified.  Thus it is meant that they are PG-Y(-). 
Loss of tolerance of Mo-R, DC-R and MoDC-R (LP6.1) is necessary for their subsequent 
transformations (LP6.2 and LP6.4). The table-cells of Tab. 2-3 containing PG-Y(+) cells, are allocated 
by beige color. 
Possibly, subprocess LP6.1 (loss of tolerance) and subprocesses LP6.2, LP6.3 and LP6.4 occur 
simultaneously strengthening each other. Process LP6 is included into the vicious cycle B. 
Table 2-3. Dermal Mo and DC transformations  
Formation subprocesses  
Origin 
LP6.1. 
Loss of 
tolerance 
LP6.2.  
MF и MoDC 
LP6.3.  
maDC-Z 
LP6.4.  
maDC-Y 
 Mo > MF   
Mo 
 Mo > MoDC MoDC > maDC-Z  
Non-resident and 
resident 
DC   DC > 
maDC-Z 
 
* Mo-T > MF-T   
PG-Y(-)Mo-T 
* Mo-T > MoDC-T MoDC-T > maDC-Z  
* Mo-R > MF-R   
Mo-T 
Mo-R 
* Mo-R > MoDC-R  MoDC-R > maDC-Y 
PG-Y(-)DC-T *  DC-T > 
maDC-Z 
 
Non-
resident 
only 
DC-T 
DC-R *   DC-R > 
maDC-Y 
 
 
These transformations occur at trauma (Fig. 2-9; Fig. 2-14; Fig. 2-15; Fig. 2-16) and at 
HPV-expansion (Fig. 2-18; Fig. 2-21; Fig. 2-22; Fig. 2-23). 
LP6.2 and LP6.3 begin due to LP4 - under influence (IFN-alpha + TNF-alpha) and are activated 
during LP5 (phase 4), and then cooperative action of LP5 and LP8 (phase 5) - under cumulative 
influence of IFN-gamma, TNF-alpha, IL-12 and IL-1beta.  
If both LP3 and LP5 stop expansion or completely eliminate LP2, then LP6.3 also stops.  
And, if for maintenance of subprocesses LP6.1, LP6.2 and LP6.4, LP8 appears to be enough, 
self-sufficient phase 6 begins.  
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In Fig. 2-4 variants of origin of dermal macrophages DMF and dermal dendritic cells DDC are represented. In the 
absence of inflammation, population of dermal macrophages FXIIIa+CD14+MF by 60% consists of cells, derived from 
dermal stem cells-precursors i.e. have resident origin. The rest 40% of DMF have non-resident origin, as they 
transform from CD14++Mo and CD14+CD16+Mo involved from blood flow. At local inflammation, total DMF number 
per unit of dermal volume is enlarged, first of all at the expense of attraction and subsequent transformation of blood 
Mo, at that share of DMF of resident origin decreases to 30%, and share of DMF of non-resident origin increases to 
70%.  
Dermal dendritic cells DDC have unique receptor CD11c and consist of two basic fractions CD14+DC (mainly 
BDCA-1(-)) and CD1a+DC (mainly BDCA-1+) (Haniffa 2009).  
In the absence of inflammation, CD1a+DC are located mainly in the top part of derma, and CD14+DC are 
distributed everywhere, including vascular areas (Angel 2006).    
Even in the absence of inflammation, the most part (80-90%) of both DDC fractions has non-resident origin, and 
only 10-20% originate from dermal stem cells-precursors.  
At local inflammation, a share of DDC of non-resident origin becomes maximal (up to 100%). In the absence of 
inflammation, non-resident DDC mainly originate from DC, those involved from blood flow (Haniffa 2009). At 
inflammation, DDC pool of non-resident origin (first of all, BDCA-1(-)DC fraction) is actively renewed. It occurs due to 
attraction of BDCA-1(-)DC from blood flow and also due to the intradermal transformation of some of involved blood 
monocytes Mo in MoDC. The most capable of such transformation are CD14+CD16+Mo, i.e. the fraction of blood 
monocytes which can be under chronic kPAMP-load tolerized much easier, and this fraction becomes 
CD14+CD16+Mo-T (incl. CD14+CD16+Mo-R)  (Part 1, SP8).  
 
Subprocess LP6.1. Loss of tolerance to kPAMP.  
Loss of tolerance (deprogramming) of tolerized Mo-T, DC-T and MoDC-T (incl. Mo-R, DC-R and MoDC-R) 
develops under the influence of cytokines-deprogrammers GM-CSF and IFN-gamma (Adib-Conquy 2002, 
Cavaillon 2008, Kylanpaa 2005, Randow 1997).  
DC secrete IL-12 during their maturation (LP6.3 and LP6.4). Th1 and Tc1 secrete IFN-gamma under the 
influence of IFN-alpha, and also at interaction with maDC (LP5 and LP8). IL-12 actively influences Th1, Tc1 
and NK all secreting IFN-gamma. Thus, IL-12 also indirectly promotes loss of tolerance (Randow 1997).  
KC, FB, etc. secrete GM-CSF, it occurs under the effect on EGFR receptor, and also under the influence 
of IL-17 (Koga 2008, Mascia 2010). Besides, during activation and differentiation, TL also secrete GM-CSF 
(Male 2006, Shi 2006). 
Subprocess LP6.1 covers all Mo-T, DC-T and MoDC-T (incl. Mo-R, DC-R and MoDC-R). These cells  
involved in skin prior to the beginning of inflammation (or during inflammation) lose tolerance. This 
subprocess begins during phase 4 and reaches its maximum during phases 5 and 6 (Tab.2-1). 
As soon as tolirized phogocytes (incl. R-phagocytes) get to non-inflamed tissues (for example, in NLS-derma), 
kPAMP-load having influenced them in blood flow disappears. Tolerized phagocytes gradually degrade earlier 
endocytosed F-content, as kPAMP-load is absent in non-inflamed tissues. Simultaneously, spontaneous gradual loss 
of tolerance takes place - the level of blocking proteins decreases. In non-inflamed tissues, in tolerized phagocytes, 
degradation of previously endocytosed F-content advances decrease of the level of blocking proteins and, as a 
consequence, tolerized phagocytes are transformed into normal phagocytes. Such transformation of a specific 
tolerized phagocyte on the average takes several days, with duration being longer in case of stronger and prolonged 
previous (influencing blood flow) kPAMP-load (depth of reprogramming) (Fitting 2004).  
Depth of reprogramming of Mo-T and DC-T  (incl. Mo-R and DC-R) involved into derma determines the level of 
intensity of local inflammation, sufficient for their loss of tolerance (Adib-Conquy 2002). If tissues are inflamed Mo-T 
and DC-T  involved from blood flow appear to be under the influence of cytokines-deprogrammers IFN-gamma, 
GM-CSF and quickly lose tolerance. It is observed, in particular, in connection with rapid decrease of the level of 
blocking proteins (IRAK-M, etc.). And, if this loss occurs before complete degradation of previously endocytosed 
F-content, R-phagocytes are activated. Activation of Mo-T (Mo-R) promotes their transformation in MF-T and MoDC-T 
(in MF-R and MoDC-R) and active secretion of proinflammatory cytokines (LP6.2).  
Tab. 2-3
MoDC-R and DC-R are activated and become mature (LP6.4), which, in the presence of previously endocytosed 
F-content, leads to secretion of proinflammatory cytokines (IL-12, IL-23 etc.) and presentation of antigens contained in 
F-content (including Y-antigen). And, if the local immune system considers Y-antigen pathogenic along with adaptive 
response against Z-antigen (LP5), false adaptive response against Y-antigen (LP8) can develop.  
Subprocess LP6.2. MF and MoDC formation.  
During this subprocess, transformation of Mo (irrespective of origin) in MF and MoDC, PG-Y(-)Mo-T (of 
non-resident origin) in PG-Y(-)MF-T and PG-Y(-)MoDC-T, as well as Mo-R (of non-resident origin) in MF-R 
and MoDC-R takes place. 
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Formation of MF occurs constantly - with low intensity during phase 1, with average intensity during 
phases 2 and 3 and with high intensity during phases 4, 5 and 6 (Tab.2-1). 
Active formation of MoDC begins during phase 3, under the influence of IFN-alpha and TNF-alpha 
secreted by PDC during LP4. Presence of PAMP (outside or inside) of Mo activates their transformation in 
MoDC. Activity of these formations in all subsequent phases 4, 5 and 6 depends on intensity of LP5 and LP8. 
Mo (MF) endocytose and-or contact with LP2-content (including both Z-antigens and PAMP).  
Having lost tolerance Mo-T (incl. Mo-R) and MF-T (incl. MF-R) also react to kPAMP endocytosed in blood 
flow. As a result, all of them are activated and secrete TNF-alpha, IL-1beta, IL-12 and IL-20 (Clark 2006b, 
Fuentes-Duculan 2010, Wang 2006).Mo (MF), which endocytose LP2-content, do not have special 
designation for their difference from inactive Mo (MF), because these differences are not principal for 
Y-model. During phase 6, the majority of active MF are MF-T and/or MF-R. 
Under their characteristics PG-Y(-)MF-T and MF-R are indistinguishable, as after transformation in MF 
presence PG-Y in F-content ceases to play any role. Their secretory activity is defined by volume of kPAMP, 
containing in F-content.    
 
Subprocess LP6.3. maDC-Z formation.  
Subprocess begins with average intensity during phase 3, high intensity during phases 4 and 5, weaken at 
the end of phase 5 and is absent during phase 6 (Tab.2-1). 
DC and MoDC endocytose LP2-content (including PAMP and Z-antigens), secrete TNF-alpha, IL-12 and 
IL-23. Under the influence of IL-12 and IL-23 acceleration of their maturation (self-activation) takes place. 
Their maturation is also positively influenced by the combination IFN-gamma and IL-1beta. DC and MoDC 
process bacterial or virus fragments containing Z-antigen, form complexes of MHC class II with Z-antigen and 
transport them to the cell wall (Sabat 2007). After that, maDC-Z appear to be ready for the beginning of 
Z-antigen presentation. So, transformation of DC and MoDC (both of non-resident and resident origin) takes 
place in maDC-Z.  
Loss of tolerance of PG-Y(-)DC-T and PG-Y(-)MoDC-T (LP6.1) gives the chance of their similar behavior, 
i.e. transformation in maDC-Z.  
Z-antigen presentation to effector Tem-Z occurs during subprocess LP5.1. Final maturation of maDC-Z 
occurs during interaction with Tem-Z, i.e. LP6.3 and LP5.1 are interdependent.  
Subprocess LP6.4. maDC-Y formation.  
The subprocess begins during phase 4 and proceeds with high intensity during phases 5 and 6 (Tab.2-1).  
Having lost tolerance DC-R and MoDC-R secrete TNF-alpha, IL-12 and IL-23. Under the influence of 
IL-12 and IL-23 acceleration of their maturation (self-activation) takes place. Their maturation is also 
positively influenced by the combination of IFN-gamma and IL-1beta. DC-R and MoDC-R process F-content 
(containing kPAMP and PG-Y), form complexes of MHC class II with Y-antigen and transport them to the cell 
wall. After that, maDC-Y appear to be ready to begin Y-antigen presentation (Sabat 2007).  
DC-R and MoDC-R having insufficient PG-Y content are incapable of transformation into maDC-Y. Such 
cells will show the activity similarly to MF-R. Only DC-R or Mo-R can be precursors of maDC-Y.  
Y-antigen presentation to effector ThN-Y occurs during subprocess LP8.1. Final maturation of maDC-Y 
occurs during interaction with ThN-Y, i.e. LP6.4 and LP8.1 are interrelated.  
Fig. 2-5 is continuation of Fig. 2-4. In this figure, basic fractions of maDC found in PLS-derma are illustrated 
(Angel 2006, Haniffa 2009, Zaba 2009a). This figure illustrates characteristics of maDC formed during subprocesses 
LP6.3 and LP6.4. 
Mature dendritic cells maDC in PLS can be divided into two groups: BDCA-1+maDC and BDCA-1(-)maDC. 
CD208+maDC (CD208=DC-LAMP) are, basically, BDCA-1+maDC, and almost all TipDC are BDCA-1(-)maDC 
(Zaba 2009a).  
Many cells from slanDC in PLS become maDC. At least those of them that actively secrete TNF-alpha, iNOS and 
IL-23 and fall under the definition of TipDC. Unfortunately, expression of CD80, CD83 (characterizing maturity 
receptors) in slanDC in PLS is not studied in these investigations (Hansel 2011, Schake 2006). However, fractions of 
mature slanDC (yellow oval) and TipDC (brown oval) are crossed only partly. Not crossed parts can be distinguished 
on expression CD16 (expression CD14 at maturation of DC vanishes). Mainly, slanDC are CD16+, and TipDC 
originate from blood CD14++CD16(-)Mo and CD14+CD16+Mo, and, hence, expression CD16 is not obligatory for 
them (Teunissen 2011).  
Here, in contrast to (Zaba 2009a), based on the results of (Haniffa 2009), it is supposed that not all 
BDCA-1+maDC have resident origin, the part of them originate from non-resident BDCA-1+DC. 
Besides, BDCA-1(-)maDC are CD14(low)CD163(low) and have the size 20% less than BDCA-1+maDC, which 
allows assumption of their different origin. Namely, BDCA-1+maDC apparently origin from BDCA-1+DC, and 
BDCA-1(-)maDC - from CD14+MoDC (larger part) and from BDCA-1(-)DC (smaller part).  
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Blood Mo, on the average, have the smaller size, than blood DC, and their transformation in MoDC at 
inflammation, as a rule, is fast (up to 18 hours) and accompanied by division (Eberl 2009). It is possible to assume 
that new cells formed in the course of fast division of Mo, their transformation in MoDC and subsequent maturation, do  
not have enough time for growth as in case with BDCA-1+DC at maturation without division. At maturation DC and 
MoDC lose receptors CD14 and CD163 and express receptors CD80, CD83, etc., inherent for maDC.  
The larger part of TipDC (actively secreting TNF-alpha and iNOS) has non-resident origin, it is possible to assume 
that they originate mainly from blood CD14+CD16+Mo-T (incl. CD14+CD16+Mo-R). The fact that they undergo 
division before transformation in CD11c+maDC means decrease of F-content content (including PG-Y) per one cell. 
After all, at each division F-content is divided between daughter cells, and F-content degrades during division and 
transformation of Mo-T in MoDC-T (incl. Mo-R in MoDC-R).  An essential part of CD208+maDC is also of non-resident 
origin, it is possible to suggest that they develop mainly from blood DC-R. At sufficient content of kPAMP (incl. PG-Y), 
transformation of DC-R into maDC-Y occurs quickly and without preliminary division.  
On the average, F-content volume (including PG-Y) in Mo-R and in DC-R at the moment of their entering from 
blood flow into derma is approximately identical.  Considering their further dermal transformations (with division and 
transformation and without division and transformation, respectively) it is possible to assert that F-content volume 
(including PG-Y) in one maDC-Y, derived from DC-R, will be several times higher, than in one maDC-Y, derived from 
Mo-R.  
Possibly therefore mainly BDCA-1+maDC-Y provide presentation of Y-antigen to ThN-Y (LP8.1). The majority of 
BDCA-1(-)maDC are TipDC, which because of the smaller volume of F-content (including PG-Y), are more similar to 
active MF (Dominguez 2010). 
These assumptions are proved by the data on colocalization of 
CD208+maDC and ThN in PLS-derma and dermal lymphoid tissues (Guttman-Yassky 2011, Nograles 2010). 
During phase 4, all maDC (irrespective of their origin) can present only Z-antigens (i.e. they are maDC-Z). During 
phase 5, maDC of resident origin can present only Z-antigens (i.e. can be only maDC-Z), and maDC of non-resident 
origin can present either Z-antigens, or Y-antigens (i.e. can be either maDC-Z, or maDC-Y). During phase 6, maDC of 
resident origin present nothing, and maDC of non-resident origin can present only Y-antigens (i.e. can be only 
maDC-Y). 
DC are sensitive to the influence of ultraviolet type B (UV-B) and under its influence can be inactivated and even 
may die. As a result, LP6 stops and the vicious cycle B weakens. It determines the seasonal nature of psoriasis and 
efficiency of helium - and UV-therapy leading to transitory remission (Gudjonsson 2004, Male 2006). 
As formation of maDC-Z (LP6.3) and maDC-Y (LP6.4) depends on the phase, it is also fair in 
respect of presentation (Fig. 2-10). These are conditional graphs of specific antigenic presentation by 
maDC (the amount of antigen presented by maDC in a unit volume of derma).   
IYD - the graph for Y-antigen (presented by maDC-Y), and IZD – the graph for Z-antigen 
(presented by maDC-Z).  
 
Interdependence between LP6 subprocesses (Fig. 2-7). 
LP6.1 depends on LP6.2, LP6.3 and LP6.4. MoDC during its formation secrete IL-12, and both 
maDC-Z and maDC-Y release a lot of IL-12. It promotes secreting IFN-gamma by Th1, Tc1 and NK. 
Thereby, IL-12 (indirectly through IFN-gamma) influences loss of tolerance (Randow 1997).  
LP6.2 depends on LP6.1. Intensity of formation of MF-T and MoDC-T (incl. MF-R and MoDC-R) 
depends on the rate of loss of tolerance of Mo-T, DC-T (incl. Mo-R, DC-R).  
LP6.3 depends on LP6.2. The more MoDC is formed, the more mature maDC-Z can be formed. 
LP6.4 depends on LP6.1. Intensity of formation of maDC-Y depends on the rate of loss of tolerance 
by Mo-R, DC-R and MoDC-R.  
LP6.4 depends on LP6.2. The more MoDC-R is formed, the more mature maDC-Y can be formed. 
 
Other dependencies. 
LP6 depends on LP1.1. The more Mo-T and DC-T (incl. Mo-R and DC-R) arrive in derma, the more 
of them can be deprogrammed and lose tolerance (LP6.1). At inflammation, the most part of dermal 
MF and DC is formed from blood Mo and DC.  
LP6.3 and LP6.4 depend from LP3.1. Self-RNA-LL37 complexes formed during LP3.1 cause 
activation of DC. It occurs through endosomal TLR8 and leads to secretion of TNF-alpha and IL-6 and 
maturation of DC in maDC.  
Self-RNA-LL37 complexes are found in PLS-derma and colocalizated with maDC. Their quantity correlates with 
CD208+maDC quantity. PLS-biopsy samples were received from 11 psoriatics. The complexes were not found in 
three of them, in two subjects the quantity of these complexes did not differ from the norm, and only in 6 psoriatics the 
quantity of the complexes considerably exceeded the norm (Ganguly 2009, fig.8).  
It is probable that excess over the norm is caused by PLS (in the biopsy site) being in phase 5, i.e. LP3.1 still 
continued. It can be, for example, LP3.1(HPV). The quantity of complexes within the norm (and also their absence) 
means that PLS (in the biopsy site) was in phase 6, i.e. LP2 (and also LP3, LP4 and LP5) terminated completely.  
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LP6 depends on LP4. Under the influence of IFN-alpha, Mo and DC increase expression of 
PAMP-receptors. 
IFN-alpha promotes formation of MoDC (Farkas 2008, Farkas 2011). And cooperation of IFN-alpha 
with TNF-alpha accelerates this formation (Guzylack-Piriou 2006). IFN-alpha also accelerates 
maturation of DC, which, at that, secrete IL-12 more actively (Piccioli 2007).  
After PDC have executed their role in LP4, they can be transformed into maDC to act further in 
LP6.3 (Zhang 2005).  
LP6.1 depends on LP5. Dependence on LP5 is principal prior to phase 5 start, when LP8 has not 
begun yet. Without intensive LP5, LP6.1 start is impossible. During LP5, activated Th1-Z (Tc1-Z) 
secrete a lot of IFN-gamma. In particular, the Koebner effect is impossible at dermal only (without 
epidermal) or at epidermal only (without dermal) trauma at the absence of conditions for entering skin 
commensals into derma. Only simultaneous traumas of epidermis and derma create conditions, at 
which dermal adaptive response LP5 can begin (Weiss 2002). And at intensive LP5, IL-12, 
IFN-gamma and GM-CSF can be secreted in the amount big enough for LP6.1 start. 
LP6.2, LP6.3 and LP6.4 depend from LP5. Intensity of secreted TNF-alpha, IL-1beta, IL-6 and 
IFN-gamma (at interaction maDC-Z with Tem-Z or mediated by FB and KC), determines the degree of 
transformation intensity of all Mo and DC. In particular, final maturation of maDC-Z occurs during 
interaction with Tem-Z (Guzylack-Piriou 2006).  
LP6.1 depends on LP8. Activated Th1-Y secrete IFN-gamma and GM-CSF. This is the way, how 
process LP8 influences the intensity of process LP6.1. This dependence is principal for transition from 
phase 5 to phase 6 (Fig. 2-7, Fig. 2-8, letter B). Without this dependence, process LP8 will not 
become self-sufficient and, hence, phase 6 will not begin. 
LP6.2, LP6.3 and LP6.4 depend from LP8. Intensity of secreted TNF-alpha, IL-1beta, IL-6 and 
IFN-gamma (at interaction of maDC-Y with ThN-Y or mediated by FB and KC), determines the degree 
of transformation intensity of all Mo and DC. In particular, maDC-Y finally mature during interaction 
with ThN-Y (Guzylack-Piriou 2006). 
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Process LP7. Lymph nodes. Clonal proliferation.  
This process is well-known and can occur during adaptive response. Subprocess LP7.1 takes place 
during LP5, and subprocess LP7.2 - during LP8. During phase 4 only LP7.1 can occur, during phase 5 
– both LP7.1 and LP7.2, and during phase 6 – LP7.2 only (Fig. 2-13). 
 
maDC (including maDC-Z and maDC-Y) by afferent lymph vessels come from area of inflammation 
in nearest regional lymph nodes LN. 
Further (within the limits of LP7.1) the following events take place:  
In lymph node, maDC-Z present Z-antigen to naive nTL (at primary response) and to central 
memory Tcm-Z (at secondary response), which provides their clonal proliferation into effector Tem-Z. 
Besides Tem-Z, Tcm-Z are also formed at primary and secondary responses.  
Then Tem-Z enter blood flow through the efferent lymph vessel. The expression of homing-
receptors on Tem-Z (in particular, CLA) provides their migration to postarterial venules, on which 
ligandic adhesive molecules (in particular E-selectin and ICAM-1) are expressed. In areas of 
inflammation this expression is promoted, in particular, by TNF-alpha. Migration of Tem-Z occurs 
mainly to the inflammation areas, from where maDC-Z have come to LN (Gudjonsson 2004, 
Male 2006). 
Part of Tcm-Z enters blood flow similarly, but go to farther regional LN to proliferate there and 
differentiate in Tem-Z, which then enter other tissues (Fig. 2-12).  
 
On the endothelium of postarterial venules, due to interaction of Tem receptors and ligandic 
adhesive molecules, infiltration of Tem from blood flow into derma, and then, their movement inside 
derma and epidermis takes place under the influence of chemokines.  
Mostly (> 90%), in the absence of inflammation, Tem are constantly present in skin. The rest of 
Tem (<10%) circulate in blood flow. Skin Tem do not express CCR7 and L-selectin, which makes 
impossible their moving into LN. The total amount of Tem reaches 1 million per cm2 of skin (among 
them specific to all antigens, in respond to which SIS earlier have formed adaptive response). Such 
location of Tem provides the fastest and effective secondary adaptive response formed by SIS at 
repeated contact with antigens (Clark 2010). 
Subprocess LP7.1. TL-Z formation. 
maDC-Z on afferent lymph vessels arrive from inflammation area into nearest regional LN. As a result of 
interaction of maDC-Z with naive nTL (at primary response) or with Tcm-Z (at secondary response) new TL-Z 
are formed, i.e. effector Tem-Z and central Tcm-Z. 
At primary response, LP7.1 start precedes dermal interaction of maDC-Z with Tem-Z. It occurs at absence 
of Z-priming, i.e. if SIS has never earlier formed adaptive response against Z-antigen. 
At secondary response, Tem-Z is already present in skin, and Tcm-Z - in LN. It occurs at Z-priming 
development, i.e. SIS has already previously formed adaptive response against Z-antigen. Such a variant is 
represented in Fig. 2-11. 
In this case interaction of maDC-Z with Tem-Z (LP5.1) begins at once, and fast activation of LP7.1 occurs 
later at deficiency of Tem-Z in the inflammation area. If process LP2 terminates before development of such 
deficiency, LP7.1 may not occur at all (Clark 2010). 
Irrespective of the order of events, we consider that with LP5 and-or LP7.1 start phase 4 begins.   
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Subprocess LP7.2. TL-Y formation. 
maDC-Y arrive on afferent lymph vessels from an inflammation area into nearest regional LN. As a result 
of interaction of maDC-Y with naive nTL (at primary response) or with Tcm-Y (at secondary response) new 
TL-Y are formed, i.e. effector Tem-Y and central Tcm-Y. 
At primary response, LP7.2 start precedes dermal interaction of maDC-Y with Tem-Y. It is possible only at 
primary PLS-plaque and only in case if SIS has never earlier formed adaptive response against PsB.  
At secondary response, Tem-Y is already present in skin, and Tcm-Y in LN. In this case, interaction of 
maDC-Y with Tem-Y (LP8.1) begins at once, and fast activation of subprocess LP7.2 occurs later if in the 
inflammation area deficiency of Tem-Y develops.  
It happens at any nonprime plaque, and, of course, on the external border of extending plaque 
(Vissers 2004). 
It happens both at primary plaque if SIS has previously formed adaptive response, for example, against 
external PsB-infection. 
Irrespective of the order of events, we consider that with LP8 and-or LP7.2 start phase 5 begins.   
 
At LP2(IN), Tem-Z being formed consist mainly of ThN-Z, for Z – is a dominant antigen of 
commensal or pathogenic bacteria penetrated derma due to trauma. 
 
At LP2(HPV), Tem-Z being formed consist mainly of ThN-Z2 and TcN-Z1.  
KC-v process and present Z1-antigen through MHC class I (being thus transformed in KC-Z1). 
maDC-Z1 do the same by cross-presentation. maDC-Z1 and KC-Z1 cooperate with TcN-Z1, both 
resident and involved from blood flow (Black 2007, Male 2006, Nestle 2009a). 
At LP2(HPV), CD4+Tem (mainly ThN-Z2) are actively formed and arrive to the area of inflammation 
(Stanley 2009). maDC-Z2 present Z2-antigen through MHC class II to ThN-Z2, both resident and 
involved from blood flow (see LP5 (HPV)). 
 
Tem-Y mainly consists from ThN-Y as Y-antigen is a peptidoglycan fragment, endocytosed by 
Mo-R and DC-R in blood flow. 
 
LP7.1 depends on LP6.3. The more dermal maDC-Z is formed, the greater possibility that the 
amount of dermal Tem-Z (cooperating with maDC-Z) will be insufficient, and the more uninvolved 
maDC-Z will enter LN.  
LP7.2 depends on LP6.4. The more dermal maDC-Y is formed, the greater possibility that the 
amount of dermal Tem-Y (cooperating with maDC-Y) will be insufficient, and the more uninvolved 
maDC-Y will enter LN.  
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Process LP8. False adaptive response to imaginary PsB-infection.  
DC-R and MoDC-R, having lost tolerance, undergo maturation with the following transformation into 
mature dendritic cells maDC-Y (LP6.4). maDC-Y process PG-Y fragments contained in them, and 
after processing present Y-antigen to ThN-Y, both resident and involved from blood flow. The skin 
immune system SIS receives a false target – an imaginary PsB-infection, regarded by SIS by 
presented Y-antigens.  
This process occurs at trauma (Fig. 2-9, Fig. 2-16) and at HPV-expansion (Fig. 2-18, Fig. 2-23), 
and is similar at other initiating and aggravating processes LP2. 
The vicious cycle B = {LP1.1 > LP6 > LP8 > LP1} is initiated at expansion of LP2 (through LP3, LP4 
and LP5) (Fig. 2-6). This cycle represents:  
 Income of DC-R and Mo-R from blood flow to the area of developing inflammation 
(LP1.1).  
 Loss of tolerance by DC-R and Mo-R and their transformation into maDC-Y (LP6.1, 
LP6.2 and LP6.4).  
 Cooperation of maDC-Y with ThN-Y, causing process LP8, which, in its turn, supports 
LP1.  
The vicious cycle B amplifies by the vicious cycle C = {LP6.4 > LP7.2 > LP1.2 > LP8 > LP6}. At 
excess of maDC-Y and shortage of ThN-Y movement of maDC-Y appears in the inflammation area 
into regional LN, where clonal proliferation of Tem-Y, mainly ThN-Y, takes place (LP7.2). Due to 
homing, ThN-Y arrive through blood flow to the inflammation area and adjacent areas (LP1.2), which 
causes intensification and expansion of plaque (LP8).  
Process LP8 influences all subprocesses LP6 through secreted cytokines (Fig. 2-6). 
For LP8 functioning, LP1, LP6 and LP7.2 actively supported by LP8 (Fig. 2-9; Fig. 2-18, Fig. 2-17), 
can be sufficient. It means that process LP2 (as well as LP3, LP4, LP5, LP6.3 and LP7.1) can come to 
the end, and LP8 will proceed (PLS will pass into phase 6).  
If LP2 is preserved, or other secondary infections develop, PLS remains in phase 5. 
The vicious cycle B can be interrupted in case of breach of SIS work, which can be realized for a 
while by application of biological drugs. However, the unique long-term decision eliminating the 
original cause of psoriasis is weakening or termination of SPP.  
Within LP8 limits, KC hyperproliferation begins (physical protection of skin). At LP2(IN) it 
accelerates trauma healing. At LP2(HPV) it complicates possibility of the complete replicative cycle of 
virus. Thereby, processes LP3 and LP5 are being assisted.  
If during LP5 it appears that the level of Mo-R and DC-R in skin is insufficient, or their loss of 
tolerance is insufficient, LP8 will not begin, and LP5 will constrain LP2 or lead to its complete 
elimination. Thus, skin in LP2-inflammation area from phase 4 will return to phase 1 (Fig. 2-25). 
 
LP8.1 depends on LP1.2. LP8.1 intensity depends on income of ThN-Y from blood flow.  
LP8 depends on LP6. Without preliminary and sufficient formation of maDC-Y, LP8.1 start is 
impossible, as well as its support without constant formation of new maDC-Y (LP6.4). Also, LP8 
support is influenced by formation of MF-T and MoDC-T (incl. MF-R and MoDC-R) secreting 
proinflammatory cytokines (LP6.2).  
 
It is shown that LP8 does not depend directly on LP4 (Bissonnette 2010). Process LP4 is transitory 
and necessarily preceding to development of new plaque, but not participating in its support. Due to 
LP4, subprocesses LP6 are initiated. And then subprocesses LP6 are supported by only LP5 and-or 
LP8. 
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Subprocess LP8.1. Y-antigen presentation by maDC-Y to effector ThN-Y. 
Due to loss of tolerance (LP6.1) and fast maturation (LP6.4) maDC-Y process PG-Y (as a part of 
F-content) and present Y (fragments of interpeptide bridges) to effector ThN-Y.  
ThN-Y are activated, proliferate and secrete TNF-alpha, IFN-gamma, IL-17 and IL-22. Cytokine 
IFN-gamma is mainly secreted by Th1-Y. Cytokine IL-17 (IL-17A and IL-17F) is mainly secreted by Th17-Y. 
Cytokine IL-22 is mainly secreted by Th22-Y (Guttman-Yassky 2011, Nestle 2009a, Nestle 2009b, 
Tonel 2009). 
IL-23 secreted by MF and maDC (LP6) plays important role in ThN stimulation for secretion of these 
cytokines. Genetic deviations in the condition of receptors for IL-12 and-or IL-23, can influence ThN-reaction 
intensity (Cargill 2007, Di Cesare 2009, Gudjonsson 2009, Meglio 2010, Tonel 2010). 
Under the influence of TNF-alpha, expression of adhesive molecules on EC of postarterial venules 
increases, with the subsequent increase of permeability of endothelium (LP1). 
 
Events occur variously, it depends on whether there are resident ThN-Y in skin or not, i.e. whether 
Y-priming have taken place (Clark 2010, Sabat 2007, Sabat 2011). If Y-priming has taken place, ThN-Y is 
present in derma. It means that the patient either already has psoriasis, or he\she has (or had) some skin, 
tonsillar (SP6) or generalized PsB-infections (Fig. 2-24).  
In this case, maDC-Y, having executed PG-Y processing, presents Y to resident ThN-Y. LP8 begins 
quickly, at that, the threshold level of (PG-Y)-carriage by blood DC-R and Mo-R for its initialization can be 
lower.  
ThN-Y amount in skin is enough to provide the active beginning and support of false adaptive response in 
case of interaction with maDC-Y. At that, the need in clonal proliferation of ThN-Y in LN (LP7.2) increases 
later, when maDC-Y amount starts to exceed ThN-Y amount essentially. 
Y-priming (not because of psoriasis) increases probability of primary psoriasis and lowers the middle age 
of its occurrence. Such priming explains fast development (flash) in some patients of abundant primary 
plaques.  
 
If Y-priming was absent, ThN-Y in derma is absent, i.e. the patient did not and does not have psoriasis, as 
well as skin, tonsillar or generalized PsB-infections. In this case, maDC-Y at the absence of ThN-Y, express 
CCR7 and begin chemotactic movement through afferent lymph vessels into nearest LN. In LN clonal 
proliferation of Tem-Y (mainly ThN-Y) takes place, then they get to blood flow through the efferent lymph 
vessels (LP7.2).   
If such beginning of psoriasis is possible, it should be necessary conditioned by the combination of high 
level (PG-Y)-carriage of blood DC-R and Mo-R and intensive adaptive response LP5 during phase 4.  
LP2, initiating primary plaques, should be more intensive, than LP2, initiating secondary plaques (when 
ThN-Y is already present in skin).  
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Subprocess LP8.2. KC hyperproliferation. Change of skin architecture.  
Growth of basal membrane area and vascularity increase.  
This subprocess is a consequence of subprocess LP8.1 and develops in time of its intensification. KC 
hyperproliferation begins at once in basal layers of epidermis at a skin site, where LP8.1 has begun.  
However, visible pinpoint plaque appears on the surface of skin with a several-day delay. This natural 
delay is necessary for displacement of normal KC of the overbasal layers by incompletely differentiated KC, 
quickly rising from the basal layers. Thus, changes of architecture of skin begin, being definitively formed in 
process of expansion and aggravation of plaque. These changes cover epidermis and lower derma and are 
accompanied by the growth of basal membrane area and vascularity increase. 
 
IFN-gamma, IL-17, IL-20, IL-22 and TNF-alpha influence KC and cause their hyperproliferation 
(Nestle 2009a, Nestle 2009b, Tonel 2009). Thus, IL-20 is secreted by KC, and then both IL-20 (in the 
autocrine way) and IL-22 promote much more intensive hyperproliferation (Guttman-Yassky 2011, 
Sabat 2011). TNF-alpha and IL-17 is synergic influence on KC (Chiricozzi 2010). 
  
The hyperproliferation is realized by  
 
 increase of the volume of the basal layer because of increase of the basal membrane area; 
 increase of the fraction of growth (a part of proliferating KC in the basal layer) from 10-30% to 
100%; 
 increase of the amount of cycles of TA-keratinocytes division (TA - Transit Amplifying), which 
proceeds after their lifting to the overbasal layers.  
 
In PLS, simultaneous increase of dermal papillas height and reduction of thickness of the layer above the 
papillas takes place (Fig. 2-17). At that, epidermis thickness as a whole is enlarged.  
These changes are a consequence of accelerated proliferation (basal and overbasal layers), forwarded 
and incomplete differentiation (spinous and granular layers) and accelerated desquamation (cornual layer) of 
keratinocytes (Castelijns 2000, Grabe 2007, Iizuka 2004, Weinstein 1985).  
Within the limits of Y-model, the accelerated desquamation of KC realizes physical protection of SIS 
against an imaginary external PsB-infection.  
KC in PLS secrete cytokines TNF-alpha, IL-1beta, IL-6, TGF-beta, etc. 
KC in PLS secrete chemokines (CCL2, CCL20, CX3CL1, CXCL1, CXCL3, CXCL5, CXCL8, CXCL9, 
CXCL10, CXCL11, etc.) and AMP (LL37, HBD1, HBD2, S100A7, S100A8, S100A9, etc.). It occurs under the 
influence of IFN-gamma, IL-17, IL-20, IL-22 and TNF-alpha.  
In particular, IL-17 and IL-22 are capable of synergic influence on KC providing active secretion of HBD-2 
(Ghannam 2011). 
It is the way of VEGF secretion causing angiogenesis. At early stages of inflammation, CCL2, HBD-2 are 
more actively secreted, and, as a consequence, blood CCR2+DC and CCR2+Mo are mostly involved. At 
intensification of PLS-inflammation, KC secrete CCL20 more actively, and, as a consequence, blood 
CCR6+DC, CCR6+Tem are involved.  
Secretion of chemokines and AMP, increase of vascularity and the basal membrane area, provides more 
intensive income of immunocytes in derma from blood flow (LP1) per unit of skin surface (Nestle 2009a, 
Nestle 2009b, Tonel 2009).  
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Phases of psoriatic plaque development  
Let's turn to the detailed description of each phase (Tab.2-1, Tab. 2-2, Fig. 2-8, Fig. 2-10,  
Fig. 2-19). Phases 1, 2, 3 and 4 correspond to conditions of a particular NLS site preceding plaque 
development, phases 5 and 6 correspond to initialization and support of plaque.  
During all phases, SPP acts, without which development and existence of plaque are impossible.  
In the phase name one or two marker local processes characterizing this phase are listed. Intensity 
of processes is illustrated by color: white (weak), beige (medium) and pink (high). 
The processes taking place during LP2-inflammation, are bounded by the big lilac circle (LP1, LP2, 
LP3, LP4, LP5, LP6, LP7). The processes defining initialization and support of plaque, are framed by 
the big pink rectangle "PLS-inflammation" (LP1, LP6, LP7, LP8). The processes both in the circle and 
in the rectangle, are common for LP2-inflammation and PLS-inflammation (LP1, LP6, LP7). 
Subprocesses LP6.3 and LP7.1 take place only during LP2-inflammation, subprocess LP7.2 - only 
during PLS-inflammation.  
The phases are also characterized by conditional graphs of unit antigenic presentation and 
logarithmic curves of unit quantity of effector ThN (Fig. 2-10 and Fig. 2-19). 
Images and transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are specified only in the figures 
corresponding to phases 1, 2 and 6. In the figures corresponding to phases 3, 4 and 5, they are 
absent for the purpose of not raising complexity. Their possible transformations are identical to 
transformations of usual Mo and DC (Tab. 2-3). 
Phase 1. Prepsoriasis. Marker - homeostatic LP1.  
Phase 1 is the normal state of NLS. Phase 1 transfers into phase 2 at the moment of LP2 start (and 
LP3 begins once along with it). If LP4 begins simultaneously with LP3 (for example at LP2(IN)) phase 
1 turns into phase 3.  
Phase 1 precedes LP2 occurrence, it is common for all types of LP2. NLS can be Y-primed or not. 
In Fig. 2-11, Y-primed NLS is represented (resident ThN-Y are present). It means that future plaque is 
secondary, and if it is primary (i.e. the very first plaque in psoriatic’s life ), hence, phase 0 occurred in 
the past (Fig. 2-24).  
Y-primed NLS can become PLS with much greater probability, than Y-nonprimed NLS. LP2 (PsB) 
is an exception, it is the situation, when previous Y-priming does not influence further chain of events. 
At LP2 (PsB), during phase 0, immediate transition to phase 2 takes place. 
As one of two possible variants, Tem-Z image also assumes previous Z-priming (Fig. 2-11). 
During this phase, IZD and IYD are absent.  
Renewal of pool of immunocytes (LP1) occurs homeostatically (the process intensity is weak). 
Mo-T and DC-T (incl. Mo-R and DC-R) degrade F-content faster, than they lose tolerance, and 
gradually transform into normal Mo and DC.  
NLS differs from the norm by increased level of PDC. At LP2 (HPV), it is defined by latent 
HPV-carriage of KC.  
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Phase 2. Prepsoriasis. Marker - LP2 and LP3.  
Phase 2 begins at the moment of LP2 start (along with LP3). Phase 2 turns to phase 3 at the 
moment of LP4 start. Phase 2 can return back to phase 1 in case of LP2 end (along with LP3) before 
LP4 start.  
Phase 2 is at LP2(HPV), it includes medium-intensive LP1, LP2 and LP3 in the state of mutual 
balance (Fig. 2-20). During this phase, LP3 constrains diffusion of HPV among basal KC, and KC-v 
release special proteins constraining possible start of LP4 and LP5. LP6.2 takes place with average 
intensity, as MF necessary for this constrain are formed during this subprocess. 
Tem-Z image also assumes (as one of two possible variants) previous Z-priming (Fig. 2-11). During 
this phase, IZD and IYD are absent.  
On conditional graphs, phase 2 does not differ from phase 1, because of lack of adaptive response 
(Fig. 2-19).  
After open trauma LP2(IN), phase 2 is absent, since LP4 (and phase 3) begins at once. At trauma 
that does not affect derma at all, or at trauma with damage of derma without epidermis injury, 
koebnerization is impossible, as Z-antigens do not get into derma (Weiss 2002). 
Phase 3. Prepsoriasis. Marker - LP4.  
Phase 3 begins at the moment of LP4 start. Phase 3 transfers to phase 4 at the moment of LP5 or 
LP7.1 start. This phase is transit and it includes high-intensive LP1, LP2, LP3 and LP4, and also 
medium-intensive LP6.2 and LP6.3. 
Phase 3(IN). 
The scheme of interaction of (sub)processes at LP2(IN) is illustrated in Fig. 2-9. 
Phase 3 at LP2(IN) is illustrated in Fig. 2-14.  
Phase 1 transfers to this phase right after open trauma of derma. 
Phase 3(HPV). 
The scheme of interaction of (sub)processes at LP2(HPV) is illustrated in Fig. 2-18. 
Phase 3 at LP2(HPV) is illustrated in Fig. 2-21. 
This phase is transit and begins in the result of active epidermal HPV-expansion (among basal layers) or attempts 
of dermal HPV-expansion (at HPV carriage of invasive types). During LP6.3 - maDC-Z1 and maDC-Z2 are formed.  
Phase 4. Prepsoriasis. Marker - LP5 
Phase 4 begins at the moment of LP5 or LP7.1 start. Phase 4 turns to phase 5 at the moment of 
LP8 start. Phase 4 can go to phase 1 if LP2 (along withLP3, LP4 and LP5) ends prior to LP8 start. 
Phase 4 can go to phase 2 (at LP2(HPV)) if LP4 and LP5 both come to end before LP8 begins.  
Owing to LP4 providing abundant secretion of IFN-alpha, LP5 is quickly initiated - preventive 
adaptive response. Sharp growth of IZD - unit presentation of Z-antigen by maDC-Z takes place, and, 
as a consequence, exponential increase of Tem-Z quantity can be seen. Tem-Z proliferate both in skin 
(LP5) and in lymph nodes (LP7.1).  
During phase 4, process LP4 gradually goes down (being suppressed), as the increased level of 
TNF-alpha suppresses PDC ability to secrete IFN-alpha. It is supposed that by phase 5 start, LP4 
intensity becomes insignificant, that is why process LP4 is absent in the figures illustrating phases 5 
and 6. 
 
Phase 4 includes high-intensive LP1, LP2, LP3, LP5, LP6.2 and LP6.3 and medium-intensive LP4, 
LP6.1, LP6.4 and LP7.1. At that, LP7.1 intensity can be high if Z-priming was absent.  
 
Owing to LP6.4 activity, IYD increases. If IYD reaches the critical level (depending on unit quantity 
of resident ThN-Y) than LP8.1 can begin (i.e. phase 5).  
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Phase 4(IN). 
The scheme of interaction of (sub)processes at LP2(IN) is illustrated in Fig. 2-9. 
Phase 4 at LP2(IN) is illustrated in Fig. 2-14.  
During healing accompanied by LP3 and LP5 after trauma, IZD decreases gradually - unit presentation of 
Z-antigen.  
During phase 5 at trauma healing, decrease of LP2 intensity takes place, and, as a consequence, LP3 and LP5 
also weaken. 
Phase 4(HPV). 
The scheme of interaction of (sub)processes at LP2(HPV) is illustrated in Fig. 2-18. 
Phase 4 at LP2(HPV) is illustrated in Fig. 2-21. 
During LP6.3 - maDC-Z1 and maDC-Z2 are formed.  
They present two dominant HPV-antigenes, accordingly: Z1 (through MHC class I) and Z2 (through MHC class II).  
During LP5.1 - maDC-Z1 interacts with TcN-Z1, and maDC-Z2 with ThN-Z2. As a result of this interaction, TcN-Z1 
and ThN-Z2 are activated, proliferate and secrete cytokines. 
During LP5.2, interaction of KC-Z1 and TcN-Z1 takes place leading to destruction of KC-Z1. 
Phase 5. Psoriasis. Marker - LP5 and LP8.  
Phase 5 begins simultaneously with LP8 start. Phase 5 turns to phase 6 at the moment of LP2 
completion (along with LP3, LP4 and LP5).  
Phase 5 will be able to go to phase 1 (remission) if it appears that after LP2 completion (along with 
LP3, LP4, LP5, LP6.3 and LP7.1) LP8 does not become self-sufficient and, therefore terminates 
quickly. Phase 5 corresponds to all processes in Fig. 2-9 (at LP2(IN)) or in Fig. 2-18 (at LP2(HPV)).  
Phase 5(IN). 
The scheme of interaction of (sub)processes at LP2(IN) is il lustrated in Fig. 2-9. 
Phase 5 at LP2(IN) is initiation and support of plaque after trauma (Koebner effect) is illustrated in Fig. 2-16. 
Simultaneously with trauma healing and decrease of unit presentation of Z-antigen, LP8 –false adaptive response 
against Y - subdominant antigen presented by maDC-Y can begin. It occurs, if IYD reaches critical level before the 
resolution of inflammation accompanying trauma healing. 
Phase 5(HPV). 
The scheme of interaction of (sub)processes at LP2(HPV) is illustrated in Fig. 2-18. 
Phase 5 at LP2 (HPV) is initialization and support of plaque during LP5 against HPV.  
It is illustrated in Fig. 2-23. During active adaptive response against Z1 and Z2 - dominant HPV-antigenes, 
initialization of LP8 - false adaptive response against Y - subdominant antigen presented by maDC-Y can begin. It can 
occur, if IYD reaches the critical level before LP5 – adaptive response against HPV-expansion stops.  
If, despite LP3 and LP5 action, full release from HPV does not occur, HPV remains inside plaque aggravating it. In 
this case full transition to phase 6 does not occur. 
Phase 6. Psoriasis. Marker - LP8.  
Phase 6 begins at the moment of LP2 end (along with LP3, LP4 and LP5, LP6.3 and LP7.1) at LP8 
self-sufficiency.  
Phase 6 can go to phase 1 (remission) that occurs at decrease of SPP severity.  
Phase 6 can transfer to phase 5 at renewal of initial LP2 or joining of another LP2 (secondary 
infection). Plaque having arisen at trauma healing (Koebner effect) or HPV-expansion suppression 
remains (Fig. 2-17). The processes framed by the pink rectangle "PLS-inflammation" (Fig. 2-6,  
Fig. 2-9, Fig. 2-18) become self-sufficient. The processes that are out of this rectangle (as well as 
LP6.3 and LP7.1), terminate. It occurs if Y - subdominant antigen, presented by maDC-Y becomes 
dominant. For this purpose it is necessary provision by vicious cycles B and C sufficient quantity of 
maDC-Y and ThN-Y (per unit of PLS dermal volume).  
 
Process LP8 will be self-sufficient until the decrease of unit income of Y-antigen (the quantity 
brought by DC-R and Mo-R from blood flow per unit of time per unit of dermal volume of PLS). LP8 
severity in plaque, expansion or remission of this plaque depends only on unit income of Y-antigen. 
Unit income of Y-antigen is defined by SPP severity.  
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Phases. Additions.  
At transition from phase 5 (or from phase 6) to phase 1, invisible Y-primed NLS-spot is preserved in 
the site of former plaque and around it. Inside this NLS-spot, there is high concentration of resident 
TL-Y (in the site of former plaque) gradually decreasing to the external border of the surrounding ring 
(Fig. 2-24, A, phase 1). 
 
In plaque, there can be sites of phase 5 (LP2-inflammation and PLS-inflammation) and sites of 
phase 6 (only PLS-inflammation) without clear boundaries between them. LP2-inflammation 
intensification leads to PLS-inflammation intensification and expansion of phase 5 sites. Weakening of 
LP2-inflammation leads to weakening of PLS-inflammation and reduction of phase 5 sites. In  
Fig. 2-25, phase transitions possible at LP2-inflammation initialization, development and remission, as 
well as PLS-inflammation, are shown. In Fig. 2-26, variants of development of pinpoint plaque at 
LP2(HPV) are presented. 
 
The type of dermal maDC depends on the phase (Fig. 2-5, Fig. 2-19). maDC appear in LP5 start 
(phase 4) and they are only maDC-Z. With LP8 start (phase 5), also maDC-Y appear, besides 
maDC-Z. If LP8 becomes self-sufficient (phase 6), all maDC are only maDC-Y. Total number of maDC 
is proportional to the sum of IZD and IYD (dark blue and red components on conditional graphs). 
maDC-Z precursors can be DC or Mo of any origin (resident or non-resident). Only blood DC-R or 
Mo-R can be precursors of maDC-Y. 
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Discussion 
Basic characteristics of Y-model 
Y-model of pathogenesis of psoriasis is based on three factors: one systemic and two local:  
 
Systemic necessary factor (Part 1) 
 SPP severity. It is estimated by unit Y-carriage of blood DC-R and Mo-R (quantity of 
Y-antigens in DC-R and Mo-R in 1 ml of blood). It is defined by a set of the 
interconnected subprocesses:  
o Hyperpermeability of intestinal walls for F-content (SP1) 
o Specific small intestine disbacteriosis (SP2) 
o Disorder of production and-or circulation of bile acids (SP3). 
o Overload and-or disorder of detoxicating systems (SP5) 
o Chronic PAMP-nemia (SP4) 
 
Local factors in specific skin site  
 Intensity and duration of LP2-inflammation.  
 Y-priming level. It is estimated by concentration of TL-Y (Tem-Y - in derma, Tcm-Y - in 
lymph nodes); 
 
If combination of these factors for specific NLS site appears critical, it is transformed to PLS-plaque. 
The role of any of these factors (processes and subprocesses) can be strengthened by genetic 
(Elder 2010, Gudjonsson 2009, Hollox 2008) and-or functional deviations. 
Any PLS-plaque is caused by constant income in derma of blood DC-R and Mo-R containing 
endocytosed kPAMP (including PG-Y). DC-R and Mo-R arrive into skin together with other DC and Mo 
for renewal of dermal DC and MF pool. At LP2 and/or PLS-inflammation, this subprocess is 
intensified.  
Tolerization of Mo-T and DC-T (incl. Mo-R and DC-R) is caused by longer stay under chronic 
kPAMP-load (SP8) (in comparison with DC and Mo).  
 
 
PLS-plaque is a reaction of SIS caused by blood Mo-R and DC-R that, getting into derma, 
are transformed in maDC-Y and present Y-antigen to effector ThN-Y.  
This reaction includes epidermal hyperproliferation, as one of mechanisms of false adaptive 
response of SIS on imaginary PsB-infection.  
PLS-plaque initialization can occur only during LP2-inflammation including LP5 (adaptive 
response against LP2). 
In particular, it is possible at LP2(IN) - open trauma of derma and at LP2(HPV) – 
HPV-carriage of KC.  
Existence and severity of PLS-plaque is defined by intensity of income into derma of 
Y-antigen brought by Mo-R and DC-R. 
Severity of PLS-plaque is aggravated by intensity of income into derma of kPAMP brought 
by Mo-T and DC-T. 
These incomes are conditioned by SPP severity. 
Severity of PLS-plaque is aggravated by intensity of LP2-inflammation if it continue to 
develop during PLS-inflammation.  
SPP it is necessary for initialization and support of any PLS-plaque. SPP severity defines 
total severity of PLS-plaques as a whole. At decrease of SPP severity, remission of separate 
plaques takes place, up to total disappearance of all PLS-plaques. 
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Chemostatuses of blood Mo-T and DC-T (incl. Mo-R and DC-R) are similar to chemostatuses of 
nonactivated Mo and DC, which leads to analogousness of their migration behavior under the 
influence of chemokines.  
Process LP2 can be initialized by any of triggers: trauma, HPV, S.aureus, Malassezia sp., Candida 
albicans, skin PsB-infection, etc. Processes LP2 can be different in different skin sites of a psoriatic.  
Owing to processes LP3, LP5, LP6 and LP8, the level of cytokines IFN-gamma, GM-CSF, IL-1beta, 
IL-12, IL-17, IL-20, IL-22, IL-23, TNF-alpha secreted in PLS increases.  
Under their influence, KC and FB actively secrete chemokines and AMP: CCL2, CCL20, CX3CL1, 
LL37, HBD-2, HBD-3, etc.  
Chemokines and AMP get to blood flow, and even more Mo, DC, Mo-T, DC-T (incl. Mo-R, DC-R) 
and ThN-Y are attracted to the inflammation site. 
Because of the increasing income from blood flow of Mo-R and DC-R, more maDC-Y, cooperating 
with effector ThN-Y are formed.  
ThN-Y are activated, proliferate and secrete cytokines promoting hyperproliferation of KC, which is 
an attempt of skin to eliminate imaginary external PsB-infection through intensive renewal.  
If SPP severity and-or intensity and duration of LP2-inflammation are insufficient, LP8 will not be 
able to begin. Or LP8 will begin, but at LP2 end it will terminate at once, as LP8 will not be able to 
become self-sufficient. 
This alternative (beginning or impossibility of PLS-plaque beginning) also depends on the level of 
Y-priming in the site of LP2-inflammation.  
If in some NLS-site LP2 it is not accompanied by LP5, or LP5 has weak intensity (for example at 
latent HPV-carriage) LP8 might not begin or begin with delay. The reasons of delayed initialization of 
LP8 can be: delayed activation of LP5 and-or increasing SPP severity and-or increasing level of 
Y-priming (for example because of tonsillar PsB-infection).  
If an increase of SPP severity is temporary, plaques can be temporary, this exactly occurs at 
temporary guttate psoriasis. 
 
During phase 5 (LP2-inflammation and PLS-inflammation), each LP2-activation aggravates and-or 
promotes plaque expansion. For this reason, process LP2 is called initiating and aggravating.  
Similarly, secondary infections act (other than initiating LP2) that can join to already existing 
plaque. 
 
If LP8 has already begun, the further existence of initiating LP2 in this plaque can appear 
unessential, i.e. phase 5 can go to phase 6. During phase 6, plaque severity and its expansion rate 
are defined by SPP severity (Fig. 2-6, vicious cycles B and C) and by Y-priming level in the site 
surrounding this plaque. 
 Y-priming level (resident placing ThN-Y - in skin, Tcm-Y - in lymph nodes), increases during any 
PsB-infection (tonsillar, skin or systemic) (Fig. 2-24).  
The highest SPP severity is necessary for the primary plaque preceding Y-priming of the whole 
surface of skin. If Y-priming of skin has occurred, the primary plaque (especially in skin sites with 
increased level of Y-priming) can begin at lower SPP severity.  
Psoriasis, once having begun, provides constant increased Y-priming of areas adjacent to plaques, 
as well as the whole skin surface. Hence, for expansion of primary and initializations of subsequent 
plaques, lower SPP severity is enough, than that for primary plaques initialization.  
After plaque remission, an invisible NLS-spot with increased level of Y-priming remains on its place, 
which leads to increased probability of new PLS-plaque occurrence in the future in the same site 
(Clark 2011). 
 
Primary guttate psoriasis (guttate psoriasis) approximately in 30% of cases completely resolves 
spontaneously, but in 70% it turns into chronic plaques immediately or after remission (Baker 2000, 
Baker 2006b). Guttate plaques is often preceded by intensive tonsillar PsB-infection when Y-priming 
of skin takes place and temporary, but intensive SPP occurs. And, if such patient, for example, has 
latent HPV-carriage in some sites, critical combination of all three factors is formed. Temporary 
plaques appear and then spontaneously disappearing at SPP end.  
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Comparison of Y-model with other models 
In App. 2-9, results of comparative analysis of Y-model and five other models of pathogenesis of 
psoriasis are presented in the tabular form: BF-model (Baker 2006b, Fry 2007b), N-model 
(Nestle 2009a, Nestle 2009b, Perera 2012), GK-model (Guttman-Yassky 2011, Nograles 2010), 
TC-model (Tonel 2009) and GL-model (Gilliet 2008, Lande 2010). The designation of each model by 
one or two Latin letters is introduced for the first time. 
Other models (except BF) are based on the local concept, i.e. on the assumption that the reason of 
development and support of PLS-plaques is only of skin origin. Other models (except BF) do not 
consider any systemic processes. 
The basic feature of Y-model is that, first, SPP is necessary for initialization and support of any 
plaque and, secondly, SPP severity defines psoriasis severity as a whole. 
 
Let's list local (sub)processes noting their popularity or novelty (App. 2-9). Initial (sub)processes are 
a part of LP2-inflammation and do not enter vicious cycles.  
 
LP1. Attraction of immunocytes from blood flow. 
Known process. It is included in Y-model and other models as a vicious cycle link.  
LP1.1 is known and included in Y-model (a link of the vicious cycle B). It is also included in other 
models also, but not as a vicious cycle link. The unique role of Mo-R and DC-R is considered only in 
Y-model. 
Difference between Mo and DC of resident and non-resident origin (Zaba 2009a, Zaba 2009b) 
plays an important role in Y-model, but it is not considered in other models.  
LP1.2 is known (attraction ThN, PDC, Neu, NK, etc.) and included in Y-model (ThN – in the vicious 
cycle C) and in other models. 
 
LP2. Initiating and aggravating process. 
Known initial process (Koebner effect).  
LP2(IN) is included in Y-model and other models.  
In GK-model at the initialization stage derma-epidermal antigen plays the leading role (we will 
designate it - X) (Guttman-Yassky 2011). X is antigen of commensal or pathogenic bacteria which 
have got to derma as a result of trauma (Nograles 2010) (Fig. 2-28). 
LP2(HPV) has been for the first time included in Y-model. 
 
LP3. Innate response against LP2. 
Known initial process.  
LP3.1(IN) is included in Y-model and other models. 
In GK-model it is obviously not mentioned. At the initialization stage such reaction to X-antigen 
which immediately includes adaptive response is supposed. It is provided by LC and dermal 
BDCA-1+DC of resident origin carrying X-antigen into regional LN (Fig. 2-28). 
LP3.1(HPV) has been for the first time included in Y-model. 
LP3, as a whole, as a separate process is included for the first time in Y-model. In other models, 
the role of LP3, as a whole, is not reflected. 
 
LP4. Trigger of adaptive response against LP2. 
The known transit initial process is included in Y-model and other models (except BF).  
In N-, GK and GL-model, this process is considered not transit, but as constant and is included in 
vicious cycles. However, this assumption does not correspond to the recently received results 
(Albanesi 2010, Bissonnette 2010). 
 
LP5. Adaptive response against LP2. 
Known initial process.  
LP5 as a separate process has been for the first time included in Y-model. 
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In GK-model adaptive response against unknown X-antigen is partly represented (the initialization 
stage passing into the acute stage). Here the author shows the reaction of LC and dermal 
BDCA-1+DC which endocytose X-antigen and then carry it into regional LN for processing and 
presentation to nTL or Tcm. As a result effector Th1, Th17 and Th22 are formed in LN, which arrive 
subsequently in derma (Fig. 2-28). 
Its role for initialization of LP8 has been for the first time formulated in Y-model. 
 
LP5.2(HPV). One of the initial events preceding initialization of pinpoint plaque (and then promoting 
its aggravation) is attraction from derma into epidermis of CD8+Tem (N-model and TC-model). In 
Y-model, at LP2(HPV), during phase 4, such attraction of TcN-Z1 (Z1-specific CD8+TcN) occurs 
because of HPV-expansion. Such attraction really precedes initialization of LP8 (phase 5) and occurs 
during phases 4 and 5.  
 
LP6. Mo and DC transformations. 
LP6.1. Loss of tolerance of Mo-R, DC-R and MoDC-R to kPAMP. 
Known (but not at psoriasis) subprocess. 
For the first time it has been included (as a necessary link of the vicious cycle B) in Y-model.  
 
LP6.2. MF and MoDC formation. 
Known subprocess. 
The subprocess is a link of the vicious cycle B and for the first time (for MoDC) it has been included 
in Y-model. In other models, the role of MoDC is not considered. 
 
LP6.3. maDC-Z formation.. 
Known subprocess (but not at psoriasis).  
As a separate process, for the first time it has been included in Y-model. 
 
LP6.4. maDC-Y formation. 
Known subprocess is included in other models, but without antigen definition. Subprocess with 
Y-antigen is included in Y-model and it is a necessary link of the vicious cycle B. 
Y-model novelty is that Y-antigen is defined and the mechanism of its appearance in dermal DC-R 
and Mo-R is suggested. Y-model novelty is that the mechanism of loss of tolerance DC-R and Mo-R 
and their transformations in maDC-Y is suggested.  
 
LP7. Lymph nodes. Clonal proliferation. 
LP7.1. TL-Z formation. This is known initial subprocess that has been included in Y-model (and in 
GK-model also). 
LP7.2. TL-Y formation. This is known subprocess that has been included (as a link of the vicious 
cycle C) in Y-model and other models (except GL).  
In GK-model at the chronic stage effector TL are formed at interaction with CD208+DC in lymphoid 
structures (Fig. 2-28). 
The characteristic feature of Y-model is that Y-priming is considered a significant local factor (as 
well as in (Sabat 2011).  
 
LP8. False adaptive response to imaginary PsB-infection. 
LP8.1. Presentation of Y-antigen by maDC-Y to effector ThN-Y. 
This known subprocess has been included in other models, but without the definition of antigen 
(except BF-model) and without the concept of imaginary PsB-infection. The subprocess with Y-antigen 
is included in Y-model and is a necessary link of the vicious cycles B and C. 
LP8.2. KC hyperproliferation. Change of skin architecture. Growth of basal membrane area and 
vascularity increase. 
This known subprocess is included in Y-model and in other models. 
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Other differences 
In GK-model, exit of self-DNA and self-RNA from the apoptotic psoriatic KC is considered as a 
vicious cycle link. It is supposed that complexes self-RNA-LL37 being formed do stimulate secretion of 
TNF-alpha, IL-6, and IL-23 by dermal DC, and their maturation in CD208+maDC lately interacting with 
TL. However, in GK-model, no assumptions concerning antigen, presented by CD208+maDC are 
made. 
In Y-model, similar dependence (LP3.1 > LP6.3, LP6.4) is regarded when the source of self-RNA 
are injured KC (LP3.1(IN)) or destroyed KC-v (LP3.1(HPV)).  
In GL-model the exit of self-DNA from apoptotic psoriatic KC is considered as a vicious cycle link. It 
is supposed that complexes self-DNA-LL37 formed later stimulate secretion of IFN-alpha by PDC.  
In the last version of N-model (Perera 2012), the exit of self-DNA and self-RNA from incompletely 
differentiated psoriatic KC is regarded as a vicious cycle link. It is supposed that self-DNA-LL37 and 
self-RNA-LL37 complexes formed later stimulate dermal PDC to secretion of IFN-alpha. 
In Y-model, dependence (LP3.1 > LP4) is considered as transit (phase 3). The basic source of 
self-DNA during this phase is considered not apoptotic, but injured KC or destroyed KC-v. 
Dependence (LP3.1 > LP6) can become evident while LP2 (in particular, LP2(HPV)) and LP6 
operate (i.e. during phases 4 and 5). However, in Y-model, these dependencies are not considered as 
vicious cycle links. 
In other models (except BF), Neu and KC secrete LL37 and it is regarded as a vicious cycle link. In 
Y-model, LL37 secretion is a part of process LP3 that certainly influences initialization and support of 
LP4, but it is not considered as a vicious cycle link. 
 
 
 
 
Y-model novelty  
 systemic psoriatic process SPP - as the main necessary factor 
 Y-antigen is defined and the mechanism of its appearance in dermal DC-R and Mo-R is 
suggested.  
 mechanism of loss of tolerance DC-R and Mo-R and their transformation in maDC-Y is 
suggested.  
 role of Mo-R and DC-R in LP1.1 as a necessary link of the vicious cycle B 
 LP2(HPV) as an initiating process 
 LP5 as an process necessary for LP8 initialization  
 LP6.1 as a necessary link of the vicious cycle B 
 role of MoDC in LP6.2 
 mechanism of initialization of PLS-inflammation during LP2-inflammation (Koebner 
effect) is suggested. 
 Y-priming role 
 PLS-inflammation as a reaction of SIS to an imaginary external PsB-infection 
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Conclusions  
In Y-model (as well as in other models) it is admitted that genetic deviations can define the severity 
and the form of psoriasis manifestation, but they are not the reason of initialization or support of 
PLS-plaques.  
Systemic psoriatic process (SPP) has been included in Y-model as a necessary factor for 
initialization and support of plaques.  
Comparison of Y-model with other models shows that the majority of local processes included in 
Y-model have been earlier formulated in one or several models. However, as a whole, Y-model is 
principally new.  
Concepts not borrowed from other models and formulated for the first time are collected in the 
block «Y-model novelty».  
The systemic approach allows closer coming to construction of the model of pathogenesis of 
psoriatic arthritis as joint manifestation of SPP, and then to the model of pathogenesis of psoriatic 
disease as a whole.  
The new Y-model requires check up. Although numerous facts from practice of researches and 
treatment confirm and-or do not contradict Y-model, yet does not mean its validity. The results of 
future researches will allow investigators to confirm and-or specify Y-model, define more precisely the 
role of intestine PsB, quantitative parameters of dependencies between processes (both systemic and 
local). 
I hope that this work will stimulate joint researches of the dermatologists, rheumatologists, 
gastroenterologists and microbiologists and approximate complete solution of the riddle of psoriatic 
disease.  
In the future, treatment of psoriatic disease will be directed not to cosmetic and-or anti-inflammatory 
correction of local manifestations, rather elimination and-or decrease of action of original causes, i.e. 
in most cases, to the treatment of intestine dysfunctions (SP1, SP2). The efficiency of such treatment 
will depend on the patient, his/her desire and possibility to control the way of life and diet. As 
consequence, remission will be prolonged (or life-long!), probably supported by regular or periodic 
intake of medicines (bacteriophages, pre - and probiotics). 
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Appendices 
 
Appendix 2-1. Abbreviations (except TL) (added sample from Appendix 1, Part 1) 
  Abbr. Term and comments  
  AMP Antimicrobial proteins (peptides)  
*  BS Beta-hemolytic streptococci  
*  BSPG Peptidoglycan of beta-hemolitic streptococci  
*  CPs Chronic psoriasis  
 #2 DC Dendritic cells  
* #2 DC-T Tolerized DC (App.2-2)  
* #2 DC-R Reprogrammed (tolerized) and repleted by PG-Y dendritic cells are 
subfraction of tolerized fraction DC-T. (App.2-2) 
 
  DDC Dermal dendritic cells  
  EC Endothelial cells  
*  F Fragments of bacterial products with PAMP (including kPAMP)   
 #1 FB Fibroblasts  
 #1 HPV Human Papilloma Virus  
*  IB-Y Interpeptide bridges from peptidoglycan of Str.pyogenes: 
L-Ala(2-3) or L-Ala-L-Ser 
 
  iNOS Inducible nitric oxide synthase  
*  IYD Unit Y-presentation by dermal maDC-Y (quantity of Y-antigens, presented in 
unit volume of derma) 
 
*  IZD Unit Z-presentation by dermal maDC-Z (quantity of Z-antigens, presented in 
unit volume of derma). At LP2(HPV): Z is Z1 or Z2. 
 
 #1 KC Keratinocytes  
* #1 KC-v HPV-carring keratinocytes   
* #1 KC-Z1 HPV-carring keratinocytes presenting Z1-antigen  
  LC Langerhans cells  
  LP Local process  
 #1 LPS Lipopolysaccharide (endotoxin)  
  maDC Mature DC  
* #2 maDC-Y Mature DC derived from DC-R or from MoDC-R, presenting Y-antigen  
* #2 maDC-Z Mature DC, presenting Z-antigen  
  MDP Muramyl dipeptide - component Gram+ and Gram(-) PG, ligand NOD2  
  MC Mast cells  
  MHC Major histocompatibility complex  
 #2 Mo Monocytes  
* #2 Mo-T Tolerized Mo (App.2-2)  
* #2 Mo-R Reprogrammed (tolerized) and repleted by PG-Y monocytes are subfraction 
of tolerized fraction Mo-T. (App.2-2) 
 
  MoDC DC, derived from Mo  
* #2 MoDC-T DC-T, derived from Mo-T  
* #2 MoDC-R DC-R, derived from Mo-R  
 #2 MF Macrophages  
* #2 MF-T Macrophages, derived from Mo-T   
* #2 MF-R Macrophages derived from Mo-R   
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App. 2-1. (continuation) 
  Abbr. Term and comments  
 #2 Neu Neutrophils  
* #2 Neu-T Tolerized Neu (App.2-2)  
* #2 Neu-R Reprogrammed (tolerized) and repleted by PG-Y neutrophiles are subfraction  
of tolerized fraction Neu-T. (App.2-2) 
 
 #2 NK Natural killers  
  NKT Natural Killer T cell  
  NLS Non-lesional (prepsoriatic, uninvolved) skin – psoriatic skin without symptoms  
  NOD2 Intracellular receptor - ligand to MDP  
  PAMP Pathogen-associated molecular patterns  
 #2 PDC Plasmacytoid dendritic cells  
 #1 PG Peptidoglycan (in particular PG-Y)  
* #1 PG-Y Peptidoglycan A3alpha with interpeptide bridges IB-Y (but can contain and 
others also) 
 
  PLS Psoriatic lesional skin  
* #1 PsB Psoriagenic bacteria – Gram+ bacteria with peptidoglycan PG-Y  
(Part 1, SP2) 
 
*  SIS Skin Immune system  
  slanDC 6-sulfo LacNAc-expressing dendritic cells (Hansel 2011, Schakel 2006, 
Teunissen 2011). A subfraction of blood dendritic cells BDCA-1(-)DC fraction. 
It is very close to CD14(-)CD16+Mo in terms of characteristics. It can be found 
in blood flow and derma in psoriatics. A part of slanDC becomes TipDC in 
PLS.
 
*  SP Subprocess   
*  SPP Systemic psoriatic process  
  TipDC maDC actively secreting TNF-alpha and iNOS  
(in particular maDC-Y or maDC-Z) 
 
  TLR4 Membranous receptor - ligand to LPS  
  TLR9 Intracellular receptor – ligand to CpG  
* #1 Y Y-antigen = part(s) of interpeptide bridge IB-Y  
*   Y-model Model of pathogenesis of psoriasis, offered in this monograph  
*  Z1 Dominant antigen, presented through MHC class I for TcN-Z1. 
At LP2(HPV): Z1 is HPV-antigen. 
 
*  Z2 Dominant antigen, presented through MHC class II for ThN-Z2. 
At LP2(IN): Z2 is antigen of commensal or pathogenic bacteria transferred 
into derma as a result of trauma. 
At LP2 (HPV): Z2 is HPV-antigen. 
 
* #1 Z  At LP2(IN):  Z is Z2,  at LP2(HPV):  Z is Z1 or Z2.  
 
*  - new abbreviation, images: #1 – Fig. 2-1 and  #2 – Fig. 2-2,  
                  Links are given for good articles in Wikipedia. 
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Appendix 2-1a. Abbreviations for TL  
New designations ThN (for Th1/Th17/Th22) and TcN (for Tc1/Tc17/Tc22) are introduced. It has 
been made for the next reason: besides TL with clearly allocated secretion of IFN-gamma or IL-17 or 
IL-22, transitive TL, secreting more than one of these cytokines also exist (Kagami 2010, 
Nograles 2010, Zenewicz 2011). At that, Th1 can be transformed in Th17 and vice versa 
(Annunziato 2010, Kurschus 2010). 
 
  Abbr. Term and comments 
 #3 TL T-lymphocytes (any) 
 #3 nTL Naive TL. Non-effector and nonspecific to any of antigens, they can become 
effector and specific after interaction with maDC in a lymph node. 
  Tem Effector memory TL (here called effector TL). They are formed from nTL (at 
primary response) and from Tcm (at secondary response) in a lymph node. 
Then they move to blood flow and into tissues to the site of inflammation to 
participate in adaptive response and, subsequently, stay there constantly. 
  Tcm Central memory TL (here called memory TL). They are formed from nTL (at 
primary response) in regional LN. Then they move to blood flow and then to 
farther LN of the human organism to stay there constantly. At secondary 
response Tem are quickly formed in lymph nodes from Tcm. 
  Th1 CD4+Tem, characterized by secretion: IFN-gamma(+)IL-17(-)IL-22(-) 
  Th17 CD4+Tem characterized by secretion: IFN-gamma(-)IL-17(+)IL-22(-) 
  Th22 CD4+Tem, characterized by secretion: IFN-gamma(-)IL-17(-)IL-22(+) 
*  ThN CD4+Tem secreting one or more of three cytokines IFN-gamma, IL-17 and 
IL-22. In particular, these are Th1, Th17 and Th22, but also intermediate TL 
(sometimes designated as Th1/Th17, etc.) 
  Tc1 CD8+Tem characterized by secretion: IFN-gamma(+)IL-17(-)IL-22(-) 
  Tc17 CD8+Tem, characterized by secretion: IFN-gamma(-)IL-17(+)IL-22(-) 
  Tc22 CD8+Tem, characterized by secretion: IFN-gamma(-)IL-17(-)IL-22(+) 
*  TcN In particular, these are Tc1, Tc17 and Tc22, and intermediate TL as well 
(sometimes designated as Tc1/Tc17, etc.) 
    
* #3 ThN-Y Y-specific ThN 
* #3 Tem-Y Y-specific Tem (basically ThN-Y) 
* #3 Tcm-Y Y-specific Tcm 
* #3 TL-Y Tem-Y and Tcm-Y 
* #3 TcN-Z1 Z1-specific TcN 
* #3 ThN-Z2 Z2-specific ThN 
* #3 ThN-Z Z-specific ThN 
* #3 Tem-Z Z-specific Tem (basically TcN-Z1 and ThN-Z2) 
* #3 Tcm-Z Z1-specific and Z2-specific Tcm 
* #3 TL-Z Tem-Z and Tcm-Z 
* - new abbreviation, images: #3 – Fig. 2-3. 
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Appendix 2-2. New terms (from Part 1, App. 2) 
Term Description Bibliography  
Chemostatus Range of chemokine receptors expressed by cell (CCR1, 
CCR2, CCR3 etc.) including the amount of each. 
Chemostatus of cell defines it’s behavior in reply to 
homeostatic and/or inflammatory chemokines. 
Bachmann 2006,  
Male 2006, 
Sozzani 2005 
 
PAMP-load Phagocyte-dependent consumption (linkage, endocytosis) 
of PAMP and contact with PAMP.  
Part 1, App.9  
Tolerized 
phagocytes 
The activated phagocytes under chronically increased 
PAMP-load are tolerized (reprogrammed).  
Tolerized phagocytes are designated as Neu-T, Mo-T and 
DC-T. It is supposed that tolerized phagocytes (except 
known properties) have: 
  
Property 1. Despite contact, linkage with PAMP and 
endocytosis of PAMP (as a part of endocytosed 
F-content) their chemostatuses are similar to 
nonactivated.  
 
Property 2. As tolerization occurs under chronic 
kPAMP-load then there is kPAMP in endocytosed 
F-content. Its degradation occurs slowly and not 
completely, i.e. kPAMP-carriage takes place. 
 
Properties 1 and 2 seem to depend on the blocking 
intracellular protein IRAK-M. Level of this protein in tolerized 
phagocytes becomes more than critical as a result of 
chronically increased PAMP-load. 
Property 2 depends on parity between rate of endocytosis F 
and intracellular proteolytic activity. 
 
In process of aging chemostatus of tolerized Neu changes 
similarly to chemostatus of nonactivated Neu.  
Those and others start to express actively CXCR4 that 
provides their homing into bone marrow (Part 1, SP9).  
Biswas 2009, 
Buckley 2006, 
Hedl 2007, 
Medvedev 2006, 
Nakatani 2002, 
Savina 2007, 
van't Veer 2007, 
 
Part 1,  
App. 4,  
App.10 
 
R-phagocytes  
= Reprogram-
med (tolerized) 
and repleted by 
PG-Y 
phagocytes  
R-phagocytes are tolerized phagocytes which also are 
(PG-Y)-carriers. They are designated as Neu-R, Mo-R and 
DC-R and have additional: 
 
Property 3. There is PG-Y in endocytosed F-content. 
Its degradation occurs slowly and not completely, i.e. 
takes place (PG-Y)-carriage. 
 
Property 3 (as well as Property 2) depends on parity 
between rate of endocytosis F and intracellular proteolytic 
activity. 
As endocytosis and conservation of PG-Y (as a part of 
F-content) by phagocytes occurs in a random way, also 
subfraction  
R-phagocytes in tolerized fraction is formed in a random 
way. 
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 App. 2-2 (continuation) 
Term Description Bibliography  
kPAMP =  
key PAMP 
Not all PAMP but only key PAMP (kPAMP) provide 
reprogramming of tolerized phagocytes. Tolerized 
phagocytes were likely to contact with kPAMP than with 
other PAMP and/or endocytosed F-content contained more 
kPAMP than other PAMP. 
  
kPAMP-load Phagocyte-dependent consumption (linkage, endocytosis) 
of kPAMP and contact with kPAMP  
Part 1, App.9  
PAMP-nemia Chronic increasing of kPAMP-load on blood phagocytes 
resulting in  
a) formation of essential share of tolerized phagocytes;  
b) kPAMP-level increasing in blood. 
c) increased kPAMP-carriage of tolerized phagocytes 
  
Cytokines-
deprogrammers 
Normal phagocytes aren’t tolerized (reprogrammed) and 
tolerized phagocytes (including R-phagocytes) are quickly 
lose tolerance (deprogrammed) in the presence of such 
cytokines.  
IFN-gamma, GM-CSF and IL-12 are known. IL-12 
stimulates non-monocytic cells to produce IFN-gamma.  
Adib-Conquy 
2002, Cavaillon 
2008, Kylanpaa 
2005, Randow 
1997 
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Appendix 2-3. Causative dependencies between processes and subprocesses 
Cause 
                  
  SPP LP1.1 LP1.2 LP2 LP3 LP4 LP5 LP6.1 LP6.2 LP6.3 LP6.4 LP7.1 LP7.2 LP8.1 LP8.2 
  SPP                               
LP1.1 +                       
LP1.2         
+ 
  
+ 
        + +C 
+B 
  LP2         #   #               # 
  LP3     + +     +   +            
  LP4     + + +   #                
  LP5     + + + +     +             
LP6.1   +B           +     
LP6.2         +B           
LP6.3       +   +         
  
LP6.4   
+ 
    + 
+ + 
+B +         
+C 
LP7.1             #     +             
LP7.2                     +C     #   
LP8.1     +C           +B   +B       + 
Ef
fe
ct
 
 
LP8.2                           +    
  
Notes: 
The table is made according to Y-model of pathogenesis (Fig. 2-6). 
Colors in the first column are used further for highlighting a specific (sub)process and-or causative 
dependence designated by an arrow beginning from this (sub)process.  
+ - positive influence; 
+B or +C - vicious cycles; 
# - negative influence (suppression); 
Empty table cells mean that connections are either absent or insignificant. 
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Appendix 2-4. Local processes, references and hypotheses 
References with facts Process or subprocess With psoriasis Without psoriasis Hypotheses  
LP1 Attraction of immunocytes from blood flow. 
LP1.1. Attraction Mo and DC, 
Mo-T and DC-T (incl. 
Mo-R and DC-R) from 
blood flow. 
*, but without 
mentioning Mo-T and 
Dc-T (incl. Mo-R and 
DC-R) 
* LP1-H1.  
Attraction of Mo-R 
and DC-R as a 
necessary vicious 
cycle link 
LP1.2. Attraction of other 
immunocytes from 
blood flow. 
* *  
LP2 Initiating and aggravating process.  
   LP2(IN) Open trauma of 
derma 
Kalayciyan 2007, 
Weiss 2002 and other 
models 
Gillitzer 2001, 
Ishida 2008 
  
   LP2(HPV) HPV–carriage KC  Fomina 2009, Cronin 
2008, De Koning 
2011, Favre 1998,  
Fry 2007b, Mahe 
2003, Majewski 2003, 
Prignano 2005, 
Viviano 2005, 
Weissenborn 1999 
De Koning 2005, 
Hazard 2007, 
Hebner 2006, 
Stanley 2009, 
Woodworth 2002  
 
LP2-H1.  
Not only epidermal, 
but dermal HPV-
expansion of 
invasive types can 
become a trigger of 
PLS-plaque. 
LP3 Innate response 
against LP2. 
* *  
LP4 Trigger of adaptive response against LP2. 
  LP4(IN) LP4 after trauma. Other models except 
BF-model 
Gregorio 2010 
 
  
  LP4(HPV) LP4 against HPV. no Tang 2010 see LP2-H1 
LP5 Adaptive response against LP2. LP5-H1.  
LP5 is a necessary 
process for LP8 
initialization. 
   LP5(IN) Adaptive response 
after trauma. 
see LP2(IN) see LP2(IN)   
   LP5(HPV) Adaptive response 
against HPV. 
see LP2(HPV) see LP2(HPV) LP5-H2.  
Attraction of TcN-Z1 
from derma into 
epidermis as an 
event preceding LP8 
initialization. 
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App. 2-4 (continuation) 
References with facts Process or subprocess With psoriasis Without psoriasis Hypotheses 
LP6 Mo and DC transformations. 
LP6.1 Loss of tolerance to 
kPAMP. 
 no Buckley 2006, 
Cavaillon 2008, 
Kylanpaa 2005, 
Medvedev 2006 
 
LP6-H1.  
LP6.1 - is a 
necessary vicious 
cycle link. 
LP6.2 MF and MoDC 
formation. 
Fuentes-Duculan 
2010, Zaba 2009a 
(except MoDC) 
Angel 2006, 
Haniffa 2009 
LP6-H2.  
MoDC-R formation 
is a probable vicious 
cycle link. 
LP6.3 maDC-Z formation  
 
Zaba 2009a Angel 2006, 
Haniffa 2009 
 
LP6.4 maDC-Y formation  
 
Zaba 2009a Angel 2006, 
Haniffa 2009 
LP6-H4.  
LP6.4 - is a 
necessary vicious 
cycle link. 
LP7 Lymph nodes. Clonal 
proliferation. 
Nestle 2009a,  
Vissers 2004 
Clark 2010, 
Stanley 2009 
 
LP8 False adaptive 
response to imaginary 
PsB-infection.  
Immune response in 
other models without 
specific antigen. 
Against Y-antigen in 
BF-model. 
no   
*  -  (sub)process is known, references are available;  
       LPn-Hm = hypothesis Hm, proposed in process LPn. 
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Appendix 2-5. Chemokine receptors, chemokines and AMP,  
certainly or possibly involved in LP1.  
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Notes to App. 2-5.  
Basic chemokines and AMP associated with local psoriatic processes in skin are included in the 
table (Nickoloff 2007b, Nestle 2009a). In case if a chemokine receptor is a ligand of chemokine or 
AMP, the value of maximal affinity between them is specified in the table cell according to IUPHAR 
(Murphy 2010). In case the value in IUPHAR is absent, mark “*” is given in the table and information 
on their interaction is received from another source. Green color – the receptor/chemokine work at 
homeostasis, pink - during attraction of immunocytes in PLS (Mantovani 2004). Ovals including certain 
list of chemokines and AMP are present only on schemes of Fig. 2-9 and Fig. 2-18. References in the 
form of capital Latin letter are made to the following notes: 
 
A) CCL2 (MCP-1) and CCR2.  
CCL2 is secreted in the norm (Ginhoux 2007). CCL2 is secreted by KC in PLS significantly above 
the norm (Vestergaard 2004). KC also secrete CCL2 in NLS near to plaque. In PLS and NLS secretion 
is concentrated in the basal layer (Gillitzer 1993). 
 
B) CCL5 (RANTES) and CCR5.  
CCL5 is secreted both in the norm and at inflammation. The level of CCL5 in PLS is significantly 
higher than in NLS, CCR5+ prevail among CD68+Mo found out in PLS compared with similar Mo in 
NLS. However, CCR5 receptor does not play an essential role in psoriasis pathogenesis 
(De Groot 2007). In PLS only KC secrete CCL5, the level of which is 3-4 times more than in the norm 
(Raychaudhuri 1999); TNF-alpha in PLS actively promotes secretion of CCL5 by basal KC 
(Giustizieri 2001). Attraction of NK in PLS occurs basically due to CXCL10 and CCL5. At that, 80% of 
involved NK are CD56(bright)CD16(-) (Ottaviani 2006). 
 
C) CCL20 (MIP-3alpha) and CCR6. 
CCL20 is secreted in the norm for attraction of blood Mo - precursors of LC (Ginhoux 2007); CCL20 
promotes chemotaxis of CCR6+DC in derma to epidermis (Homey 2000, Hedrick 2010). 
  
D) CX3CL1 (fractalkine) and CX3CR1. 
CX3CL1 is secreted by EC for attraction of CX3CR1+CD16+Mo from blood flow (Ancuta 2003). 
CX3CL1+DDC are found out in PLS-derma in the number of 187 against 6 (per sq. mm) in normal 
derma. Proinflammatory DC and MoDC actively secrete CX3CL1 promoting attraction of CX3CR1+Mo 
and CX3CR1+DC from blood flow – their own potential precursors (Raychaudhuri 2001). CX3CL1 is 
actively secreted by KC in PLS, and much less - in NLS (Sugaya 2003). 
 
E) CXCL9 (MIG) and CXCR3. 
Secretion of CXCL9 in PLS is higher than in NLS, where it exceeds the norm (Chen 2010). CXCL9 
is highly expressed in capillaries and in papillaes. It is secreted by MF and by endothelial cells EC. In 
norm and in NLS, it is practically absent (Goebeler 1998). It is secreted in PLS mainly by EC (in 
dermal vessels) and by mononuclear cells. In PLS-epidermis (secreted by KC) and in near NLS much 
lesser amount of it is present, and in distant NLS it is completely absent (Rottman 2001).  
 
F) CXCL10 (IP-10) and CXCR3. 
CXCL10 is secreted in PLS in greater amount than in NLS, where it exceeds the norm 
(Chen 2010). It is secreted in PLS mainly by EC (in dermal vessels) and by mononuclear cells. In 
PLS-epidermis and near NLS only insignificant amount can be found, and in distant NLS it is absent 
completely (Rottman 2001). Attraction of NK in PLS occurs basically due to CXCL10 and CCL5. The 
basic source of CXCL10 in inflamed skin are activated KC, at that psoriatic KC are capable of 
secreting CXCL10 more than the normal ones (Ottaviani 2006). 
 
G) CXCL11 (ITAC) and CXCR3. 
Secretion of CXCL11 in PLS is higher than in NLS, where it exceeds the norm (Chen 2010). 
 
© 2011-2012,  Peslyak MY,  Model of pathogenesis of psoriasis. Part 2. Local processes.  e1.3.                                                              51 
H) CXCL12 (SDF-1alpha) and CXCR4 are a homeostatic pair. 
CXCL12 is constantly secreted in normal skin (Bogunovic 2006, Urosevic 2005).  
 
I) CXCL16 and CXCR6. 
Expression of CXCL16 is very active in basal layers of KC in PLS, and is increased in all capillary 
EC in PLS-derma (Oh 2009). 
 
J) HBD-2, HBD-3 and CCR2.  
Earlier it has been assumed that HBD-2 is a ligand of CCR6 - receptor expressed by blood DC, but 
practically not expressed by Mo (Yang 1999). However, later, it has been shown that CCR6 receptor is 
not involved in chemotaxis of Mo supported by HBD-2 and HBD-3 (Soruri 2007). Recently it has been 
established that HBD-2 and HBD-3 support chemotaxis through CCR2 receptor and, hence, they can 
support attraction of blood CCR2+Mo and CCR2+DC. Preliminary incubation of Mo with CCL2 has 
disturbed such migration (Rohrl 2010). It is necessary to note that secretion of all AMP both 
quantitatively and spatially depends of LP2 and the depth of skin damage as well (Diamond 2009, 
Poindexter 2005). Probably, this is the reason of essentially various results observed at mRNA HBD-2 
psoriasis: 2-time excess of the norm (Li 2004), 5000 times (Gambichler 2008), and 20000 times 
(De Jongh 2005). In PLS-epidermis, the most part of HBD-2 is secreted by KC in the top spinous and 
granular layers, it reaches maximal concentration in the intercellular space in the cornual layer, where 
it envelops all KC completely (Huh 2002). In normal skin the maximal concentration of HBD-2 is 
observed in the basal layer (Poindexter 2005).  
 
K) HBD-2 and CCR6.  
HBD-2 is strongly expressed in PLS (De Jongh 2005). HBD-2 is a ligand of CCR6 (Yang 1999). 
HBD-2 is a chemoattractant for Mo and MF, but not through CCR6, rather through CCR2 (Soruri 2007, 
Rohrl 2010). 
 
L) CCL17 (TARC) and CCR4. 
At psoriasis modeling in mice, CCL27 blocking did not affect attraction of TL into skin, only 
additional blocking of interaction between CCL17 and CCR4 stopped this attraction (Sabat 2007). 
 
M) Chemerin and ChemR23 (CMKLR1).  
ChemR23 is present in PLS in large amounts (Skrzeczynska-Moncznik 2009a, 
Skrzeczynska-Moncznik 2009b). ChemR23 promotes attraction of PDC and NK in PLS and promotes 
colocalization of NK and DC. 
 
N) LL37 and FPRL1.  
LL37 is a ligand of FPRL1 - receptor expressed by blood Mo and DC. Interaction of LL37 and 
FPRL1 supports chemotaxis of Mo and DC to the inflammation site (Sozzani 2005). 
 
O) CCL27 (CTACK) and CCR10.  
CCL27 is constantly secreted by KC in normal skin (Baker 2006c, Bogunovic 2006). Chemokine 
CCL27 is important for attraction of ТL in PLS (Sabat 2007). 
 
P) CXCL1 and CXCR1, CXCR2. 
CXCR1 is secreted by KC, it is important for attraction of Neu in PLS (Baker 2006c). 
 
Q) CXCL8 (IL-8) and CXCR1, CXCR2. 
CXCR8 is secreted by KC, it is important for attraction of Neu and CD8+TL in PLS (Baker 2006c). 
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Appendix 2-6. Chemokine receptors and blood immunocytes.  
/100 
D
A 
Mo * E
DC 
F 
C 
BDCA-3+DC 
H 
O 
90 
Q
* 
E
50 
Q
* 
E
P 
 
Notes to App. 2-6.  
Green color - receptor works at homeostasis, pink - mainly during attraction of immunocytes in 
PLS. If in a reference there is no information either on a share of expressing cells, or on expression 
intensity, designation stands «*» in the table. If comments are necessary - a capital Latin letter 
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directing to one of notes is added in the table. A Latin letter in the last column refers to all lines 
opposite to it.  
 
A) Mo - three fractions according to the nomenclature of blood monocytes (Ziegler-Heitbrock 2010). 
For each receptor, the percentage of cells expressing it in a certain fraction is specified. An empty 
table cell means that the data are absent (Ancuta 2003). 
 
B) CD14+CD16+Mo.  
This fraction expresses CCR2, CCR5, CXCR4 and CX3CR1 (Serbina 2008). In the absence of 
inflammation their homeostatic traffic in derma provides chemokine CXCL12 (SDF-1alpha), which is a 
ligand of CXCR4 receptor (Urosevic 2005). Chemokine CXCL12 is constantly secreted by dermal 
endothelial cells, and CXCR4 receptor is expressed by all fractions of blood monocytes 
(Strauss-Ayali 2007). Besides CXCL12, dermal endothelial cells constantly secrete chemokine 
CX3CL1 (fractalkine) (Ziegler-Heitbrock 2007), which also promotes homeostatic attraction of blood 
CD16+Mo with increased expression of CX3CR1 (Gautier 2009). 
 
C) CD33+CD14+Mo; CD33+CD14(-)CD11c+DC and CD33(dim)CD14(-)pDC. 
For each receptor, the percentage of cells expressing it and /MFI - average intensity of 
fluorescence are specified. Mo and PDC, but not myeloid DC, are attracted by high concentrations of 
CXCL10 (Cravens 2007). At the present, full data characterizing chemokine receptors expression by 
fractions of blood BDCA-1+ and BDCA-1(-)DC are unknown. Recently a new chemokine XCR1 
receptor has been found in blood BDCA-1(-)BDCA-3+DC, however there is no information about 
secretion of its ligand - XCL1 - at psoriasis (Crozat 2010). 
 
D) Three fractions of monocytes and three fractions of dendritic cells (BDCA-1+DC, 
BDCA-1(-)BDCA-3+DC and PDC) according to the nomenclature (Ziegler-Heitbrock 2010). 
For ChemR23, the percent of cells expressing it and /MFI - average intensity of fluorescence are 
specified. At comparison with migration, in reply to CXCL12, chemerin induced the same migration of 
DC, but only 50% of migration of PDC (Vermi 2005). 
 
E) Mo, DC, Neu and TL. 
LL37 is a ligand of FPRL1 - receptor expressed by blood Mo and DC. Interaction of LL37 and 
FPRL1 supports chemotaxis of Mo, DC, Neu and TL to the inflammation site (Sozzani 2005). 
 
F) PDC. 
Attraction of PDC in NLS-derma takes place due to ChemR23 receptor – a ligand of chemerin 
(Albanesi 2010). Traffic of PDC at homeostasis and inflammation in skin, besides ChemR23 receptor, 
is also provided by receptors CXCR3 (ligand of CXCL10) and CXCR4 (ligand of CXCL12) 
(Sozzani 2010).  
 
G) DC. 
As to their attraction by chemokine CX3CL1 (fractalkine), experimental data concerning its ligand 
expression (CX3CR1 receptor) are ambiguous. This receptor expresses by maDC, but there is diverse 
information on its expression by DC. It is shown that mRNA CX3CR1 expression in immature and 
mature MoDC is almost identical, and chemotaxis of all dendritic cells (initiated CX3CL1) is essential 
and almost identical (Dichmann 2001). On the other hand, CX3CR1 expression is found only in maDC 
(Liu 2011). The level of CX3CR1 expression in maDC defines their movement inside derma after their 
maturation. All chemokine receptors responsible for DC attraction in inflamed tissues are listed in 
(Lukacs-Kornek 2008). 
 
H) DC and PDC. 
In an early work, chemokine receptors of two fractions of blood dendritic cells were investigated. In 
the same work it is noticed that expression of chemokine receptor not always defines chemotaxis to 
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the influence of a ligand of this receptor. In particular, in chemotactic tests PDC reacted only to 
CXCL12 (SDF-1alpha) (Penna 2001). 
 
I) CD56(low)CD16+NK. 
Attraction of CD16+NK in inflamed tissues occurs through their chemokine receptors ChemR23 
(ligand of chemerin), CX3CR1 (ligand of CX3CL1 - fractalkine) and CXCR1 (ligand of CXCL1, CXCL6 
and CXCL8). Getting into inflamed tissues, NK, besides destruction of infected cells, also cooperate 
with DC accelerating their maturation, and own cytotoxicity as well. Besides attraction of PDC, NK 
promotes colocalization of NK and DC in inflamed tissues (Moretta 2008).  
 
J) NK  
Attraction of NK is regulated by chemerin (it is shown in vitro), which can define their excess in PLS 
(and also excess of PDC) (Skrzeczynska-Moncznik 2009a). 
 
K) CD56++CD16(-)NK. 
These cells accumulate in PLS under the influence of CCL5 and CX3CL1 as CCR5 and CX3CR1 
are well expressed by them. Besides, CXCR3 are well expressed by them (Ottaviani 2006). 
 
L) Neu. All chemokine receptors expressed by Neu are listed in (Kobayashi 2008). 
 
M) Neu express CCR2 (Rohrl 2010). 
 
N) Neu well express CXCR2 receptor (it is a ligand of cytokine-chemokine CXCL8 and a ligand of 
CXCL1) defining their attraction to inflammation sites (Reddy 2010). 
 
O) Neu changes expression of its chemokine receptors along with aging (more details are in Part 1, 
SP9). Consecutive change of expression of receptors involved in release of new Neu from bone 
marrow, their aging and partial return to bone marrow is analysed in (Rankin 2010). 
 
P) CD4+TL and CD8+TL.  
In the table cell, % of epidermal TL in PLS with the corresponding receptor is specified. In 
PLS-epidermis, the majority of CD4+TL and about a half of CD8+TL express CCR4, whereas only 
30% of CD8+TL and 16% of CD4+TL express CXCR3. In PLS-epidermis, 72% of CD4+TL and 51% of 
CD8+TL express CCR6, which is significantly higher than in blood TL (Teraki 2004). The same 
information is given in (Sabat 2007). 
  
Q) CCR4 and CXCR3 on TL. 
In PLS, CCR4+ cells were CD3+TL or CD68+Mo or CD68+MF. In PLS, CXCR3+ cells are mainly 
CD3+ТL (Rottman 2001). The same information is given in (Sabat 2007). 
 
R) CCR6 on CD4+TL and CD8+TL 
Among all blood immunocytes, CCR6 expression is found mainly on CD4+TL and CD8+TL, and it 
is more intensive on CD4+TL. At more detailed study, it was found out that CCR6 expression is mainly 
observed on Tem (Liao 1999). 
  
S) CCR4 and CCR10 on Tem. 
 After interaction of CLA+Tem with E-selectin, expressed on EC, Tem get under the influence of 
CCL27 as their part expresses CCR10. Besides, Tem also express CCR4 and this is the reason for its 
attraction by CCL17 (Sabat 2007, Clark 2010). 
 
T) There is no any unique marker to separate Th17 from Th1, therefore several markers were used.  
CCR6 is expressed on 81% of IL-17A+ cells and only on 26% of IFN-gamma+ cells, being the best 
marker distinguishing Th17 from Th1. Recently, CCR4 and CCR10 have been identified on Th22 
(Kagami 2010). The same data for Th1 and Th17 are presented in (Harper 2009). 
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Appendix 2-7. Cytokines and cells. Secretion and influence.  
ThN TcN                Cells Mo MF PDC DC ma DC Neu NK Th1 Th17 Th22 Tc1 Tc17 Tc22 
EC MC FB KC 
secr.  A              A  
infl.                 A 
secr.                B B 
infl. B   B    B B     
secr.   C               
infl. D   D D  E E E     
secr.       H E,H – – E,H  – –     
infl. B   B,F F  E           F 
secr. F F  F F             
infl.    F,P F,P            F 
secr.   C P,G P,G    G     G  G G 
infl.    G    G G     
secr. H H  H H             
infl.    H H  H H   H       
secr.      I  – I – – I –  I   
infl.                I I 
secr.  J   J            J 
infl.                 J 
secr.  K  K   K – – K – – K     
infl.                 K 
secr.    L L         L    
infl.        L L L       L 
secr.  M   M             
infl.                  
secr.                N  
infl.                 N 
secr.                O O 
infl.                O O 
secr. P P C P P  P P   P    P  P 
infl. D  D D,P D,P         P   F 
 
Notes to App. 2-7.  
Basic cytokines and cells associated with processes in PLS are included in the table. Each table 
cell is divided into the upper and lower parts. The upper part of a table cell corresponds to ability of 
biological cell to secrete a specific cytokine, and lower part – to the ability of cytokine to influence the 
biological cell actively. If a certain type of cells is also defined by its disability to secrete a specific 
cytokine (for example, ThN and TcN), designation «-» can be seen in the table. An empty table cell 
means that secretion (influence) is absent or insignificant. If comments are necessary - one or several 
Latin letters is given in the table cell meaning references to the notes:  
 
A) EGF (epidermal growth factor) 
It is secreted by MF and FB, influences KC and FB, in particular, stimulating GM-CSF secretion 
(Mascia 2010, Nestle 2009b). It can be secreted by MF.  
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B) GM-CSF, IFN-gamma. 
Tolerized Mo-T, DC-T and MoDC-T (incl. Mo-R, DC-R and MoDC-R) lose tolerance to PAMP-
content under the influence of cytokines-deprogrammers GM-CSF, IFN-gamma (LP6.1). KC and FB 
secrete GM-CSF (Koga 2008, Mascia 2010). Activated ThN and TcN also secrete GM-CSF (Male 
2006, Shi 2006). 
  
C) IFN-alpha, TNF-alpha, IL-6.  
PDC secrete IFN-alpha in great amount, and slightly less amounts of TNF-alpha and IL-6 (LP4).  
 
D) IFN-alpha, TNF-alpha.  
Under the influence of IFN-alpha, Mo and DC increase expression of PAMP-receptors (in particular, 
TLR4). Under cooperative influence of IFN-alpha and TNF-alpha transformation of Mo in MoDC 
(LP6.2), as well as maDC formation (LP6.3 and LP6.4) is accelerated. Increased level of TNF-alpha 
suppresses ability PDC to secrete IFN-alpha. 
 
E) IFN-alpha, IFN-gamma. 
LP5 depends from LP4. IFN-alpha influences activation of ThN and TcN and formation of Tcm, 
especially, if LP2 is a virus (Seo 2010, Zhang 2005). IFN-alpha also promotes activation of TL (in 
particular, of Th1) and increases their secretion of IFN-gamma (Eriksen 2005).  
IFN-alpha promotes formation of Th22 (Nestle 2009a).  
Th1 and Tc1 secrete IFN-gamma under the influence of IFN-alpha, during activation due to 
interaction with maDC as well.  
Under the influence of IFN-alpha and IFN-gamma, NK increase their cytotoxic (cytolytic) activity. 
 
F) IFN-gamma, IL-1beta, TNF-alpha. 
Mo, MF, DC and maDC secrete IL-1beta at activation and during interaction with antigens. 
IFN-gamma and IL-1beta together influence maturation of maDC (LP6.3 and LP6.4). 
IFN-gamma and TNF-alpha influence expression of adhesive molecules on KC, which promotes 
interaction of KC and activated ThN (LP8.2).  
Influence of TNF-alpha and IL-1beta on KC promotes active secretion of CCL2, CCL20 and HBD-2.  
 
G) IL-6. 
All ThN and TcN involved and present in PLS get under the influence of a high level of IL-6 
secreted by EC, DC, and Th17. It allows ThN and TcN to avoid suppression from Treg and gives Th17 
the chance to participate actively in inflammation (Goodman 2009). KC and FB also secrete IL-6 
activating DDC (Nestle 2009a). 
 
H) IL-12. 
It is secreted by DC and maDC at activation and maturation. IL-12 accelerates transformation of 
DC in maDC (autocrine influence). At maturation, maDC secrete even more IL-12. Mo (to a lesser 
degree), and CD163+MF both actively secrete IL-12 (Fuentes-Duculan 2010). IL-12 influences Th1, 
Tc1 and NK and they secrete IFN-gamma (Randow 1997). 
 
I) IL-17. 
Activated ThN (basically Th17) and TcN (basically Tc17) secrete IL-17A and IL-17F (Nestle 2009a, 
Nestle 2009b). MC and Neu in PLS secrete IL-17 (Lin 2011, Res 2010). IL-17 influences KC and FB 
secreting GM-CSF (Koga 2008, Mascia 2010). IL-17 promotes hyperproliferation of KC also secreting 
chemokines and AMP. Increased secretion of IL-17 is regarded as one of vicious cycle links (App.2-9).  
  
J) IL-20. 
It is secreted by maDC and MF (Wang 2006), and by KC as well (Baker 2006c). It causes 
hyperproliferation and acanthosis influencing (including autocrine way) KC (Guttman-Yassky 2011, 
Sabat 2011). 
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K) IL-22. 
It is secreted by activated ThN (basically Th22) and TcN (basically Tc22), but also by NK 
(Kagami 2010, Sabat 2011, Zenewicz 2011). IL-22 in PLS is also secreted by MF and DC (Res 2010). 
IL-22 stimulates KC to secretion of chemokines and AMP; IL-22 stimulates KC to secretion of IL-20;  
IL-22 (together with IL-20) inhibits differentiation of KC, which causes hyperproliferation and 
acanthosis; IL-22 causes production of MMP1 and MMP3, which weakens extracellular matrix 
(Guttman-Yassky 2011, Sabat 2011, Wolk 2009). Increased secretion of IL-22 is considered as one of 
vicious cycle links (App.2-9). 
 
L) IL-23. 
IL-23 is secreted basically by dermal DC and maDC (at activation and maturation) and activates 
ThN. EC also secrete IL-23 (Meglio 2010, Tonel 2010). IL-23 influences Th1 and stimulates Th17 to 
secretion of IL-17, and Th22 - to secretion of IL-22 (Guttman-Yassky 2011, Zenewicz 2011). Besides, 
IL-23 influences KC promoting formation of STAT3 (Nestle 2009a). Increased secretion of IL-23 is 
considered as one of vicious cycle links (App.2-9). 
 
M) iNOS (inducible nitric oxide synthase). 
It has antimicrobial and antitumoral properties. It is secreted by TipDC, in which some researchers 
find more signs of MF (Dominguez 2010).  
 
N) KGF (keratinocyte growth factor). 
It is secreted by FB, and can influence proliferation of KC (Lowes 2007, Nestle 2009b). 
 
O) TGF-beta. 
It is secreted and interacts with KC and FB (Nestle 2009b). 
 
P) TNF-alpha. 
Activated MF secrete the basic part of TNF-alpha (Clark 2006b). 
Also, TNF-alpha is secreted by Mo and DC during activation, and by DC during maturation.  
Self-RNA-LL37 complexes formed during LP3.1 cause activation and maturation of DC. It takes 
place involving endosomal TLR8 and stimulates DC and maDC to secretion of TNF-alpha and IL-6 
(Guttman-Yassky 2011). 
MC (mast cells) also secrete TNF-alpha (Sabat 2011).  
Activated Th1, Tc1, NK and KC secrete TNF-alpha (Nestle 2009b). 
TNF-alpha together with IL-1beta activates DC and promotes maturation. 
TNF-alpha influences EC increasing expression of E-selectin (a ligand of CLA) and ICAM-1, which 
provides attraction of Tem from blood flow (Tonel 2009, Sabat 2011).  
Increased secretion of TNF-alpha is one of vicious cycle links (App.2-9).  
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Appendix 2-8. Psoriasis on NLS-transplants placed onto AGR129-mice.  
Investigations of the psoriasiform plaques arising on mouse’s skin immediately or on 
NLS-transplants after their transplantation have been conducted for a long time (Gudjonsson 2007). 
However, only in 2004 it become possible to create the line of knockout mice AGR129, in which 
spontaneous development of typical PLS-plaques on NLS-transplants was seen for the first time. Not 
only good engraftment of transplant appeared to be characteristic for this line of mice, but also 
conservation of donor resident immune cells, first of all TL and DC, the most part of which, as a rule, is 
destroyed by NK of a recipient mouse. These studies and their subsequent analysis also showed that 
under certain circumstances the initialization and development of PLS-plaque can occur at 
participation of only resident immune cells (Boyman 2004, Boyman 2007, Nestle 2005a, Tonel 2009, 
Tonel 2010). 
AGR129-mice are RAG-2(-)/(-), which provides inferiority of mouse B-lymphocytes and TL. 
Deficiency on receptors to IFN-alpha and IFN-gamma provides significantly lowered cytotoxic 
(cytolytic) activity of mouse NK cells both in vitro and in vivo. AGR129-mice appeared to be excellent 
recipients of human NLS-transplants. For initialization and development of PLS-plaque on 
NLS-transplant no exogenous cells or factors are required, except for those contained in 
NLS-transplant itself. One of defining factors for PLS-plaque development is activation and 
proliferation of donor Tem, being already in NLS at the moment of transplantation.  
 
In psoriatics with the confirmed diagnosis (12 patients) fragments of NLS (6 x 2 x 0,04 cm) from the 
lower part of the back or breech (31 samples) were taken. These fragments were replaced onto 
AGR129-mice. In 28 cases from 31 (90%) since the 4th week after transplantation, plaques 
spontaneously appeared on NLS-transplants, having completely developed by the 6-8th week. 
Histological condition of NLS as of the date of transplantation was similar to normal human skin. The 
histology of mature plaque developed on NLS-transplant after its transplantation, was comparable to 
biopsy of PLS-plaque of a donor with psoriasis.  
Various combinations have been checked up at transplantation of donor human skin and a recipient 
line of mice. It has appeared that development of plaque of psoriatic phenotype takes place only at 
NLS-transplantation onto AGR129-mice. Papillomatosis and acanthosis revealed at different moments 
of PLS-plaque development on NLS-transplants onto AGR129-mice, were absent on the control 
transplants (p <0,0002) (Boyman 2004). 
 
Inflammation in NLS-transplant, immediately after its engraftments, is similar to LP2(IN) - dermal 
trauma of NLS, which create conditions for LP4 start (Gregorio 2010, Tang 2010). Absence of any 
donor cells in infiltrate (including NK) limits possibilities of innate response LP3(IN) on restriction and 
elimination of LP2-inflammation. It makes inevitable LP4 start and fast transition to adaptive response 
LP5(IN) to trauma. It was exactly the phenomenon observed at the detailed time-dependent analysis 
of events in NLS-transplants (Boyman 2004, Nestle 2005a). 
In these works, the role of PDC (actively secreting IFN-alpha) in PLS-plaque initialization was 
proved for the first time. It was shown that the quantity of PDC in NLS exceeds the norm, and in PLS it 
is greater than in NLS.  
Besides, it was revealed that a share of PDC in blood of psoriatics is decreased to 0,18% in 
comparison with 0,32% in the norm.  
It became possible to show at research of NLS-transplants that in dermal department PDC begins 
active secretion of IFN-alpha in 7 days after transplantation, this secretion reaches the maximum by 
the 14th day, but then quickly decreases. Visible psoriatic epidermal activation begins only on the 21st 
day after transplantation, and developed PLS-plaque is formed definitively on the 35th day. Active 
PDC-secretion of IFN-alpha in derma is an early and transient event preceding plaque occurrence. It 
is proved that PDC do secrete IFN-alpha, and the most important thing is that this secretion is an 
indispensable condition of the subsequent appearance of plaque (Nestle 2005a). 
It is known that PDC actively secrete IFN-alpha at interaction of the endosomal receptor TLR9 with 
CpG – endocytosed fragments of virus DNA (Cao 2007). However, the role of antimicrobial protein 
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LL37 in intensification of influence of CpG on TLR9 as well as influence of fragments of self-DNA (own 
DNA) on TLR9 were elucidated in the late years (Lande 2007, Gilliet 2008, Hurtado 2010).  
At NLS-transplantation, a trauma of donor derma takes place and, as a consequence, in 
extracellular dermal space donor DNA and RNA appear. Due to the trauma in NLS-transplant, donor 
KC, Neu and FB actively secrete LL37 (Dorschner 2001). Self-DNA-LL37 and self-RNA-LL37 
complexes are formed. Donor PDC endocytose these complexes, deliver them to endosomal TLR7 
and TLR9. Then complexes cooperate with receptors (self-DNA-LL37 with TLR9, self-RNA-LL37 with 
TLR7). As a consequence, PDC actively secrete IFN-alpha (Ganguly 2009, Nograles 2010, 
Tang 2010). 
 
On the other hand, donor KC can have latent HPV-carriage (Favre 1998). Restraint of 
HPV-expansion in NLS is provided by NK, however, after NLS-transplantation, replenishment of NK 
pool from blood flow occurs only at the expense of mouse NK, cytolytic activity of which in 
AGR129-mice is essentially decreased. As a consequence, HPV-expansion begins, the quantity of 
extracellular virus CpG is increased. PDC endocytose them. CpG also as well as self-DNA-LL37 
complexes influence on TLR9. And LL37 strengthens this influence. Thereby, active secretion of 
IFN-alpha can be caused not only by trauma, but also latent HPV-carriage. In the absence of 
HPV-carriage and at normal engraftment of NLS-transplant, consequence of trauma disappear 
gradually (LP2, LP3, LP5 processes are completed) and plaque on NLS-transplant appears to be in 
phase 6. If HPV-carriage on NLS-transplant takes place, such plaque remains in phase 5 (Fig. 2-7, 
Fig. 2-8). 
Within the limits of Y-model, NLS-transplant contains Mo-T and DC-T (incl. Mo-R and DC-R), 
arrived at homeostatic renewal of dermal Mo and DC of non-resident origin before transplantation (Fig. 
2-4, Fig. 2-11). Mo-R and DC-R arrive from blood flow together with F-content (including PG-Y) and, 
being reprogrammed, keep tolerance. They gradually degrade F-content, therefore those Mo-R and 
DC-R preserve the possibility to be transformed into maDC-Y that arrived from blood flow immediately 
before transplantation. 
Donor derma contains an overwhelming amount (> 90%) of Tem in comparison with their quantity 
present in blood flow (< 10%) (Clark 2006a, Clark 2010). As activity of LP8 is caused also by LP7.2, 
an essential part of Tem in NLS-transplant should be ThN-Y. ThN-Y after interaction with maDC-Y can 
be activated and proliferate, enlarging the total amount of CD3+TL in NLS-transplant (Tonel 2010). 
AGR129-mice are knockout on the receptors for IFN-alpha and IFN-gamma. It means that secreted 
in NLS-transplant IFN-alpha (initialization) and IFN-gamma (support) will mainly influence donor cells.  
Under the influence of IFN-alpha, secreted by PDC, transformation of Mo-R into MoDC-R (LP6.2) 
takes place (Farkas 2011).  
Under the influence of IFN-gamma and GM-CSF, loss of tolerance of part of Mo-R and DC-R to 
kPAMP-content (LP6.1) occurs and their transformation into maDC-Y takes place (LP6.4). The same 
phenomenon is promoted by self-RNA-LL37 complexes influencing DC-R and MoDC-R via endosomal 
TLR8 (Ganguly 2009).  
Thereby, preconditions to LP8 start appear. In this experiment, only the vicious cycle B takes place, 
as LP7.2 (for donor TL-Y) is impossible (Fig. 2-6). 
PLS-plaques started on the 21st day and prevailed until the termination of observation of mice-
recipients (56 days). Long (more than 30 days) action of LP8 without attraction of new DC-R and 
Mo-R (LP1.1) from blood flow can have the following reasons: 
 ability of maDC to present antigens continuously;  
 kPAMP-preactivation of Mo-R and DC-R providing increased resistance of maDC-Y to 
influence of cytotoxic cells (Mueller 2006); 
 insufficient quantity of the cytotoxic cells capable of elimination of maDC-Y in the 
transplant;  
 
As a result, it appears that there are enough of maDC-Y (formed from dermal Mo-R and DC-R 
present in NLS at the moment of transplant capture) and effector ThN-Y (proliferating from ThN-Y 
present in NLS at the moment of transplant capture) for initialization and long maintenance of LP8 
(more than 30 days).  
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It is possible to conclude that IYD level - unit Y-presentation, necessary for initialization and support 
of LP8 in NLS-transplant on AGR129-mice, is lower than the level necessary for initialization and 
support of LP8 in PLS (Fig. 2-10).  
It is possible to assume that at further observation of NLS-transplant (after the 56th day) 
PLS-plaque would have gradually regressed and disappeared. Or it could have been transformed into 
LP2(HPV)-plaque in case of HPV-carriage on the transplant. It should occur because of reduction of 
maDC-Y quantity that are not replenished from blood flow and gradually die. LP8.1 subprocess 
(similarly to LP8, as a whole) will be completed gradually because of IYD decrease.  
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Appendix 2-9. The comparative analysis of models of psoriasis pathogenesis.  
After SPP local (sub)processes of Y-model are listed in the table.  
First three columns contain the information about (sub)processes and dependencies of Y-model. In 
the first column, color designates the group of lines associated with the concrete process. In the 
second column, causative dependencies are shown. In the third column, comments are given. 
The last five columns contain the information about other models of pathogenesis, grouped 
according to (sub)processes and dependencies of Y-model.  
An empty table cell means that the model does not contain any information about (sub)process 
and-or dependence. Figure under the model name, contains original illustration. 
Abbreviations. ChemA = chemokines and AMP, Cyt = Cytokines. 
 
 Other models 
Y-model BF-model N-model GK-model TC-model GL-model 
 Cause > Effect (Sub)process. Comments. 
Baker 2006b, 
Fry 2007b 
Nestle 2009a,  
Nestle 2009b, 
Perera 2012 
Guttman-
Yassky 2011 Tonel 2009 Gilliet 2008 
 Fig. 2-6 Part 1, fig.2 Fig. 2-27 Fig. 2-28 Fig. 2-29 Fig. 2-30 
Systemic processes 
  SP1   
  SP2  
Intestine.  
Beta-streptococcal 
carriage. 
  SP3   
  SP4  (PG-Y)-load  on blood Mo 
  SP5   
  SP6  
Tonsils.  
Beta-streptococcal 
infection. 
  SP7   
  SP8  (PG-Y)-carriage of blood Mo 
  
Similar process in Y-
model is Y-priming 
(phase 0), when Tem-
Y and Tcm-Y are 
formed. 
Most activated ТL 
become anergic or 
perish, whereas 
TL-Y remain 
because of contact 
with PG-Y(+)Mo.  
It occurs in tonsillar 
(or intestine) 
regional LN. 
 SPP > LP1.1 
Systemic psoriatic 
process (SPP) is 
necessary and it 
defines the severity of 
psoriasis as a whole. 
Systemic process 
defined by the 
presence of  
PG-Y(+)Mo at 
blood flow and  
in LN. 
Systemic processes are not considered. 
 
Continued on next page. 
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Other models Y-model 
 Cause > Effect (Sub)process. Comments. 
BF-model N-model GK-model TC-model GL-model 
Local processes 
 LP1. Attraction  
of immunocytes from blood flow. 
 
 ChemA > LP1.1 LP1.1 – link  of the vicious cycle B. 
PG-Y(+)Mo migrate 
into skin to activate 
ТL-Y. 
It is mentioned, but without participation of Mo-T and DC-T  
(incl. Mo-R and DC-R).  
It is not considered as a vicious cycle link. 
 ChemA > LP1.2 LP1.2 – link  of the vicious cycle C. 
Attraction of TL-Y 
is one of the 
reasons of psoriatic 
inflammation. 
Th1 (expressing 
CLA, CXCR3 and 
CCR4) and Th17 
(expressing CLA 
and CCR4 and 
CCR6) migrate from 
blood flow into 
derma due to 
chemokines CCL20, 
CXCL9, CXCL10 
and CXCL11, etc. 
Attraction of ThN and PDC is a vicious cycle links. 
 ChemA > LP1.2 LP1.2  
Neu are involved by 
CXCL8, CXCL1, etc. 
into epidermis 
through derma from 
blood flow (2009b). 
  
CXCL8 
involves Neu 
from blood 
flow. 
  LP1.2  NKT also participate (2009b). Are not considered. 
 LP2. Initiating and aggravating 
process. 
The external trigger 
(Fry 2007b) or  
Кer-antigen (one of 
keratins) 
Stress or infection or 
medicinal 
preparations or 
trauma influencing 
skin. 
Trauma or skin 
infection. 
Derma-epidermal 
X-antigen. 
Trauma or skin 
infection. 
Mechanical 
trauma. 
  
LP2(IN).  
Self-RNA and self-
DNA get to the 
extracellular space 
from damaged KC. 
 Self-RNA and self-DNA get to the extracellular space from damaged KC. 
Self-DNA get to the extracellular 
space from damaged KC. 
  
LP2(HPV).  
Self-DNA, HPV-DNA 
and self-RNA get to 
the extracellular space 
from destroyed KC-v. 
 
 
Continued on next page. 
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Other models Y-model 
 Cause > Effect (Sub)process. Comments. 
BF-model N-model GK-model TC-model GL-model 
 LP3. Innate response against LP2. It is not regarded separately (except GK-model). 
 LP3 > Cyt > LP3 -  
KC secrete 
IL-1alpha/beta,  
IL-18, TNF-alpha 
activating other KC. 
 
 Cyt > LP6 -  
These cytokines 
activate both LC 
and DDC. 
 
 LP3 > ChemA Neu and KC secrete LL37.  Neu and KC secrete LL37. 
 LP3.1(IN) > LP4   
In the extracellular space self-RNA-LL37 
and self-DNA-LL37 complexes are 
formed. Then, PDC endocytose these 
complexes, which cooperate with TLR7 
and TLR9 accordingly. 
In the extracellular space self-
DNA-LL37 complexes are 
formed. Then, PDC endocytose 
these complexes, which 
cooperate with TLR9. 
 LP3.1 > (LP6.3, LP6.4) 
Self-RNA-LL37 
complexes stimulate 
DC to secretion of 
TNF-alpha, IL-6 and 
IL-23 and to 
maturation DC in 
maDC. 
 
Self-RNA-LL37 
complexes activate 
DC and promote 
their maturation in 
maDC. 
Self-RNA-LL37 
complexes stimulate 
DC to secretion of 
TNF-alpha, IL-6 and 
IL-23 and to 
maturation DC in 
maDC. 
 
 LP3.1(HPV) > LP4 
PDC endocytose 
CpG-LL37 complexes, 
which cooperate with 
endosomal TLR9. 
  
 LP4. Trigger of adaptive response 
against LP2. 
  
 LP4 > Cyt 
PDC actively secretes 
IFN-alpha and a little 
of TNF-alpha. 
 PDC actively secretes IFN-alpha. 
 LP4 > LP6   IFN-alpha activates maturation and differentiation of DC. 
 LP5. Adaptive response against LP2. 
The immune 
response after 
trigger influence or 
against Кer-antigen. 
It is not regarded 
separately Not completely It is not regarded separately 
 LP6. Mo and DC transformations. 
 
PG-Y(+)MF 
formation. 
Mo-T and DC-T (incl. Mo-R and DC-R) - are absent. Mo and DC of resident 
and non-resident origin are not separated. LP6.1 - is absent. LP6.2 - only 
MF formation, MoDC formation - is not considered.  
LP6.3 and LP6.4 - are not parted (except GK-model). 
 LP6 > Cyt  > LP8.1   
DC secrete IL-23. 
TipDC secrete  
IL-23, iNOS and 
TNF-alpha. 
TipDC secrete TNF-
alpha, iNOS, IL-20, 
IL-12 and IL-23 
activating Th1 and 
Th17. 
TNF-alpha is 
secreted by 
activated MF, 
DDC and, to a 
lesser degree, 
by KC and ТL. 
 
 Cyt > LP6   
IL-1beta, IL-6 and 
TNF-alpha activate 
DDC. 
 
High levels of 
TNF-alpha 
promote 
maturation of 
DC. 
 
 
Continued on next page. 
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Other models Y-model 
 Cause > Effect (Sub)process. Comments. 
BF-model N-model GK-model TC-model GL-model 
 LP7.  
Lymph nodes. Clonal proliferation. 
     
  LP7.1. maDC-Z. Migration into LN.  
LC and  
BDCA-1+DDC 
endocytose  
X-antigen and carry 
it into LN. 
  
  LP7.2. maDC-Y. Migration into LN.  
 
Activated DDC 
migrate to draining 
LN for presentation 
of an unknown 
antigen (of own or 
microbial origin) to 
nTL and promote 
their differentiation 
in Th17 and-or in 
Th1 (2009a). Also, 
in Tc17 and-or in 
Tc1 (2009b). 
   
  
LP7.1. Interaction 
maDC-Z and TL-Z  
in LN. 
  
As a result of 
interaction with 
maDC in LN effector 
Th1, Th17 and Th22 
are formed. 
  
  
LP7.2. Interaction 
maDC-Y and TL-Y  
in LN. 
 
DC and TL form 
perivascular groups 
and lymphoid 
structures around 
blood vessels due to 
chemokines, such 
as CCL19 secreted 
by MF (2009b). 
CD208+maDC are 
colocalized with TL 
in the lymphoid 
structures including 
CCR7+ cells and 
cells secreting 
CCL19. 
  
 Cyt > LP7.2 > LP1.2   
Effector Th17, Tc17, 
Th1 and Tc1 leave 
from LN into blood 
flow, circulate there 
and are slowed 
down in skin 
capillaries because 
of interactions 
ligand-receptor 
controlled by 
selectin and integrin 
(2009b). 
 
TNF-alpha 
promotes EC to 
express E-
selectin (CLA-
ligand) and 
ICAM-1, which 
provides 
attraction of 
Tem from blood 
flow. 
 
 
Continued on next page. 
© 2011-2012,  Peslyak MY,  Model of pathogenesis of psoriasis. Part 2. Local processes.  e1.3.                                                              65 
 
Other models Y-model 
 Cause > Effect (Sub)process. Comments. 
BF-model N-model GK-model TC-model GL-model 
 LP8. False adaptive response to 
imaginary PsB-infection. 
The immune 
response to 
imaginary beta-
streptococcal 
infection 
    
  
LP8.1. Y-antigen 
presentation by 
maDC-Y to effector 
ThN-Y. 
Y-antigen 
presentation by 
maDC-Y to TL-Y. 
Dermal DC present 
unknown 
autoantigens to TL. 
   
Dermal DC 
present 
unknown 
autoantigens to 
autoreactive 
TL. 
 Cyt > LP8.1 > Cyt  
Cytokines 
(including IFN-
gamma) secreted 
by TL-Y cause 
proliferation KC 
and development 
of psoriatic plaque. 
Both Th1 and Tc1 
secrete IFN-gamma 
and TNF-alpha 
(2009b). Th17 (and 
Tc17 - 2009b) 
secrete IL-17A,  
IL-17F and IL-22. 
Th1 secrete  
IFN-gamma. 
  
IL-23 stimulates 
Th17 and Th22 to 
secretion of IL-17 
and IL-22. 
Th1 and Th17 
secrete IFN-
gamma, IL-17 
and IL-22. 
These cytokines 
influence KC 
and lead to 
psoriatic 
changes. 
Activated Th17 
secrete IL-22 
and IL-17. 
  
In Y-model, it is 
considered as a part 
of LP5.2(HPV). 
 
CD8+Tem express 
VLA-1 binding with 
collagen IV (via 
alpha1beta1-
integrin). It allows 
them to get from 
derma to epidermis 
through the basal 
membrane. 
 
alpha1beta1-
integrin is 
expressed only 
on epidermal 
TL. They define 
psoriatic 
changes as 
increase of their 
number (and not 
TL as a whole) 
correlates with 
plaque 
beginning. 
 
 Cyt > LP8.2   
IL-17A, IL-17F,  
IL-22, IFN-gamma, 
TNF-alpha influence 
KC and stimulate 
their 
hyperproliferation. 
 
IL-22 and other 
cytokines of IL-20 
family cause 
hyperproliferation 
and acanthosis.  
 
IFN-gamma,  
IL-17 and IL-22 
induce in KC 
expression of 
ICAM-1, CD40 
and MHC-II. 
Under the 
influence of 
these cytokines, 
KC 
hyperproliferate. 
Which leads to 
acanthosis. IL-
22 influence KC 
through receptor 
IL-22R >  
STAT3 > 
hyperprolife-
ration. 
IL-22 and IL-17 
induce KC 
hyperprolife-
ration.  
 
They activate 
Neu. 
 
Continued on next page. 
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Other models Y-model 
 Cause > Effect (Sub)process. Comments. 
BF-model N-model GK-model TC-model GL-model 
 Cyt > LP8.2 > Cyt   
KC secrete IL-1beta, IL-6, 
TNF-alpha and TGF-beta. 
FB secrete KGF, EGF and 
TGF-beta. 
KC and FB cooperate 
through secreted cytokines, 
and that leads to tissue 
reorganization and 
deposition of extracellular 
matrix (for example, 
collagen and 
proteoglycans). 
 
KC secrete IL-
1beta, IL-6 and 
TNF-alpha. 
 
 Cyt > LP8.2 > ChemA 
KC secrete LL37, but 
it is not accepted by  
vicious cycle link. 
 
IL-17A, IL-17F, IL-22,  
IFN-gamma, TNF-alpha 
influence KC and stimulate 
secretion of LL37, HBD1, 
HBD2, S100A7, S100A8, 
S100A9, and chemokines 
CCL20, CXCL1, CXCL3, 
CXCL5, CXCL8, CXCL9, 
CXCL11. 
IFN-gamma 
influences KC-
secretion of 
chemokines CXCL1, 
CXCL2, CXCL3, 
CXCL5, CXCL8, 
CXCL9, CXCL10, 
CXCL11 and VEGF 
causing 
angiogenesis 
IFN-gamma and IL-
17 influence KC-
secretion of 
chemokines, AMP 
and lipokalin-2. In 
particular KC 
secrete LL37 that is 
accepted by a 
vicious cycle link. 
 
IL-22 and IL-17 
influence KC-
secretion of 
chemokines 
(for example 
CXCL8) and 
AMP.  
 
In particular, 
KC secrete 
LL37, which is 
accepted by a 
vicious cycle 
link. 
 
In addition 
During LP3.1 from damaged KC or 
destroyed KC-v self-DNA and self-RNA 
get to the extracellular space, and LL37-
complexes are formed.  
 
These events are considered as 
transit and-or aggravating, but not as 
vicious cycle links.  
 
Self-DNA and self-RNA 
come from incompletely 
differentiated KC in the 
extracellular space. 
Self-DNA-LL37 and  
self-RNA-LL37 
complexes are endocytosed 
by PDC and influence TLR9 
(Perera 2012) 
Self-DNA and self-
RNA get from 
apoptotic KC to the 
extracellular space. 
Self-RNA-LL37 
complexes (self-
RNA from apoptotic 
KC) stimulate DC to 
secretion of TNF-
alpha, IL-6, and IL-
23 and their 
maturation in 
CD208+maDC. It is 
accepted by vicious 
cycle links. 
 
Self-DNA get 
to the 
extracellular 
space from 
apoptotic KC.  
Self-DNA-LL37 
complexes 
(self-DNA from 
apoptotic KC) 
stimulate PDC 
to secretion of 
IFN-alpha. It is 
accepted by 
vicious cycle 
links. 
Genetic deviations can define severity 
and the type of psoriasis, but they are not 
the reason of its initialization or support. 
However, they can affect the intensity of 
any of processes. 
Genetic 
predis-
position. 
Environment factors can 
cause psoriasis in 
genetically predisposed 
people carrying alleles of 
susceptibility. 
 Genetic predisposition. 
Possible 
dependence on 
the genetic 
variations of  
IL-23R 
influencing 
Th17-LL37 
axis. 
Notes. Light blue color designates main pathogenetic links according to N-model. Italics designates the 
information which is not supported by other references.  
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Appendix 2-10. List of essential changes and additions 
This appendix is intended for readers who are familiar with the previous edition of this book (e1.2) 
and allows to get briefly acquainted only with essential changes and additions (Tab. 2-4). In the text 
the significant new or revised fragments are marked with a vertical line on the right. The new works 
included into the bibliography are also marked the same way.  
Tab. 2-4. Changes and additions  
What Where  
Tolerized phagocytes are designated Neu-T, Mo-T and DC-T.   
Also derived from Mo-T macrophages and dendritic cells are 
designated MF-T and MoDC-T.   
For all tolerized phagocytes special images are offered (Fig. 2-2) .  
In figures these images as a rule are used for PG-Y(-) tolerized 
phagocytes.  
Concerning chemostatus of senescent Neu-T specification is made. 
App. 2-1 и 2-2. 
Definition of tolerized phagocytes is specified:   
kPAMP-carriage is recognized by obligatory (Property 2).   
Definition of R-phagocytes is specified:  
(PG-Y)-carriage is recognized by obligatory (Property 3).  
As a result there was actually renaming entities:   
Before: a) tolerized b) R-phagocytes and c) PG-Y(+) R-phagocytes;  
Now:     a) and b) tolerized and c) R-phagocytes. 
It has entailed the most part from changes listed further.   
App. 2-1 и 2-2. 
In all fragments where earlier there were materials  about  
R-phagocytes (Mo-R and DC-R) corrections were made: 
Before: "R-phagocytes",  
Now: «Tolerized phagocytes (incl. R-phagocytes)». 
Before: «Mo-R and DC-R»,  
now: «Mo-T and DC-T (incl. Mo-R and DC-R)», etc.    
In several places. 
Illustrations.  Fig. 2-1 and Fig. 2-2 are corrected and added so that to 
become identical with fig. 4 and fig. 5 of Part 1.  
The Fig. 2-6, Fig. 2-7, Fig. 2-8, Fig. 2-9, Fig. 2-11, Fig. 2-17,  
Fig. 2-18, Fig. 2-20 are corrected   
 
In figures Fig. 2-11 (phase 1), Fig. 2-17 (phase 6), Fig. 2-20 (phase 
2) images of Mo-T, DC-T and MoDC-T are added.  Thus it is meant 
that all of them are PG-Y(-). 
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Tab. 2-4 (continuation)   
 
What Where  
Name SPP is changed: 
Before:  
«Increased kPAMP-carriage of R-phagocytes.» 
Now:  
«Increased kPAMP-carriage of tolerized phagocytes.  
Increased (PG-Y)-carriage of R-phagocytes». 
It is made in connection with change of the formulation of 
subprocess SP8. 
Part 1, SPP 
Fig. 2-8,  
Fig. 2-9,  
Fig. 2-18 
Name of LP1.1 is changed. 
Before: 
«Attraction of Mo, Mo-R, DC, DC-R from blood.» 
Now: 
«Attraction of Mo and DC, Mo-T and DC-T (incl. Mo-R and DC-R) 
from blood.» 
It is made in connection with specification of concept of  
R-phagocytes. 
The description of role Mo-T and DC-T in psoriatic inflammation is 
added. 
LP1.1, 
Fig. 2-8,  
Fig. 2-9,  
Fig. 2-18 
Name of LP6.1 is changed. 
Before:   
“Loss of tolerance of Mo-R, DC-R and MoDC-R to kPAMP.”  
Now:  
“Loss of tolerance to kPAMP.” 
It is made in connection with addition of Mo-T, DC-T and MoDC-T in 
process LP6.  
Tab. 2-3 and Fig. 2-7 are corrected and added. 
LP6 
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Figures 
 
Fig. 2-1. Bacteria, bacterial products, viruses and tissue cells (symbols). 
(Part1, fig.4). Appendix 2-1. 
USL1-e 
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Fig. 2-2. Immune cells (symbols). 
(Part1, fig.5). Appendix 2-1. 
USL2-e 
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Fig. 2-3. T-lymphocytes (symbols). 
USL3-e 
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Fig. 2-4. Origin of dermal DC and MF. 
DDC_DMF-e 
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Fig. 2-5. Fractions CD11c+maDC in PLS-derma. 
CD208+(DC-LAMP+)DC - green oval, SlanDC - yellow oval, TipDC - brown oval.  
A part of maDC belongs to two or even three fractions at once. 
DmaDC-e 
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Fig. 2-6. Y-model of pathogenesis of psoriasis (LP2 is not specified). Interaction of local processes. 
Dashed lines – transit process LP4 and influences connected to it. Dotted arrows with small 
squares - suppression. Letters B and C - vicious cycles. 
UNI-e 
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Fig. 2-7. Interdependence of subprocesses of Mo and DC transformations. 
LP6-e 
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Fig. 2-8. Y-model of pathogenesis of psoriasis (LP2 is not specified). Phases of psoriatic plaque 
development. 
Dotted arrows – suppression. Letters B and C - vicious cycles. White color - process occurs with 
weak intensity; beige - inflammatory, average intensity; pink - inflammatory, high intensity. 
UNI_PHA-e 
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Fig. 2-9. Y-model of pathogenesis of psoriasis at LP2(IN) - open trauma of derma. 
Dashed lines - suppression. On LP2 end (phase 6) only the processes framed by the pink rectangle 
"PLS-inflammation" remain. 
UNI_IN-e 
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Fig. 2-10. Phases of psoriatic plaque development at LP2(IN) and previous Y-priming. Conditional 
graphs. 
LP4 - adaptive response trigger; LP3 - innate response, LP5 - adaptive response against dominant 
Z-antigen of commensals, LP8 - false adaptive response against Y-antigen.  
a) Unit antigenic presentation of maDC (the quantity of antigen presented by maDC in the unit of 
volume of derma): IYD - defined by Y-antigen (presented by maDC-Y), IZD - defined by Z-antigen 
(presented by maDC-Z).  
b) Logarithmic curves of unit quantity of effector ThN in the unit of volume of derma:  
KYT = ln (unit of quantity of ThN-Y), KZT = ln (unit of quantity of ThN-Z). 
PHS_IN-e 
© 2011-2012,  Peslyak MY,  Model of pathogenesis of psoriasis. Part 2. Local processes.  e1.3.                                                              79 
 
Fig. 2-11. Prepsoriasis. Phase 1, common for all LP2 (as LP2 has not started yet).  
Here (as anywere): Mo-R = PG-Y(+)Mo-T; MF-R = PG-Y(+)MF-T ; DC-R = PG-Y(+)DC-T; 
PH_1-e 
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Fig. 2-12. Process LP7.1. Lymph node. Primary and secondary responses. Formation of TL-Z, i.e. 
Tem-Z and Tcm-Z. 
LYM-prim-e 
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Fig. 2-13. Process LP7. Lymph node. Clonal proliferation. Phases 4, 5 and 6. 
It is supposed that priming by Z-antigens and Y-antigens took place, i.e. secondary response 
developed both to Z-antigen and Y-antigen. Tem-Z are quickly formed from Tcm-Z, and Tem-Y are 
quickly formed from Tcm-Y. At LP2(IN) formed Tem-Z consist basically from ThN-Z. At LP2(HPV), 
formed Tem-Z consist basically from ThN-Z2 and TcN-Z1. Tem-Y consist basically from ThN-Y. 
LYM-e 
© 2011-2012,  Peslyak MY,  Model of pathogenesis of psoriasis. Part 2. Local processes.  e1.3.                                                              82 
 
Fig. 2-14. Prepsoriasis. Phase 3 at LP2(IN) - open trauma of derma. 
Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are identical to transformations of Mo 
and DC, therefore their images are absent. 
PH_3IN-e 
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Fig. 2-15. Prepsoriasis. Phase 4 at LP2(IN) - open trauma of derma.  
Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are identical to transformations of Mo 
and DC, therefore their images are absent. 
PH_4IN-e 
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Fig. 2-16. Psoriasis. Phase 5 at LP2(IN) - open trauma of derma. Trauma healing. 
Plaque initialization occurs after trauma during LP3 - innate and LP5 - adaptive responses against 
commensals (Koebner effect). Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are 
identical to transformations of Mo and DC, therefore their images are absent. 
PH_5IN-e 
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Fig. 2-17. Psoriasis. Phase 6, common for all LP2 (as LP2 has ended). 
The basic process is self-sufficient LP8.  
PH_6-e 
© 2011-2012,  Peslyak MY,  Model of pathogenesis of psoriasis. Part 2. Local processes.  e1.3.                                                              86 
 
Fig. 2-18. Y-model of pathogenesis of psoriasis at LP2(HPV) - HPV-carriage of KC.  
Dashed lines - transit process LP4 and influences connected to it.  
Dotted arrows with small squares - suppression. 
UNI_EH-e 
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Fig. 2-19. Phases of psoriatic plaque development at LP2(HPV) and previous Y-priming. Conditional 
graphs. 
LP4 - trigger of adaptive response; LP3 - innate response, LP5 - adaptive response against 
Z-antigen, LP8 - false adaptive response against Y-antigen.  
a) Unit antigenic presentation by maDC (quantity of antigen presented by maDC in the unit of 
volume of derma):  
IYD - defined by Y-antigen (presented by maDC-Y), IZD - defined by Z1-antigen (presented by 
maDC-Z1) and Z2-antigen (presented by maDC-Z2).  
b) Logarithmic curves of the unit quantity of effector Tem in the unit of volume of derma:  
KYT = ln(unit quantity of ThN-Y), KZT = ln (unit quantity of Tem-Z). 
PHS_EH-e 
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Fig. 2-20. Prepsoriasis. Phase 2 at LP2(HPV) - HPV-carriage of KC.  
Here (as anywere): Mo-R = PG-Y(+)Mo-T; MF-R = PG-Y(+)MF-T ; DC-R = PG-Y(+)DC-T; 
PH_2EH-e 
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Fig. 2-21. Prepsoriasis. Phase 3 at LP2(HPV) - HPV-carriage of KC. 
Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are identical to transformations of Mo 
and DC, therefore their images are absent. 
 
PH_3EH-e 
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Fig. 2-22. Prepsoriasis. Phase 4 at LP2(HPV) - HPV-carriage of KC.  
Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are identical to transformations of Mo 
and DC, therefore their images are absent. 
 
PH_4EH-e 
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Fig. 2-23. Psoriasis. Phase 5 at LP2(HPV) - HPV-carriage of KC.   
Possible transformations of PG-Y(-)Mo-T and PG-Y(-)DC-T are identical to transformations of Mo 
and DC, therefore their images are absent. 
PH_5EH-e 
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Fig. 2-24. Y-priming of skin. Transition of whole skin from phase 0 into phase 1. 
PRIM-e 
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Fig. 2-25. Phase transitions. 
PNS_TRANS-e 
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Fig. 2-26. PLS-plaque development at LP2(HPV) - HPV-carriage of KC.  
PIN_PHS 
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Notes to Fig. 2-26. 
 
a) Site of НPV-carriage of KC in phase 2; is closer to the edge of this site HPV-carriage of KC 
smoothly disappears; In the whole site LP2(HPV) and LP3(HPV) develop. In the site center 
HPV-expansion has begun. 
  
b) In the site of HPV-expansion LP4 has begun and, hence, phase 2 has transferred in phase 3 
(orange);  
 
c) Site of LP4 (and phase 3) extend to until LP4 weakening because of decrease of HPV-carriage 
level of KC. In the middle of the ring, LP5 against HPV is initiated, i.e. there is transition to phase 4 
(dark blue); 
 
d) As a result of LP4, LP5 against HPV begins (phase 4). LP8 does not begin because of a low 
level of IYD and-or KYT (Fig. 2-19) 
 
e) HPV-expansion is suppressed, up to full elimination of HPV-carriage (phase 1). However, where 
LP5 against HPV was absent (the external ring), skin remains in phase 2.  
 
f) On the site of action of LP5 against HPV, levels of IYD and KYT appear sufficient for initialization 
of LP8 (phase 5 - pink). The pinpoint PLS-plaque initiates.  
 
g) Simultaneous expansion of sites of phase 4 and phases 5 occurs. It can happen in different 
ways, but, anyway, the site of phase 4 will transform completely into phase 5.  
 
h1-i1) It is eccentric, so that LP8 extends to NLS site, where is no HPV-carriage of KC and in this 
site LP8 becomes self-sufficient (phase 6 - red); One part of PLS-plaque is in phase 5, and another 
part - in phase 6. 
 
h2-i2) It is central, in such a way that in the middle of PLS-plaque HPV-carriage of KC stops 
completely and LP8 becomes self-sufficient in this site (phase 6 - red); One part of PLS-plaque is in 
phase 5, and another part - in phase 6. 
 
h3) It is central, but without elimination of HPV-carriage of KC somewhere. PLS-plaque is entirely in 
phase 5. 
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Fig. 2-27. N-model of pathogenesis of psoriasis. 
Reproduced from (Nestle 2009a, fig.5) with permission from NATURE PUBLISHING GROUP via 
Copyright Clearance Center. 
M_Nestle+ 
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N-model description (Fig. 2-27) according last version (Perera 2012).  
 
(1) A genetically predisposed individual encounters one of many potential environmental triggers, 
which sets in motion immune responses from both the innate and adaptive arms of the immune 
system. 
 
(2) Initial triggers such as physical trauma or bacterial products start a cascade of events. Stressed 
keratinocytes (KC) produce proinflammatory cytokines IL-1alpha/beta, IL-18, TNF-alpha via 
inflammasome activation, thereby activating other KC, DDC and LC. Stressed KC release self-DNA 
and self-RNA into extracellular compartment. Self-DNA-LL37 and self-RNA-LL37 complexes are 
formed.  
 
(3) Psoriatic keratinocytes prematurely enter terminal differentiation, causing the release of 
self-DNA and self-RNA into the extracellular compartment. Self-DNA-LL37 and self-RNA-LL37 
complexes are formed. 
  
(4) PDC induced by chemerin, relocate from blood flow to derma. PDC endocytose viral dsDNA, 
ssRNA (if trigger is a skin viral infection) or complexes self-DNA-LL37 and self-RNA-LL37 and 
produce IFN-alpha. 
  
(5) IFN-alpha activates and matures DC. Mature DC circulate to draining lymph nodes (LN), where 
present putative autoantigen to naive T cells. 
 
(6) TL differentiation and clonal expansion in LN occur; the resulting effector Th1, Th17, Th22 and 
Tc1, Tc17 and Tc22, bearing skin-homing receptors (CCR4, CCR6, CCR10, CXCR3), circulate to 
derma under the guidance of selectins and integrin-receptor ligand interactions. 
 
(7) Key processes during disease maintenance are the presentation of putative autoantigen to 
effector TL and the release of IL-23 by DDC, the production of proinflammatory mediators such as 
TNF-alpha and NO by TipDC, and the production of IL-17A, IL-17F, and IL-22 by Th17 and Tc17 
cells and IFN-gamma and TNF-alpha by Th1 and Tc1. These mediators act on keratinocytes, 
leading to the activation, proliferation, and production of antimicrobial peptides (e.g., LL-37 and 
HBD), chemokines (e.g., CXCL1, CXCL9, CXCL10, CXCL11, and CCL20), and S100 proteins (e.g., 
S100A7-9) by keratinocytes. 
  
DC and effector TL form perivascular clusters and lymphoid-like structures around blood vessels in 
the presence of chemokines such as CCL19 produced by MF. A key checkpoint of psoriatic plaque 
initiation is the migration of TL from derma in epidermis; This migration is controlled through the 
interaction of alpha1beta1integrin (VLA-1) on TL and collagen IV at the basement membrane.  
Unconventional TL, including NKT, contribute to the disease process.  
Feedback loops involving keratinocytes, fibroblasts, and endothelial cells contribute to tissue 
reorganization with endothelial-cell activation and proliferation and deposition of extracellular matrix.  
Neutrophils in the epidermis are attracted by chemokines, including CXCL8 and CXCL1 
.  
(8) KC continue to proliferate; there is continued TL recruitment; and the proinflammatory cycle 
continues unchecked until therapeutic intervention takes place or, very rarely, until spontaneous 
remission occurs. 
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Fig. 2-28. GK-model of pathogenesis of psoriasis.  
Reproduced from (Guttman-Yassky 2011, fig.2B) with permission of MOSBY, INC. via Copyright 
Clearance Center. 
M_Guttman-Yassky_2011 
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GK-model description (Fig. 2-28) based on (Guttman-Yassky 2011, Nograles 2010). 
 
Initial, acute and chronic stages of psoriatic plaque. 
 
Initial stage. 
Trauma or skin infection lead to occurrence dermal-epidermal X-antigen.  
 
From damaged KC to extracellular space get self-RNA and self-DNA. Neu and KC secrete LL37.  
In extracellular space complexes self-DNA-LL37 are formed. Then they endocytosed by PDC and 
influence through TLR9. 
 
PDC produce IFN-alpha, which induces maturation and differentiation of inflammatory DC.  
Both LC and BDCA-1+DDC endocytose X-antigen and carry it to LN. As a result of interaction with 
maDC in LN are formed effector Th1, Th17 and Th22. 
 
Acute stage. 
Inflammatory DC produce TNF-alpha, iNOS, IL-20, and IL-23, which induce Th1 and Th17 cell 
responses. The Th1-cytokine IFN-gamma induces KC to produce proinflammatory chemokines and 
increase production of VEGF, which promotes angiogenesis. DC secrete IL-23, which stimulates 
Th17 and Th22 for production of IL-17 and IL-22.  
IL-17 induces KC to produce chemoattractants for TL, Neu and Mo. IL-22 and other IL-20 family 
cytokines promote epidermal acanthosis. IL-17 and IL-22 induce KC for production of AMP that 
include defensins, lipocalin 2 and LL-37.  
 
Chronic stage. 
LL-37 upregulation results in a self-amplifying inflammatory loop from self-DNA-LL37 complexes 
that stimulate PDC production of IFN-alpha and self-RNA-LL37 complexes that stimulate production 
of TNF-alpha, IL-6, and IL-23 by DC and their maturation into CD208+maDC. CD208+maDC 
colocalize with TL in lymphoid structures that include CCR7+ cells, which produce CCL19.  
Formation of effector Th17, Th22, Tc22. 
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Fig. 2-29. TC-model of pathogenesis of psoriasis. 
Reproduced from (Tonel 2009, fig. 1) with permission of PERGAMON via Copyright Clearance 
Center. 
M_Tonel_2009 
Development of psoriatic plaque.  
Various stimuli (such as physical trauma, infections, etc.) can all trigger an initial PLS-plaques in 
those individuals who already have a genetic predisposition. After the initial trigger, one of the 
earliest events driving the inflammatory eruption are the secretion of IFN-alpha from plasmacytoid 
dendritic cells (PDC) and the production of TNF-alpha by cells of the innate and adaptive immune 
system.  
Large amounts of IFN-alpha released by PDC induce activation of the local immune effector cells 
enabling them to secrete cytokines that further promote the inflammatory cascade.  
TNF-alpha is a highly active cytokine of the inflammatory infiltrate and is mainly released by 
activated macrophages, dermal DC and in a lesser extent by keratinocytes and T cells. The high 
levels of TNF-alpha lead to the maturation of DC into potent antigen presenting cells (APC), and 
secondly, in conjunction with other cytokines, TNF-alpha up-regulates the expression of endothelial 
E-selectin and ICAM-1 attracting further CLA+T cells into the skin.  
In addition, the panel of cytokines released by T lymphocytes also contributes to the stimulation of 
epidermal keratinocytes and is at least partially responsible for typical changes seen in psoriasis. 
They induce the expression of ICAM-1, CD40 and MHC-II, the release of various cytokines, and 
trigger keratinocyte hyperproliferation leading to epidermal hyperplasia (acanthosis).  
Finally, alpha1beta1 integrin is expressed only on epidermal but not dermal T cells defining key 
effectors in psoriasis as intraepidermal but not total T cells correlate with onset of the disease. 
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Fig. 2-30. GL-model of pathogenesis of psoriasis. 
Reproduced from (Gilliet 2008, fig. 3) with permission of ELSEVIER LTD. via Copyright Clearance 
Center.  
 
A model for initiation and maintenance of autoimmune skin inflammation in psoriasis.  
Mechanical injury to prepsoriatic skin induces LL37 production by keratinocytes. LL37 forms a 
complex with self-DNA released by damaged cells and triggers TLR9-mediated PDC activation to 
produce type I IFN (IFN-alpha/beta) in prepsoriatic skin.  
Type I IFN trigger local maturation of myeloid dendritic cell and activation of autoreactive T cells 
leading to the formation of psoriatic skin lesions. In this process, activated Th17 cells produce IL-22 
and IL-17, which induce epidermal hyperplasia and chemokine (e.g. IL-8)-dependent recruitment of 
neutrophils, respectively.  
IL-17 and IL-22 stimulate psoriatic keratinocytes to sustain the expression of cationic antimicrobial 
peptides (AMP) including LL37, which further forms complexes with self-DNA that is abundantly 
released in psoriatic skin lesions by apoptotic cells. As a result, self-DNA-LL37 complexes 
constantly promote dendritic cell maturation and activation of autoreactive T cells, providing a self-
sustaining feedback mechanism that amplifies and maintains autoimmune skin inflammation in 
psoriasis. 
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